Chapter 3: Marital status in ART

Fertility and Sterility
81, 19-20
DOI: 10.1016/j.fertnstert.2004.02.066

Citation Report

#	Article	IF	Citations
1	Association study for single nucleotide polymorphisms in the CYP17A1 gene and polycystic ovary syndrome. International Journal of Molecular Medicine, 1998, 22, 249.	1.8	10
2	Insulin sensitizers in the treatment of polycystic ovary syndrome. , 2001, , 65-80.		1
3	Irsutismo e androgenizzazione: iter diagnostico. L Endocrinologo, 2003, 4, 108-117.	0.0	0
5	The prevalence of androgen excess among patients with minimal unwanted hair growth. American Journal of Obstetrics and Gynecology, 2004, 191, 1914-1920.	0.7	67
6	SÃndrome del ovario poliquÃstico: nuevas perspectivas. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2004, 51, 506-511.	0.8	1
7	Obstetrician/Gynecologist. Postgraduate Obstetrics & Gynecology, 2004, 24, 1-6.	0.1	0
8	Polycystic Ovarian Syndrome and the Metabolic Syndrome. American Journal of the Medical Sciences, 2005, 330, 336-342.	0.4	45
9	Recurrent miscarriage: pathophysiology and outcome. Current Opinion in Obstetrics and Gynecology, 2005, 17, 591-597.	0.9	155
10	The optimal diet for women with polycystic ovary syndrome?. British Journal of Nutrition, 2005, 94, 154-165.	1.2	66
11	Incidence of polycystic ovaries and polycystic ovary syndrome amongst women in Melbourne, Australia. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2005, 45, 17-19.	0.4	42
12	Polycystic ovarian syndrome: marked differences between endocrinologists and gynaecologists in diagnosis and management. Clinical Endocrinology, 2005, 62, 289-295.	1.2	107
13	Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS). Clinical Endocrinology, 2005, 62, 644-649.	1.2	205
14	The peroxisome proliferator activated receptor gamma Pro12Ala polymorphism is associated with a lower hirsutism score and increased insulin sensitivity in women with polycystic ovary syndrome. Clinical Endocrinology, 2005, 62, 573-579.	1.2	68
15	Polycystic ovaries and ovarian hyperstimulation syndrome: a systematic review*. Acta Obstetricia Et Gynecologica Scandinavica, 2005, 84, 611-616.	1.3	50
16	Thiazolidinediones for Treatment of Polycystic Ovary Syndrome. Pharmacotherapy, 2005, 25, 244-252.	1.2	35
21	Polycystic ovaries and ovarian hyperstimulation syndrome: a systematic review. Acta Obstetricia Et Gynecologica Scandinavica, 2005, 84, 611-616.	1.3	73
22	Preoperative luteinizing hormone levels predict the ovulatory response to laparoscopic ovarian drilling in patients with clomiphene citrate-resistant polycystic ovary syndrome. Gynecological Endocrinology, 2005, 21, 307-311.	0.7	14
23	Cerebral artery hemodynamics in polycystic ovary syndrome. Gynecological Endocrinology, 2005, 21, 287-291.	0.7	4

#	Article	IF	Citations
24	FEM1A is a candidate gene for polycystic ovary syndrome. Gynecological Endocrinology, 2005, 21, 330-335.	0.7	11
25	Associations between two single nucleotide polymorphismsin the adiponectin gene and polycystic ovary syndrome. Gynecological Endocrinology, 2005, 21, 165-169.	0.7	29
26	Risk Factors for Young Premenopausal Women With Endometrial Cancer. Obstetrics and Gynecology, 2005, 105, 575-580.	1.2	277
27	Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth. Human Reproduction Update, 2005, 11, 631-643.	5.2	133
28	A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination. Human Reproduction, 2005, 20, 2879-2886.	0.4	102
29	Approach to Adolescent Polycystic Ovary Syndrome (PCOS) in the Pediatric Endocrine Community in the USA. Journal of Pediatric Endocrinology and Metabolism, 2005, 18, 499-506.	0.4	36
30	Randomized Controlled Trial Evaluating Response to Metformin Versus Standard Therapy in the Treatment of Adolescents with Polycystic Ovary Syndrome. Journal of Pediatric Endocrinology and Metabolism, 2005, 18, 761-8.	0.4	78
31	The Evaluation and Treatment of Hirsute Women. Women's Health, 2005, 1, 429-435.	0.7	4
32	Screening Women With Polycystic Ovary Syndrome for Metabolic Syndrome. Obstetrics and Gynecology, 2005, 106, 131-137.	1.2	271
33	Use of Follicle-Stimulating Hormone Test to Predict Poor Response in In Vitro Fertilization. Obstetrics and Gynecology, 2005, 105, 645-652.	1.2	16
34	Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups. Fertility and Sterility, 2005, 83, 1717-1723.	0.5	236
35	Polycystic ovary syndrome in Mexican-Americans: prevalence and association with the severity of insulin resistance. Fertility and Sterility, 2005, 84, 766-769.	0.5	90
36	Anatomical evidence for in utero androgen exposure in women with polycystic ovary syndrome. Fertility and Sterility, 2005, 84, 1689-1692.	0.5	80
37	Polycystic ovary syndrome in adolescent girls. Seminars in Pediatric Surgery, 2005, 14, 111-117.	0.5	18
38	Ovarian steroids modulate neuroendocrine dysfunction in polycystic ovary syndrome. Journal of Endocrinological Investigation, 2005, 28, 882-892.	1.8	19
39	LH suppression following different low doses of the GnRH antagonist ganirelix in polycystic ovary syndrome. Journal of Endocrinological Investigation, 2005, 28, 990-997.	1.8	9
40	Patient-tailored conventional ovulation induction algorithms in anovulatory infertility. Trends in Endocrinology and Metabolism, 2005, 16, 381-389.	3.1	36
41	Prevalence of ultrasonography proved polycystic ovaries in North Indian women with type 2 diabetes mellitus. Reproductive Biology and Endocrinology, 2005, 3, 35.	1.4	25

#	Article	IF	Citations
43	Polycystic Ovary Syndrome in Adolescents. Paediatric Drugs, 2006, 8, 311-318.	1.3	38
44	Relationship between epidemiological features and aetiology of male infertility as diagnosed by a comprehensive infertility service provider. Reproductive BioMedicine Online, 2006, 12, 209-214.	1.1	21
45	The CC genotype of the GNAS T393C polymorphism is associated with obesity and insulin resistance in women with polycystic ovary syndrome. European Journal of Endocrinology, 2006, 155, 763-770.	1.9	16
46	Diagnosis, epidemiology, and genetics of the polycystic ovary syndrome. Best Practice and Research in Clinical Endocrinology and Metabolism, 2006, 20, 193-205.	2.2	135
47	Valproate Is Associated with New-Onset Oligoamenorrhea with Hyperandrogenism in Women with Bipolar Disorder. Biological Psychiatry, 2006, 59, 1078-1086.	0.7	117
48	Short-term effect of orlistat on dietary glycotoxins in healthy women and women with polycystic ovary syndrome. Metabolism: Clinical and Experimental, 2006, 55, 494-500.	1.5	33
49	Changes in weight, papilledema, headache, visual field, and life status in response to diet and metformin in women with idiopathic intracranial hypertension with and without concurrent polycystic ovary syndrome or hyperinsulinemia. Translational Research, 2006, 148, 215-222.	2.2	23
50	Genetic analysis of the follicle stimulating hormone receptor gene in women with polycystic ovary syndrome. Journal of Endocrinological Investigation, 2006, 29, 975-982.	1.8	20
51	Neonatal outcome in polycystic ovarian syndrome patients treated with metformin during pregnancy. Journal of Maternal-Fetal and Neonatal Medicine, 2006, 19, 415-419.	0.7	29
52	Higher-order multiple pregnancy associated with metformin in women with polycystic ovary syndrome: two cases and review of the literature. Fertility and Sterility, 2006, 85, 227.e1-227.e4.	0.5	5
53	Diagnosis of polycystic ovaries by three-dimensional transvaginal ultrasound. Fertility and Sterility, 2006, 85, 214-219.	0.5	82
54	Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility, 2006, 85, 996-1001.	0.5	87
55	Two weeks of metformin improves clomiphene citrate-induced ovulation and metabolic profiles in women with polycystic ovary syndrome. Fertility and Sterility, 2006, 85, 1448-1451.	0.5	60
56	Polymorphisms of the peroxisome proliferatorâ€“activated receptor-Î³ and its coactivator-1Î± genes in Chinese women with polycystic ovary syndrome. Fertility and Sterility, 2006, 85, 1536-1540.	0.5	34
57	How many of the items in the polycystic ovary syndrome can be validated statistically?. Fertility and Sterility, 2006, 85, 529.	0.5	4
58	How many of the items in the polycystic ovary syndrome can be validated statistically?. Fertility and Sterility, 2006, 85, 530-531.	0.5	2
59	Family size in women with polycystic ovary syndrome. Fertility and Sterility, 2006, 85, 1837-1839.	0.5	16
60	Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome. Fertility and Sterility, 2006, 86, 385-397.	0.5	60

#	Article	IF	Citations
61	Single nucleotide polymorphism in exon 17 of the insulin receptor gene is not associated with polycystic ovary syndrome in a Korean population. Fertility and Sterility, 2006, 86, 380-384.	0.5	41
62	Prognostic factors for ovulatory response with clomiphene citrate in polycystic ovary syndrome. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2006, 126, 201-205.	0.5	20
63	Polycystic ovarian syndrome, insulin resistance and thickness of the endometrium. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2006, 127, 218-221.	0.5	31
64	Follicular sterol composition in gonadotrophin stimulated women with polycystic ovarian syndrome. Molecular and Cellular Endocrinology, 2006, 249, 92-98.	1.6	15
65	Prevalence of Metabolic Syndrome in Young Korean Women with Polycystic Ovary Syndrome. The Journal of Korean Diabetes Association, 2006, 30, 285.	0.1	3
68	Comparing rosiglitazone with ethinylestradiol/cyproterone acetate in the treatment of polycystic ovary syndrome. Expert Review of Obstetrics and Gynecology, 2006, 1, 81-92.	0.4	2
69	The adolescent gynecology patient. Expert Review of Obstetrics and Gynecology, 2006, 1, 49-56.	0.4	0
70	Polycystic Ovary Syndrome and Mental Health: A Review. Obstetrical and Gynecological Survey, 2006, 61, 723-732.	0.2	168
71	Metabolic disorders in patients with recent gestational diabetes mellitus. Journal of Obstetrics and Gynaecology Research, 2006, 32, 408-415.	0.6	12
72	Pituitary?ovarian response to the gonadotrophin-releasing hormone-agonist test in anovulatory patients with polycystic ovary syndrome: predictive role of ovarian stroma. Clinical Endocrinology, 2006, 65, 396-401.	1.2	15
73	Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome. Clinical Endocrinology, 2006, 66, 061031010617005-???.	1.2	47
74	Ovarian and Adrenal Hyperandrogenism. Annals of the New York Academy of Sciences, 2006, 1092, 130-137.	1.8	44
75	Indices of Low-Grade Inflammation in Polycystic Ovary Syndrome. Annals of the New York Academy of Sciences, 2006, 1092, 175-186.	1.8	98
76	Insulin Resistance in PCOS. Endocrine, 2006, 30, 13-18.	2.2	114
77	Diagnostic Criteria for Polycystic Ovarian Syndrome. Endocrine, 2006, 30, 3-12.	2.2	46
78	Preconception Care Between Pregnancies: The Content of Internatal Care. Maternal and Child Health Journal, 2006, 10, 107-122.	0.7	112
81	Risk of T2DM and impaired fasting glucose among pcos subjects: Results of an 8-year follow-up. Current Diabetes Reports, 2006, 6, 77-83.	1.7	117
82	Polycystic ovarian syndrome â€“ prognosis and outcomes. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2006, 20, 751-778.	1.4	52

#	Article	IF	Citations
83	Metformin treatment of polycystic ovary syndrome improves health-related quality-of-life, emotional distress and sexuality. Human Reproduction, 2006, 21, 1925-1934.	0.4	99
84	Genomic and post-genomic approaches to polycystic ovary syndrome--progress so far: Mini Review. Human Reproduction, 2006, 21, 2766-2775.	0.4	48
85	Outcome of clinical pregnancies after ovulation induction using metformin. Journal of Obstetrics and Gynaecology, 2006, 26, 233-235.	0.4	18
86	Is it Necessary to Measure Free Testosterone to Assess Hyperandrogenemia in Women? The Role of Calculated Free and Bioavailable Testosterone. Experimental and Clinical Endocrinology and Diabetes, 2006, 114, 182-187.	0.6	23
87	Low Serum 25-Hydroxyvitamin D Concentrations are Associated with Insulin Resistance and Obesity in Women with Polycystic Ovary Syndrome. Experimental and Clinical Endocrinology and Diabetes, 2006, 114, 577-583.	0.6	250
88	Endocrinology of Recurrent Pregnancy Loss. Seminars in Reproductive Medicine, 2006, 24, 033-039.	0.5	88
89	Serum inhibin A, VEGF and TNFÎ± levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Human Reproduction, 2006, 21, 1260-1265.	0.4	150
90	The Combination of Increased Ovarian Volume and Follicle Number is Associated with More Severe Hyperandrogenism in German Women with Polycystic Ovary Syndrome. Experimental and Clinical Endocrinology and Diabetes, 2006, 114, 175-181.	0.6	25
91	The Evaluation of the Role of Beta-Hydroxy Fatty Acids on Chronic Inflammation and Insulin Resistance. Mediators of Inflammation, 2006, 2006, 1-6.	1.4	9
92	The LH/FSH ratio has little use in diagnosing polycystic ovarian syndrome. Annals of Clinical Biochemistry, 2006, 43, 217-219.	0.8	47
93	Investigation of adrenal functions in patients with idiopathic hyperandrogenemia. European Journal of Endocrinology, 2006, 155, 307-311.	1.9	8
94	A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome. Human Reproduction Update, 2006, 12, 13-21.	5.2	344
95	Are polycystic ovaries associated with cardiovascular disease risk as polycystic ovary syndrome?. Gynecological Endocrinology, 2006, 22, 324-328.	0.7	22
96	Depression and Body Image among Women with Polycystic Ovary Syndrome. Journal of Health Psychology, 2006, 11, 613-625.	1.3	201
97	Association between Circulating Tumor Necrosis Factor-Alpha, Interleukin-6, and Insulin Resistance in Normal-Weight Women with Polycystic Ovary Syndrome. Metabolic Syndrome and Related Disorders, 2006, 4, 122-128.	0.5	77
98	Polycystic ovary syndrome in bulimic women â€“ an evaluation based on the new diagnostic criteria. Gynecological Endocrinology, 2006, 22, 388-394.	0.7	49
99	Metformin-Diet Ameliorates Coronary Heart Disease Risk Factors and Facilitates Resumption of Regular Menses in Adolescents with Polycystic Ovary Syndrome. Journal of Pediatric Endocrinology and Metabolism, 2006, 19, 831-42.	0.4	45
100	Intractable Early Childhood Obesity as the Initial Sign of Insulin Resistant Hyperinsulinism and Precursor of Polycystic Ovary Syndrome. Journal of Pediatric Endocrinology and Metabolism, 2007, 20, 41-51.	0.4	44

#	Article	IF	Citations
101	The Impact of Simultaneous Measurement of Testosterone and Androstenedione in Women with Suspected Androgen Excess. Clinical Chemistry, 2007, 53, 804-805.	1.5	3
102	Polycystic Ovary Syndrome and Pregnancy: Is Metformin the Magic Bullet?. Diabetes Spectrum, 2007, 20, 85-89.	0.4	8
104	Female infertility due to abnormal autoimmunity: frequently overlooked and greatly underappreciated. Part II. Expert Review of Obstetrics and Gynecology, 2007, 2, 465-475.	0.4	10
105	Calpain-10 variants and haplotypes are associated with polycystic ovary syndrome in Caucasians. American Journal of Physiology - Endocrinology and Metabolism, 2007, 292, E836-E844.	1.8	31
106	Evidence of subpopulations with different levels of insulin resistance in women with polycystic ovary syndrome. Human Reproduction, 2007, 22, 2974-2980.	0.4	38
107	Suitability of recommended limits for fasting glucose tests in women with polycystic ovary syndrome. Cmaj, 2007, 176, 933-938.	0.9	28
108	Prevalence of the Metabolic Syndrome in German Women with Polycystic Ovary Syndrome. Experimental and Clinical Endocrinology and Diabetes, 2007, 115, 130-135.	0.6	74
110	The metabolic syndrome in women. Nature Clinical Practice Endocrinology and Metabolism, 2007, 3, 696-704.	2.9	101
111	Obesity and Polycystic Ovary Syndrome. Obesity Management, 2007, 3, 69-73.	0.2	170
112	Activin A and Follistatin in Menstrual Blood: Low Concentrations in Women With Dysfunctional Uterine Bleeding. Reproductive Sciences, 2007, 14, 383-389.	1.1	11
113	Retinol-binding protein 4 levels are elevated in polycystic ovary syndrome women with obesity and impaired glucose metabolism. European Journal of Endocrinology, 2007, 157, 201-207.	1.9	40
114	Age-Related Changes in Antral Follicle Count among Women with and without Polycystic Ovaries. Gynecologic and Obstetric Investigation, 2007, 64, 199-203.	0.7	10
115	Diagnostic value of calculated testosterone indices in the assessment of polycystic ovary syndrome. Clinical Chemistry and Laboratory Medicine, 2007, 45, 202-7.	1.4	57
116	Influence of Body Mass Index on Measured and Calculated Androgen Parameters in Adult Women with Hirsutism and PCOS. Experimental and Clinical Endocrinology and Diabetes, 2007, 115, 380-386.	0.6	38
117	Polycystic Ovarian Syndrome and Obstructive Sleep Apnea. Current Respiratory Medicine Reviews, 2007, 3, 278-281.	0.1	0
118	Acceleration of Luteinizing Hormone Pulse Frequency in Adolescent Girls with a History of Central Precocious Puberty with versus without Hyperandrogenism. Hormone Research in Paediatrics, 2007, 68, 278-285.	0.8	10
119	Influence of pesticides on male fertility. Scandinavian Journal of Work, Environment and Health, 2007, 33, 13-28.	1.7	83
120	Diagnostic Performance of Serum Total Testosterone for Japanese Patients with Polycystic Ovary Syndrome. Endocrine Journal, 2007, 54, 233-238.	0.7	20

#	Article	IF	Citations
121	Diagnosis of Polycystic Ovary Syndrome. Clinical Obstetrics and Gynecology, 2007, 50, 168-177.	0.6	80
122	Acromegaly Masquerading as Polycystic Ovary Syndrome. , 2007, 17, 119-121.		0
123	Polycystic Ovary Syndrome: Early Detection in the Adolescent. Clinical Obstetrics and Gynecology, 2007, 50, 178-187.	0.6	51
124	Genetic approaches to polycystic ovarian syndrome. Current Opinion in Obstetrics and Gynecology, 2007, 19, 355-359.	0.9	22
125	Reproductive endocrine function in women with epilepsy: The role of epilepsy type and medication. Epilepsy and Behavior, 2007, 10, 77-83.	0.9	55
126	Safety of testosterone treatment in postmenopausal women. Fertility and Sterility, 2007, 88, 1-17.	0.5	108
127	Molecular mechanisms of insulin resistance and associated diseases. Clinica Chimica Acta, 2007, 375, 20-35.	0.5	240
128	Need for liver evaluation in polycystic ovary syndrome. Journal of Hepatology, 2007, 47, 313-315.	1.8	12
129	Polycystic ovary syndrome in men: Steinâ€“Leventhal syndrome revisited. Medical Hypotheses, 2007, 68, 480-483.	0.8	31
130	Gender-Specific Care of Diabetes. Women's Health, 2007, 3, 735-764.	0.7	3
131	Metformin before and during pregnancy and lactation in polycystic ovary syndrome. Expert Opinion on Drug Safety, 2007, 6, 191-198.	1.0	34
132	Dermatologic Manifestations of Polycystic Ovary Syndrome. American Journal of Clinical Dermatology, 2007, 8, 201-219.	3.3	75
133	Characteristics of different phenotypes of polycystic ovary syndrome in a Bulgarian population. Gynecological Endocrinology, 2007, 23, 604-609.	0.7	55
134	Efficacy of an oral contraceptive containing drospirenone in the treatment of women with polycystic ovary syndrome. European Journal of Contraception and Reproductive Health Care, 2007, 12, 30-35.	0.6	42
135	Effects of polycystic ovary syndrome on health-related quality of life. Expert Review of Pharmacoeconomics and Outcomes Research, 2007, 7, 597-603.	0.7	13
136	A patient with combined polycystic ovary syndrome and autoimmune polyglandular syndrome type 2. Gynecological Endocrinology, 2007, 23, 252-256.	0.7	10
137	Cardiovascular complications of obesity in adolescents. Journal of Endocrinological Investigation, 2007, 30, 70-80.	1.8	31
138	Prevalence and metabolic characteristics of adrenal androgen excess in hyperandrogenic women with different phenotypes. Journal of Endocrinological Investigation, 2007, 30, 111-116.	1.8	50

#	Article	IF	Citations
139	Luteinizing hormone pulsatility in patients with major ovarian hyperandrogenism. Journal of Endocrinological Investigation, 2007, 30, 636-646.	1.8	7
140	Total ghrelin levels during acute insulin infusion in patients with polycystic ovary syndrome. Journal of Endocrinological Investigation, 2007, 30, 820-827.	1.8	25
141	Polycystic Ovary Syndrome: A Common Reproductive and Metabolic Disorder Necessitating Early Recognition and Treatment. Primary Care - Clinics in Office Practice, 2007, 34, 761-789.	0.7	17
142	Prevalence of Nonalcoholic Fatty Liver Disease in Women With Polycystic Ovary Syndrome. Clinical Gastroenterology and Hepatology, 2007, 5, 496-501.	2.4	156
143	Does measuring early basal serum follicular lutinising hormone assist in predicting In vitro fertilization (IVF)/Intracytoplasmic sperm injection (ICSI) outcome?. Reproductive Biology and Endocrinology, 2007, 5, 32.	1.4	5
144	Association of Serum and Follicular Fluid Leptin Concentrations with Granulosa Cell Phosphorylated Signal Transducer and Activator of Transcription 3 Expression in Fertile Patients with Polycystic Ovarian Syndrome. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4771-4776.	1.8	35
145	Glucose tolerance abnormalities in Australian women with polycystic ovary syndrome. Medical Journal of Australia, 2007, 187, 328-331.	0.8	32
146	Efficacy of laparoscopic ovarian drilling for polycystic ovary syndrome resistant to clomiphene citrate. Journal of Obstetrics and Gynaecology Research, 2007, 33, 174-180.	0.6	16
147	Clinical, endocrine and ultrasonographic features of polycystic ovary syndrome in Thai women. Journal of Obstetrics and Gynaecology Research, 2007, 33, 677-680.	0.6	27
148	Quality of life and psychological morbidity in women with polycystic ovary syndrome: body mass index, age and the provision of patient information are significant modifiers. Clinical Endocrinology, 2007, 66, 373-379.	1.2	174
149	Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome. Clinical Endocrinology, 2007, 66, 070213054521008-???.	1.2	161
150	Lack of electrocardiographic changes in women with polycystic ovary syndrome. Clinical Endocrinology, 2007, 67, 46-50.	1.2	5
151	Unravelling the phenotypic map of polycystic ovary syndrome (PCOS): a prospective study of 634 women with PCOS. Clinical Endocrinology, 2007, 67, 735-742.	1.2	156
152	Total and high molecular weight (HMW) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placeboâ€controlled study in polycystic ovary syndrome. Clinical Endocrinology, 2008, 68, 165-174.	1.2	38
153	Endocrine Effects of Valproate in Adolescent Girls with Epilepsy. Epilepsia, 2007, 48, 470-477.	2.6	59
154	Peroxisome Proliferatorâ€Activated Receptors: New Players in the Field of Reproduction. American Journal of Reproductive Immunology, 2007, 58, 289-310.	1.2	42
155	Vascular Compliance in Women With Polycystic Ovary Syndrome and Healthy Women. Journal of the Cardiometabolic Syndrome, 2007, 2, 40-44.	1.7	3
156	Practice patterns of screening for sleep apnea in physicians treating PCOS patients. Sleep and Breathing, 2007, 11, 233-237.	0.9	25

#	Article	IF	Citations
157	The adrenal and polycystic ovary syndrome. Reviews in Endocrine and Metabolic Disorders, 2007, 8, 331-342.	2.6	109
158	The association of TAAAAn repeat polymorphism in sex hormone-binding protein gene with polycystic ovary syndrome in Chinese population. Endocrine, 2008, 34, 62-67.	1.1	11
159	Hyperandrogenism, ovulatory dysfunction, and polycystic ovary syndrome with valproate versus lamotrigine. Annals of Neurology, 2008, 64, 200-211.	2.8	92
160	Management of polycystic ovarian syndrome. Trends in Urology Gynaecology & Sexual Health, 2008, 13, 14-19.	0.1	2
161	The Pathophysiology of Amenorrhea in the Adolescent. Annals of the New York Academy of Sciences, 2008, 1135, 163-178.	1.8	96
162	Endocrine and metabolic differences among phenotypic expressions of polycystic ovary syndrome according to the 2003 Rotterdam consensus criteria. American Journal of Obstetrics and Gynecology, 2008, 198, 670.e1-670.e10.	0.7	88
163	ORIGINAL ARTICLE: Paternal Thrombophilic Gene Mutations Are Not Associated with Recurrent Miscarriage. American Journal of Reproductive Immunology, 2008, 60, 325-332.	1.2	33
164	ORIGINAL ARTICLE: The Polycystic Ovary Syndrome Does Not Predict Further Miscarriage in Japanese Couples Experiencing Recurrent Miscarriages. American Journal of Reproductive Immunology, 2009, 61, 62-67.	1.2	18
165	Retinol-binding protein in nonobese women with polycystic ovary syndrome. Clinical Endocrinology, 2008, 68, 786-790.	1.2	4
166	Metabolic and cardiopulmonary effects of detraining after a structured exercise training programme in young PCOS women. Clinical Endocrinology, 2008, 68, 976-981.	1.2	45
167	Cardiometabolic abnormalities in the polycystic ovary syndrome: Pharmacotherapeutic insights. , 2008, 119, 223-241.		38
169	HMG-CoA Reductase Inhibitors. Drugs, 2008, 68, 1771-1785.	4.9	24
170	Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications. Expert Reviews in Molecular Medicine, 2008, 10, e3.	1.6	217
171	Active smoking compromises IVF outcome and affects ovarian reserve. Reproductive BioMedicine Online, 2008, 16, 96-102.	1.1	148
173	Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1105-1120.	1.8	372
174	Effects of environmental and occupational pesticide exposure on human sperm: a systematic review. Human Reproduction Update, 2008, 14, 233-242.	5.2	126
175	Menstrual confusion. International Journal of Gynecology and Obstetrics, 2008, 100, 1-3.	1.0	3
176	Whither PCOS? The Challenges of Establishing Hyperandrogenism in Adolescent Girls. Journal of Adolescent Health, 2008, 43, 103-105.	1.2	27

#	Article	IF	Citations
177	A novel single nucleotide polymorphism of INSR gene for polycystic ovary syndrome. Fertility and Sterility, 2008, 89, 1213-1220.	0.5	44
178	Association of genetic variants of insulin degrading enzyme with metabolic features in women with polycystic ovary syndrome. Fertility and Sterility, 2008, 90, 378-384.	0.5	13
179	Association study between single nucleotide polymorphisms in the VEGF gene and polycystic ovary syndrome. Fertility and Sterility, 2008, 89, 1751-1759.	0.5	27
180	Pregnancy loss in pregnancies conceived after in vitro oocyte maturation, conventional in vitro fertilization, and intracytoplasmic sperm injection. Fertility and Sterility, 2008, 90, 546-550.	0.5	95
181	Clinical and metabolic characteristics of polycystic ovary syndrome without polycystic ovary: a pilot study on Chinese women. Fertility and Sterility, 2008, 90, 1139-1143.	0.5	14
182	FTO gene associates to metabolic syndrome in women with polycystic ovary syndrome. Biochemical and Biophysical Research Communications, 2008, 373, 230-234.	1.0	80
183	Low-grade chronic inflammation is not accompanied by structural arterial injury in polycystic ovary syndrome. Diabetes Research and Clinical Practice, 2008, 81, 179-183.	1.1	19
184	Clinical and metabolic effects of medroxyprogesterone acetate and ethinyl estradiol plus drospirenone in women with polycystic ovary syndrome. International Journal of Gynecology and Obstetrics, 2008, 103, 44-49.	1.0	28
187	Response to paroxetine and venlafaxine in OCD is not determined by common CYP2D6 polymorphisms. Journal of Biotechnology, 2008, 136, S190.	1.9	0
188	Insulin Gene Polymorphism in Women with Polycystic Ovary Syndrome. Journal of International Medical Research, 2008, 36, 1180-1187.	0.4	20
189	Ovarian hyperthecosis and response to antiandrogens: An uncommon presentation of a common disorder. Journal of Obstetrics and Gynaecology, 2008, 28, 249-250.	0.4	1
190	Rosiglitazone as Treatment for Clomiphene Citrate-Resistant Polycystic Ovary Syndrome: Factors Associated with Clinical Response. Journal of Women's Health, 2008, 17, 1445-1452.	1.5	11
191	Oxidative Stress in Nonobese Women with Polycystic Ovary Syndrome: Correlations with Endocrine and Screening Parameters. Gynecologic and Obstetric Investigation, 2008, 65, 233-239.	0.7	56
192	Polycystic ovary syndrome in women using valproate: A review. Gynecological Endocrinology, 2008, 24, 562-570.	0.7	62
193	Differences in low-grade chronic inflammation and insulin resistance in women with previous gestational diabetes mellitus and women with polycystic ovary syndrome. Gynecological Endocrinology, 2008, 24, 199-206.	0.7	39
194	Associations between serum testosterone levels, cell proliferation and progesterone receptor content in normal and malignant breast tissue in postmenopausal women. Gynecological Endocrinology, 2008, 24, 405-410.	0.7	10
195	Shorter CAG repeats in the androgen receptor gene may enhance hyperandrogenicity in polycystic ovary syndrome. Gynecological Endocrinology, 2008, 24, 669-673.	0.7	37
196	Serum ghrelin level in women with polycystic ovary syndrome and its relationship with endocrine and metabolic parameters. Gynecological Endocrinology, 2008, 24, 625-630.	0.7	24

#	Article	IF	Citations
197	A 31-year-old woman with infertility and polycystic ovaries diagnosed with non-classic congenital adrenal hyperplasia due to a novel CYP21 mutation. Journal of Endocrinological Investigation, 2008, 31, 176-180.	1.8	23
198	Follicle dynamics and anovulation in polycystic ovary syndrome. Human Reproduction Update, 2008, 14, 367-378.	5.2	460
199	LDL Species Heterogeneity in the Atherogenic Dyslipidemia of Polycystic Ovary Syndrome. American Journal of Clinical Pathology, 2008, 129, 802-810.	0.4	13
200	Assessment, diagnosis and treatment of a patient with hirsutism. Nature Clinical Practice Endocrinology and Metabolism, 2008, 4, 294-300.	2.9	17
201	Androgens and Insulin â€“ Two Key Players in Polycystic Ovary Syndrome. Gynakologisch-geburtshilfliche Rundschau, 2008, 48, 9-15.	0.9	38
202	An RCT of metformin versus orlistat for the management of obese anovulatory women. Human Reproduction, 2008, 24, 966-975.	0.4	38
203	Randomized controlled trial comparing laparoscopic ovarian diathermy with clomiphene citrate as a first-line method of ovulation induction in women with polycystic ovary syndrome. Human Reproduction, 2008, 24, 219-225.	0.4	65
204	Management of polycystic ovary syndrome in postmenopausal women: a medical black hole. Climacteric, 2008, 11, 89-90.	1.1	4
205	Psychological implications of infertility in women with polycystic ovary syndrome. Human Reproduction, 2008, 23, 2064-2071.	0.4	96
206	Ovarian Stimulation in Obese and Non-Obese Polycystic Ovary Syndrome Using a Low-Dose Step-Up Regimen with Two Different Starting Doses of Recombinant Follicle-Stimulating Hormone. Journal of International Medical Research, 2008, 36, 1197-1204.	0.4	7
207	Soluble CD36 and Risk Markers of Insulin Resistance and Atherosclerosis Are Elevated in Polycystic Ovary Syndrome and Significantly Reduced During Pioglitazone Treatment. Diabetes Care, 2008, 31, 328-334.	4.3	89
208	Comparison of Single and Combined Treatment with Exenatide and Metformin on Menstrual Cyclicity in Overweight Women with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2670-2678.	1.8	195
209	Impaired Insulin Activation and Dephosphorylation of Glycogen Synthase in Skeletal Muscle of Women with Polycystic Ovary Syndrome Is Reversed by Pioglitazone Treatment. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3618-3626.	1.8	35
211	Obesity, body composition and metabolic disturbances in polycystic ovary syndrome. Human Reproduction, 2008, 23, 2113-2121.	0.4	80
212	Pregnancy loss following treatment with assisted reproductive technologies. Expert Review of Obstetrics and Gynecology, 2008, 3, 767-774.	0.4	2
213	Diagnostic Criteria for Polycystic Ovary Syndrome: Pitfalls and Controversies. Journal of Obstetrics and Gynaecology Canada, 2008, 30, 671-679.	0.3	125
214	Insulin-sensitizing agents and reproductive function in polycystic ovary syndrome patients. Current Opinion in Obstetrics and Gynecology, 2008, 20, 364-373.	0.9	14
215	Metabolic complications of obesity in childhood and adolescence: more than just diabetes. Current Opinion in Endocrinology, Diabetes and Obesity, 2008, 15, 21-29.	1.2	140

#	Article	IF	Citations
216	Diagnosis of Metabolic Disorders in Women with Polycystic Ovary Syndrome. Obstetrical and Gynecological Survey, 2008, 63, 796-802.	0.2	14
217	A single nucleotide polymorphism in exon 7 of sorbin and SH3-domain-containing-1 (SORBS1) in Korean PCOS patients. Molecular Medicine Reports, 0, , .	1.1	2
219	Treatment for polycystic ovary syndrome: a critical appraisal of treatment options. Expert Review of Endocrinology and Metabolism, 2008, 3, 349-359.	1.2	4
220	Pediatric, Adolescent, & Young Adult Gynecology. , 2009, , .		9
221	Recombinant follitropin alfa/lutropin alfa in fertility treatment. Biologics: Targets and Therapy, 2009, , 5.	3.0	6
222	European Consensus onÂtheÂevaluation ofÂwomen presenting withÂexcessive hair growth. European Journal of Dermatology, 2009, 19, 597-602.	0.3	28
223	Polycystic Ovary Syndrome, Depression, and Affective Disorders. Endocrine Practice, 2009, 15, 475-482.	1.1	24
224	Current trends in the treatment of polycystic ovary syndrome with desire for children. Therapeutics and Clinical Risk Management, 2009, 5, 353.	0.9	13
225	Anteroposterior diameter of the infrarenal abdominal aorta is higher in women with polycystic ovary syndrome. Vascular Health and Risk Management, 2009, 5, 561.	1.0	26
226	Polycystic Ovary Syndrome, Obesity and Reproductive Implications. Women's Health, 2009, 5, 529-542.	0.7	54
227	Aromatase Inhibitors for Ovulation and Pregnancy in Polycystic Ovary Syndrome. Annals of Pharmacotherapy, 2009, 43, 1338-1346.	0.9	13
228	Insulin sensitizers for women with polycystic ovarian syndrome. Expert Review of Endocrinology and Metabolism, 2009, 4, 183-192.	1.2	3
229	Clinical biochemistry of assisted conception. Annals of Clinical Biochemistry, 2009, 46, 197-204.	0.8	1
230	Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Human Reproduction Update, 2009, 15, 477-488.	5.2	284
231	Anti-MÃ¼llerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. American Journal of Physiology - Endocrinology and Metabolism, 2009, 296, E238-E243.	1.8	258
232	Long-Term Effects of Valproic Acid on Reproductive Endocrine Functions in Turkish Women with Epilepsy. Gynecologic and Obstetric Investigation, 2009, 67, 223-227.	0.7	15
233	The interaction between follicular fluid total antioxidant capacity, infertility and early reproductive outcomes duringin vitrofertilization. Redox Report, 2009, 14, 205-213.	1.4	13
234	Efficacy of ER-Î± Polymorphisms and the Intrafollicular IGF System for Predicting Pregnancy in IVF-ET Patients. Gynecologic and Obstetric Investigation, 2009, 67, 73-80.	0.7	12

#	Article	IF	Citations
235	Insulin Modulation of Luteinizing Hormone Secretion in Normal Female Volunteers and Lean Polycystic Ovary Syndrome Patients. Neuroendocrinology, 2009, 89, 131-139.	1.2	58
236	No association of the Arg51Gln and Leu72Met polymorphisms of the ghrelin gene and polycystic ovary syndrome. Human Reproduction, 2009, 24, 485-490.	0.4	14
237	Long-term follow-up of patients with polycystic ovary syndrome: reproductive outcome and ovarian reserve. Human Reproduction, 2009, 24, 1176-1183.	0.4	99
238	In GnRH antagonist/rec-FSH stimulated cycles, advanced endometrial maturation on the day of oocyte retrieval correlates with altered gene expression. Human Reproduction, 2009, 24, 1085-1091.	0.4	84
239	Pharmacological Options for Treatment of Hyperandrogenic Disorders. Mini-Reviews in Medicinal Chemistry, 2009, 9, 1113-1126.	1.1	4
240	Thyroid-stimulating hormone is associated with insulin resistance independently of body mass index and age in women with polycystic ovary syndrome. Human Reproduction, 2009, 24, 2924-2930.	0.4	68
241	Abnormal Uterine Bleeding: a Focus on Polycystic Ovary Syndrome. Women's Health, 2009, 5, 313-324.	0.7	5
243	Polycystic Ovarian Syndrome and the Risk of Cardiovascular Disease and Thrombosis. Seminars in Thrombosis and Hemostasis, 2009, 35, 613-620.	1.5	44
244	Pharmacogenomics of ovulation induction: facilitating decisions on who, when and how to treat. Pharmacogenomics, 2009, 10, 1377-1379.	0.6	7
245	The mean and the biological variation of insulin resistance does not differ between polycystic ovary syndrome and type 2 diabetes. Annals of Clinical Biochemistry, 2009, 46, 218-221.	0.8	9
246	Continuation of metformin in the first trimester of women with polycystic ovarian syndrome is not associated with increased perinatal morbidity. European Journal of Pediatrics, 2009, 168, 203-206.	1.3	38
247	Comparison of letrozole with continuous gonadotropins and clomiphene-gonadotropin combination for ovulation induction in 1387 PCOS women after clomiphene citrate failure: a randomized prospective clinical trial. Journal of Assisted Reproduction and Genetics, 2009, 26, 19-24.	1.2	63
248	Evaluating the equivalence of clomiphene citrate with and without metformin in ovulation induction in PCOS patients. Journal of Assisted Reproduction and Genetics, 2009, 26, 165-171.	1.2	17
249	Clinical spectrum of premature pubarche: Links to metabolic syndrome and ovarian hyperandrogenism. Reviews in Endocrine and Metabolic Disorders, 2009, 10, 63-76.	2.6	85
250	The prevalence and risk factors for glucose intolerance in young Korean women with polycystic ovary syndrome. Endocrine, 2009, 36, 326-332.	1.1	42
251	Association of the common rs9939609 variant of FTO gene with polycystic ovary syndrome in Chinese women. Endocrine, 2009, 36, 377-382.	1.1	42
252	Polycystic ovary syndrome and cardiovascular disease risk. Current Cardiovascular Risk Reports, 2009, 3, 65-70.	0.8	1
253	Construction of a polycystic ovarian syndrome (PCOS) pathway based on the interactions of PCOS-related proteins retrieved from bibliomic data. Theoretical Biology and Medical Modelling, 2009, 6, 18.	2.1	28

#	Article	IF	Citations
254	Relationship between heart rate recovery and inflammatory markers in patients with polycystic ovary syndrome: a cross-sectional study. Journal of Ovarian Research, 2009, 2, 3.	1.3	18
255	Assessment of ultrasonographic features of polycystic ovaries is associated with modest levels of inter-observer agreement. Journal of Ovarian Research, 2009, 2, 6.	1.3	30
256	Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome. Clinical Endocrinology, 2009, 70, 233-237.	1.2	66
257	Plasma monocyte chemoattractant proteinâ€1 (MCPâ€1) and macrophage inflammatory proteinâ€1Î± are increased in patients with polycystic ovary syndrome (PCOS) and associated with adiposity, but unaffected by pioglitazone treatment. Clinical Endocrinology, 2009, 71, 652-658.	1.2	66
258	Nurseâ€led peer support group: experiences of women with polycystic ovary syndrome. Journal of Advanced Nursing, 2009, 65, 2046-2055.	1.5	46
259	Expression of 11Î²-hydroxysteroid dehydrogenase 1 and 2 in subcutaneous adipose tissue of lean and obese women with and without polycystic ovary syndrome. International Journal of Obesity, 2009, 33, 1249-1256.	1.6	26
260	An association between nonâ€alcoholic fatty liver disease and polycystic ovarian syndrome. Journal of Gastroenterology and Hepatology (Australia), 2009, 24, 243-247.	1.4	93
261	Effects of an EE/CA compared with EE/CA-metformin on serum ADMA levels in women with polycystic ovary syndrome. Open Medicine (Poland), 2009, 4, 423-427.	0.6	4
262	A comparison between finasteride, flutamide, and finasteride plus flutamide combination in the treatment of hirsutism. Journal of Endocrinological Investigation, 2009, 32, 37-40.	1.8	17
263	Abnormal serum alanine aminotransferase levels are associated with impaired insulin sensitivity in young women with polycystic ovary syndrome. Journal of Endocrinological Investigation, 2009, 32, 695-700.	1.8	32
264	Association between a single nucleotide polymorphism in MTHFR gene and polycystic ovary syndrome. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2009, 145, 85-88.	0.5	26
265	Infertile women with isolated polycystic ovaries are deficient in endometrial expression of osteopontin but not Î±vÎ²3 integrin during the implantation window. Fertility and Sterility, 2009, 91, 489-499.	0.5	27
266	Body mass index is an independent risk factor for the development of endometrial polyps in patients undergoing in vitro fertilization. Fertility and Sterility, 2009, 91, 1056-1060.	0.5	64
268	Comparison of hormonal and metabolic markers after a high-fat, Western meal versus a low-fat, high-fiber meal in women with polycystic ovary syndrome. Fertility and Sterility, 2009, 91, 1175-1182.	0.5	25
269	Inappropriate gonadotropin secretion in polycystic ovary syndrome. Fertility and Sterility, 2009, 91, 1168-1174.	0.5	46
270	Efficacy predictors for metformin and clomiphene citrate treatment in anovulatory infertile patients with polycystic ovary syndrome. Fertility and Sterility, 2009, 91, 2557-2567.	0.5	35
271	Endothelial function and its relationship to leptin, homocysteine, and insulin resistance in lean and overweight eumenorrheic women and PCOS patients: a pilot study. Fertility and Sterility, 2009, 91, 2537-2544.	0.5	37
272	Morbid obesity is associated with lower clinical pregnancy rates after in vitro fertilization in women with polycystic ovary syndrome. Fertility and Sterility, 2009, 92, 256-261.	0.5	106

#	Article	IF	Citations
273	Degree of hyperinsulinemia, independent of androgen levels, is an important determinant of the severity of hirsutism in PCOS. Fertility and Sterility, 2009, 92, 643-647.	0.5	59
274	The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertility and Sterility, 2009, 91, 456-488.	0.5	1,639
275	What is the preferred GnRH analogue for polycystic ovary syndrome patients undergoing controlled ovarian hyperstimulation for in vitro fertilization?. Fertility and Sterility, 2009, 91, 1466-1468.	0.5	23
276	Adiponectin levels reflect the different phenotypes of polycystic ovary syndrome: study in normal weight, normoinsulinemic patients. Fertility and Sterility, 2009, 92, 2078-2081.	0.5	14
277	Apneaâ€“hypopnea index in nonobese women with polycystic ovary syndrome. International Journal of Gynecology and Obstetrics, 2009, 105, 226-229.	1.0	28
279	Insulin Resistance in PCOS. , 2009, , 35-61.		22
280	Enoxaparin-metformin and enoxaparin alone may safely reduce pregnancy loss. Translational Research, 2009, 153, 33-43.	2.2	19
281	Hyperreninemia Characterizing Women with Polycystic Ovary Syndrome Improves after Metformin Therapy. Kidney and Blood Pressure Research, 2009, 32, 24-31.	0.9	18
282	Fertility Issues in Women with Diabetes. Women's Health, 2009, 5, 701-707.	0.7	63
283	A novel variant of ER-alpha, ER-alpha36 mediates testosterone-stimulated ERK and Akt activation in endometrial cancer Hec1A cells. Reproductive Biology and Endocrinology, 2009, 7, 102.	1.4	57
284	No association of the insulin gene VNTR polymorphism with polycystic ovary syndrome in a Han Chinese population. Reproductive Biology and Endocrinology, 2009, 7, 141.	1.4	18
285	Developmental Programming of Polycystic Ovary Syndrome: Role of Prenatal Androgen Excess. , 2009, , 83-103.		2
286	Diagnosis and Management of Polycystic Ovary Syndrome. , 2009, , .		3
287	Family-Based Association Study of the <i>MCF2L2</i> Gene and Polycystic Ovary Syndrome. Gynecologic and Obstetric Investigation, 2009, 68, 171-173.	0.7	5
288	Nonalcoholic Fatty Liver Disease in Women. Women's Health, 2009, 5, 191-203.	0.7	110
289	A woman with polycystic ovary syndrome treated for infertility by in vitro fertilization. Nature Reviews Endocrinology, 2009, 5, 462-465.	4.3	2
290	The role of genes in the polycystic ovary syndrome: Predisposition and mechanisms. Gynecological Endocrinology, 2009, 25, 603-609.	0.7	47
291	Serum visfatin in Asian women with polycystic ovary syndrome. Gynecological Endocrinology, 2009, 25, 536-542.	0.7	28

#	Article	IF	Citations
292	Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with polycystic ovary syndrome. Gynecological Endocrinology, 2009, 25, 110-116.	0.7	30
293	Metformin administration was associated with a modification of LH, prolactin and insulin secretion dynamics in women with polycystic ovarian syndrome. Gynecological Endocrinology, 2009, 25, 427-434.	0.7	34
294	Serum leptin levels correlate with clinical and biochemical indices of insulin resistance in women with polycystic ovary syndrome. European Journal of Contraception and Reproductive Health Care, 2009, 14, 153-159.	0.6	47
295	Anxiety and depression in adolescents with polycystic ovary syndrome and Mayer-Rokitansky-KÃ¼ster-Hauser syndrome. Journal of Psychosomatic Obstetrics and Gynaecology, 2009, 30, 83-88.	1.1	83
296	The role of serum PRL bioactivity evaluation in hyperprolactinaemic women with different menstrual disorders. Gynecological Endocrinology, 2009, 25, 799-806.	0.7	8
297	DiagnÃ³stico del SÃndrome de Ovario PoliquÃstico: nuevos fenotipos, nuevas incÃ³gnitas. Revista Medica De Chile, 2009, 137, .	0.1	8
298	A Novel Association Between Polycystic Ovary Syndrome and Helicobacter pylori. American Journal of the Medical Sciences, 2009, 338, 174-177.	0.4	21
299	Polycystic Ovary Syndrome and Prolactinoma Association. Internal Medicine, 2009, 48, 611-613.	0.3	11
300	Ovarian Stromal Hyperthecosis. Journal of Ultrasound in Medicine, 2009, 28, 587-593.	0.8	29
301	The Polycystic Ovary Syndrome - Challenges and Opportunities in Adolescent Medicine. , 2009, , 316-339.		1
304	Hyperandrogenism May Explain Reproductive Dysfunction in Olympic Athletes. Medicine and Science in Sports and Exercise, 2009, 41, 1241-1248.	0.2	95
305	Adolescent Gynecology. Obstetrics and Gynecology, 2009, 113, 935-947.	1.2	32
306	Androgen deficiency and therapy in women. Current Opinion in Endocrinology, Diabetes and Obesity, 2010, 17, 342-349.	1.2	12
307	Digit ratios do not serve as anatomical evidence of prenatal androgen exposure in clinical phenotypes of polycystic ovary syndrome. Human Reproduction, 2010, 25, 204-211.	0.4	46
310	Role of Oxidative Stress in Polycystic Ovary Syndrome. Current Women's Health Reviews, 2010, 6, 96-107.	0.1	69
311	Management of polycystic ovary syndrome through puberty and adolescence. , 0, , 71-84.		0
312	Long-term health risks of polycystic ovary syndrome. , 0, , 85-92.		0
313	Metformin and N-acetyl Cysteine in Polycystic Ovarian Syndromeâ€“A Comparative Study. Indian Journal of Clinical Medicine, 2010, 1, 117739361000100.	0.2	11

#	Article	IF	Citations
314	Patterns of ovarian morphology in polycystic ovary syndrome: a study utilising magnetic resonance imaging. European Radiology, 2010, 20, 1207-1213.	2.3	36
315	Oral contraceptives alone and with spironolactone increase sCD40 ligand in PCOS patients. Archives of Gynecology and Obstetrics, 2010, 281, 539-543.	0.8	8
316	High sensitive serum C-reactive protein and its relationship with other cardiovascular risk factors in normoinsulinemic polycystic ovary patients without metabolic syndrome. Archives of Gynecology and Obstetrics, 2010, 281, 1009-1014.	0.8	32
317	Comparison of metformin and clomiphene citrate therapy for induction of ovulation in the polycystic ovary syndrome. Archives of Gynecology and Obstetrics, 2010, 282, 439-443.	0.8	9
319	A 9-bp Deletion Homoplasmy in Women with Polycystic Ovary Syndrome Revealed by Mitochondrial Genome-Mutation Screen. Biochemical Genetics, 2010, 48, 157-163.	0.8	26
320	Effects of Saireito on the ovarian function of patients with polycystic ovary syndrome. Reproductive Medicine and Biology, 2010, 9, 191-195.	1.0	5
321	Age, body mass index, and serum level of DHEA-S can predict glucocorticoid receptor function in women with polycystic ovary syndrome. Endocrine, 2010, 37, 129-134.	1.1	7
322	Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Medicine, 2010, 8, 41.	2.3	950
323	Large effects on body mass index and insulin resistance of fat mass and obesity associated gene (FTO) variants in patients with polycystic ovary syndrome (PCOS). BMC Medical Genetics, 2010, 11, 12.	2.1	75
324	Serum and follicular anti-Mullerian hormone levels in women with polycystic ovary syndrome (PCOS) under metformin. Journal of Ovarian Research, 2010, 3, 16.	1.3	17
325	Changes in androgens and insulin sensitivity indexes throughout pregnancy in women with polycystic ovary syndrome (PCOS): relationships with adverse outcomes. Journal of Ovarian Research, 2010, 3, 23.	1.3	53
326	Metabolic syndrome in young women with the polycystic ovary syndrome: revisiting the threshold for an abnormally decreased highâ€density lipoprotein cholesterol serum level. BJOG: an International Journal of Obstetrics and Gynaecology, 2010, 117, 175-180.	1.1	4
327	The significance of the first Latin American Consensus on polycystic ovary syndrome. International Journal of Clinical Practice, 2010, 64, 536-540.	0.8	0
328	Androgenetic alopecia in the paediatric population: a retrospective review of 57 patients. British Journal of Dermatology, 2010, 163, 378-385.	1.4	57
329	Optimal Waist Circumference for Prediction of Metabolic Syndrome in Young Korean Women With Polycystic Ovary Syndrome. Obesity, 2010, 18, 593-597.	1.5	11
330	Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens. Annals of Hepatology, 2010, 9, 402-409.	0.6	192
331	Obstetric and perinatal outcomes in pregnancies conceived following oocyte cryopreservation. , 2010, , 178-188.		0
332	Ultrasonography and the treatment of infertility in polycystic ovary syndrome. , 0, , 81-86.		0

#	Article	IF	Citations
333	Androgen Receptor CAG Repeat Polymorphism and Epigenetic Influence among the South Indian Women with Polycystic Ovary Syndrome. PLoS ONE, 2010, 5, e12401.	1.1	38
334	Insulin Resistance Is Not Conserved in Myotubes Established from Women with PCOS. PLoS ONE, 2010, 5, e14469.	1.1	24
336	Changes in the Expression of Insulin Signaling Pathway Molecules in Endometria from Polycystic Ovary Syndrome Women with or without Hyperinsulinemia. Molecular Medicine, 2010, 16, 129-136.	1.9	80
337	Role of the transcriptional factors FOXO1 and PPARG on gene expression of SLC2A4 in endometrial tissue from women with polycystic ovary syndrome. Reproduction, 2010, 140, 123-131.	1.1	41
338	Effects of Controlled-Release Alpha Lipoic Acid in Lean, Nondiabetic Patients with Polycystic Ovary Syndrome. Journal of Diabetes Science and Technology, 2010, 4, 359-364.	1.3	57
339	GNRH analog therapy in girls with early puberty is associated with the achievement of predicted final height but also with increased risk of polycystic ovary syndrome. European Journal of Endocrinology, 2010, 163, 55-62.	1.9	54
340	Usefulness of Bezafibrate for Ovulation Induction in Clomiphene Citrate-Resistant Polycystic Ovary Syndrome Patients with Dyslipidemia: A Prospective Pilot Study of Seven Cases. Gynecologic and Obstetric Investigation, 2010, 70, 166-172.	0.7	7
341	Fibrillins in Adult Human Ovary and Polycystic Ovary Syndrome: Is Fibrillin-3 Affected in PCOS?. Journal of Histochemistry and Cytochemistry, 2010, 58, 903-915.	1.3	38
342	Prevalence of Polycystic Ovary Syndrome and Related Disorders in Mexican Women. Gynecologic and Obstetric Investigation, 2010, 69, 274-280.	0.7	111
343	Evaluation of Arterial Blood Pressure and Renal Sodium Handling in a Model of Female Rats in Persistent Estrus. Clinical and Experimental Hypertension, 2010, 32, 385-389.	0.5	3
344	Metforminversusacarbose therapy in patients with polycystic ovary syndrome (PCOS): a prospective randomised double-blind study. Gynecological Endocrinology, 2010, 26, 690-697.	0.7	21
345	The association between follicular size on human chorionic gonadotropin day and pregnancy rate in clomiphene citrate treated polycystic ovary syndrome patients. Gynecological Endocrinology, 2010, 26, 546-548.	0.7	26
346	Oncological repercussions of polycystic ovary syndrome. Gynecological Endocrinology, 2010, 26, 708-711.	0.7	16
347	Hirsutism: investigation and management. Expert Review of Endocrinology and Metabolism, 2010, 5, 189-195.	1.2	4
348	Effects of Oral Contraceptives and Metformin on the Outcome of In Vitro Maturation in Infertile Women with Polycystic Ovary Syndrome. Journal of Women's Health, 2010, 19, 261-265.	1.5	6
349	Hirsutism: from Brazil to a place near you. Expert Opinion on Pharmacotherapy, 2010, 11, 177-183.	0.9	1
350	Ultrasound and its role in assisted reproduction treatment. Imaging in Medicine, 2010, 2, 135-150.	0.0	2
351	Unilateral Ovarian Enlargement in Adolescents with Polycystic Ovary Syndrome: A Variant of Bilateral Disease. Journal of Pediatric Endocrinology and Metabolism, 2010, 23, 87-95.	0.4	1

#	Article	IF	Citations
352	Menstrual dysfunction in rural young women and the presence of polycystic ovarian syndrome. Journal of Obstetrics and Gynaecology, 2010, 30, 41-45.	0.4	15
353	Umbilical vein testosterone in female infants born to mothers with polycystic ovary syndrome is elevated to male levels. Journal of Obstetrics and Gynaecology, 2010, 30, 444-446.	0.4	101
354	Comparison of inter- and intra-cycle variability of anti-Mullerian hormone and antral follicle counts. Human Reproduction, 2010, 25, 221-227.	0.4	295
355	The prevalence of non-classic adrenal hyperplasia among Turkish women with hyperandrogenism. Gynecological Endocrinology, 2010, 26, 139-143.	0.7	24
356	A European Evidence-Based Guideline for the Prevention of Type 2 Diabetes. Hormone and Metabolic Research, 2010, 42, S3-S36.	0.7	385
357	Levels of Rabs and WAVE family proteins associated with translocation of GLUT4 to the cell surface in endometria from hyperinsulinemic PCOS women. Human Reproduction, 2010, 25, 2870-2877.	0.4	21
358	PCOSMIC: a multi-centre randomized trial in women with PolyCystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene. Human Reproduction, 2010, 25, 1675-1683.	0.4	62
359	Systemic and local effects of metformin administration in patients with polycystic ovary syndrome (PCOS): relationship to the ovulatory response. Human Reproduction, 2010, 25, 1005-1013.	0.4	55
360	Very High Frequency of the Polymorphism for the Insulin Receptor Substrate 1 (IRS-1) at Codon 972 (Glycine972Arginine) in Southern Italian Women with Polycystic Ovary Syndrome. Hormone and Metabolic Research, 2010, 42, 575-584.	0.7	25
361	Association of AR rs6152G/A gene polymorphism with susceptibility to polycystic ovary syndrome in Chinese women. Reproduction, Fertility and Development, 2010, 22, 881.	0.1	14
362	Variations in alanine aminotransferase levels within the normal range predict metabolic and androgenic phenotypes in women of reproductive age. Scandinavian Journal of Clinical and Laboratory Investigation, 2010, 70, 554-560.	0.6	8
363	Does the presence of polycystic ovary syndrome increase the risk of obstetrical complications in women with gestational diabetes?. Journal of Maternal-Fetal and Neonatal Medicine, 2010, 23, 545-549.	0.7	22
364	Decreased Sperm Motility in Rats Orally Exposed to Single or Mixed Pesticides. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2010, 73, 991-1002.	1.1	59
365	Metabolic abnormalities in adolescents with polycystic ovary syndrome in south china. Reproductive Biology and Endocrinology, 2010, 8, 142.	1.4	40
366	The effects of obesity and polycystic ovary syndrome on serum lipocalin-2 levels: a cross-sectional study. Reproductive Biology and Endocrinology, 2010, 8, 151.	1.4	17
367	Digit ratios by computer-assisted analysis confirm lack of anatomical evidence of prenatal androgen exposure in clinical phenotypes of polycystic ovary syndrome. Reproductive Biology and Endocrinology, 2010, 8, 156.	1.4	22
368	Polycystic Ovarian Syndrome in Taiwanese Women. Journal of Experimental and Clinical Medicine, 2010, 2, 218-223.	0.2	4
369	Angiotensin-Converting enzyme D/I and plasminogen activator inhibitor-1 4G/5G gene polymorphisms are associated with increased risk of spontaneous abortions in polycystic ovarian syndrome. Journal of Endocrinological Investigation, 2010, 33, 77-82.	1.8	39

#	Article	IF	Citations
370	The relationship between CAG repeat length polymorphism and infertility in Southern Chinese Han women. Journal of Endocrinological Investigation, 2010, 33, 559-563.	1.8	11
371	Association of biochemical hyperandrogenism with type 2 diabetes and obesity in Chinese women with polycystic ovary syndrome. International Journal of Gynecology and Obstetrics, 2010, 108, 148-151.	1.0	50
372	Insulin and hyperandrogenism in women with polycystic ovary syndrome. Journal of Steroid Biochemistry and Molecular Biology, 2010, 122, 42-52.	1.2	229
373	An increase in systolic blood pressure and abnormal circadian blood pressure regulation in lean women with polycystic ovary syndrome. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2010, 150, 217-218.	0.5	3
374	Isolated torsion of the fallopian tube in a patient with polycystic ovarian syndrome (PCOS). European Journal of Obstetrics, Gynecology and Reproductive Biology, 2010, 150, 218-219.	0.5	4
375	Plasma interleukin-18 levels are increased in the polycystic ovary syndrome: relationship of carotid intima-media wall thickness and cardiovascular risk factors. Fertility and Sterility, 2010, 93, 1200-1207.	0.5	56
376	Asymmetric dimethylarginine levels and carotid intima-media thickness in obese patients with polycystic ovary syndrome and their relationship to metabolic parameters. Fertility and Sterility, 2010, 93, 1227-1233.	0.5	26
377	An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrateâ€“metformin in patients with polycystic ovary syndrome. Fertility and Sterility, 2010, 94, 216-220.	0.5	96
378	The insulin-resistant phenotype of polycystic ovary syndrome. Fertility and Sterility, 2010, 94, 1052-1058.	0.5	31
379	Not all women diagnosed with PCOS share the same cardiovascular risk profiles. Fertility and Sterility, 2010, 94, 826-832.	0.5	56
380	Relationship between interleukin-6 levels and ambulatory blood pressure in women with polycystic ovary syndrome. Fertility and Sterility, 2010, 94, 1437-1443.	0.5	11
381	Different phenotypes of polycystic ovary syndrome by Rotterdam criteria are differently steroidogenic but similarly insulin resistant. Fertility and Sterility, 2010, 93, 1362-1365.	0.5	15
382	Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes. Fertility and Sterility, 2010, 94, 2197-2201.	0.5	143
383	Aromatase inhibitors in women with clomiphene citrate resistance: a randomized, double-blind, placebo-controlled trial. Fertility and Sterility, 2010, 94, 2857-2859.	0.5	34
384	Validation of a total testosterone assay using high-turbulence liquid chromatography tandem mass spectrometry: Total and free testosterone reference ranges. Steroids, 2010, 75, 169-175.	0.8	119
385	Polymorphisms of the insulin receptor and the insulin receptor substrates genes in polycystic ovary syndrome: A Mendelian randomization meta-analysis. Molecular Genetics and Metabolism, 2010, 99, 174-183.	0.5	52
386	Effect of N-acetyl-cysteine after ovarian drilling in clomiphene citrate-resistant PCOS women: a pilot study. Reproductive BioMedicine Online, 2010, 20, 403-409.	1.1	37
387	Serum inhibin A concentration in women with polycystic ovarian syndrome and the correlation to ethnicity, androgens and insulin resistance. Reproductive BioMedicine Online, 2010, 20, 675-680.	1.1	8

#	Article	IF	Citations
388	Grid Analysis Improves Reliability in Follicle Counts Made by Ultrasonography in Women With Polycystic Ovary Syndrome. Ultrasound in Medicine and Biology, 2010, 36, 712-718.	0.7	32
389	An update on the pathogenesis, inflammation, and metabolism in hirsutism and polycystic ovary syndrome. Gynecological Endocrinology, 2010, 26, 281-296.	0.7	133
390	Polycystic Ovary Syndrome and Weight Management. Women's Health, 2010, 6, 271-283.	0.7	54
391	Serum fibroblast growth factor 21 levels in polycystic ovary syndrome. Gynecological Endocrinology, 2010, 26, 819-826.	0.7	37
392	Micronucleus frequency in lymphocytes and 8-hydroxydeoxyguanosine level in plasma of women with polycystic ovary syndrome. Gynecological Endocrinology, 2010, 26, 590-595.	0.7	29
393	Angiotensin converting enzyme gene insertion/deletion polymorphism in patients with polycystic ovary syndrome. Gynecological Endocrinology, 2010, 26, 393-398.	0.7	16
394	Tissue plasminogen activator and plasminogen activator inhibitor 1 in obese and lean patients with polycystic ovary syndrome. Gynecological Endocrinology, 2010, 26, 743-748.	0.7	17
396	The metabolic aspects of polycystic ovary syndrome. Expert Review of Obstetrics and Gynecology, 2011, 6, 331-341.	0.4	0
397	Assessing cardiovascular risk in Mediterranean women with polycystic ovary syndrome. Journal of Endocrinological Investigation, 2011, 34, 422-426.	1.8	19
398	Serum lipocalin-2 as an insulin resistance marker in patients with polycystic ovary syndrome. Journal of Endocrinological Investigation, 2011, 34, 97-100.	1.8	33
399	Is the Risk for Cardiovascular Disease Increased in all Phenotypes of the Polycystic Ovary Syndrome?. Angiology, 2011, 62, 285-290.	0.8	9
400	Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nature Reviews Endocrinology, 2011, 7, 219-231.	4.3	1,062
401	The plasma level and gene expression of resistin in polycystic ovary syndrome. Gynecological Endocrinology, 2011, 27, 982-987.	0.7	21
402	Ethinylestradiol/Chlormadinone Acetate for Use in Dermatological Disorders. American Journal of Clinical Dermatology, 2011, 12, 13-19.	3.3	5
403	An appraisal of serum preptin levels in PCOS. Fertility and Sterility, 2011, 95, 314-316.	0.5	30
404	Associations between free fatty acids, cumulus oocyte complex morphology and ovarian function during in vitro fertilization. Fertility and Sterility, 2011, 95, 1970-1974.	0.5	202
405	Abdominal subcutaneous fat gene expression and circulating levels of leptin and adiponectin in polycystic ovary syndrome. Fertility and Sterility, 2011, 95, 2044-2049.	0.5	65
406	The D-chiro-inositol paradox in the ovary. Fertility and Sterility, 2011, 95, 2515-2516.	0.5	109

#	Article	IF	Citations
407	Cycle scheduling with oral contraceptive pills in the GnRH antagonist protocol vs the long protocol: a randomized, controlled trial. Fertility and Sterility, 2011, 96, 590-593.	0.5	63
408	Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated inÂvitro fertilization cycles: a randomized, controlled trial. Fertility and Sterility, 2011, 96, 1384-1390.e4.	0.5	72
409	Paratubal cysts, obesity, and hyperandrogenism. Journal of Pediatric Surgery, 2011, 46, 2164-2167.	0.8	15
410	Metabolic syndrome and oocyte quality. Trends in Endocrinology and Metabolism, 2011, 22, 103-109.	3.1	100
411	Reproductive tract function and dysfunction in women. Nature Reviews Endocrinology, 2011, 7, 517-525.	4.3	33
412	Difficult-to-treat women for controlled ovarian hyperstimulation: tips and tricks. Expert Review of Endocrinology and Metabolism, 2011, 6, 617-627.	1.2	2
413	Inappropriate gonadotropin secretion in polycystic ovary syndrome: The relationship with clinical, hormonal and metabolic characteristics. Korean Journal of Obstetrics & Gynecology, 2011, 54, 659.	0.1	6
414	Usefulness of Oral Glucose Insulin Sensitivity Index in Women with Polycystic Ovary Syndrome. The Ewha Medical Journal, 2011, 34, 27.	0.1	2
415	Sperm function is affected by the electromagnetic radiation emitted by mobile phone. African Journal of Microbiology Research, 2011, 5, .	0.4	3
416	Endometrial histology and predictable clinical factors for endometrial disease in women with polycystic ovary syndrome. Clinical and Experimental Reproductive Medicine, 2011, 38, 42.	0.5	33
417	Adiponectin in Women with Polycystic Ovary Syndrome. Korean Journal of Family Medicine, 2011, 32, 243.	0.4	16
418	The paediatric uterus, ovaries and testes. , 2011, , 1468-1496.		1
419	Pioglitazone treatment decreases follicular fluid levels of tumor necrosis factor-Î± and interleukin-6 in patients with polycystic ovary syndrome. Clinical and Experimental Reproductive Medicine, 2011, 38, 98.	0.5	15
420	Management of Polycystic Ovary Syndrome in the Non-Infertility Patient. Postgraduate Obstetrics & Gynecology, 2011, 31, 1-7.	0.1	0
422	Association study between the -866G/A polymorphism in the promoter of uncoupling protein-2 gene and polycystic ovary syndrome. Molecular Medicine Reports, 2011, 4, 747-51.	1.1	1
424	Randomized controlled trial of different doses of metformin for ovulation induction in infertile women with polycystic ovary syndrome. Journal of Obstetrics and Gynaecology Research, 2011, 37, 1229-1237.	0.6	7
425	Impact of cell phone use on menâ€™s semen parameters. Andrologia, 2011, 43, 312-316.	1.0	60
426	Determinants of dyslipidaemia in probands with polycystic ovary syndrome and their sisters. Clinical Endocrinology, 2011, 74, 714-719.	1.2	17

#	Article	IF	Citations
427	The effect of pulsed 900-MHz GSM mobile phone radiation on the acrosome reaction, head morphometry and zona binding of human spermatozoa. Journal of Developmental and Physical Disabilities, 2011, 34, 20-26.	3.6	71
428	Health-related quality of life and psychological distress in polycystic ovary syndrome: a hidden facet in South Asian women. BJOG: an International Journal of Obstetrics and Gynaecology, 2011, 118, 319-328.	1.1	50
429	Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nature Genetics, 2011, 43, 55-59.	9.4	604
430	The predictive value of uterine blood flow in detecting the risk of adverse pregnancy outcome in patients with polycystic ovary syndrome. Middle East Fertility Society Journal, 2011, 16, 284-290.	0.5	6
431	Adolescent oligomenorrhea in a biracial schoolgirl cohort: a simple clinical parameter predicting impaired fasting glucose plus type 2 diabetes mellitus, insulin, glucose, insulin resistance, and centripetal obesity from age 19 to 25 years. Metabolism: Clinical and Experimental, 2011, 60, 1285-1293.	1.5	14
432	Sex Hormone-Binding Globulin, Oligomenorrhea, Polycystic Ovary Syndrome, and Childhood Insulin at Age 14 Years Predict Metabolic Syndrome and Class III Obesity at Age 24 Years. Journal of Pediatrics, 2011, 159, 308-313.e2.	0.9	47
433	State of the Art Review: Emerging Therapies: The Use of Insulin Sensitizers in the Treatment of Adolescents with Polycystic Ovary Syndrome (PCOS). International Journal of Pediatric Endocrinology (Springer), 2011, 2011, 9.	1.6	54
434	Spindle and chromosome configurations of in vitro-matured oocytes from polycystic ovary syndrome and ovulatory infertile women: a pilot study. Journal of Assisted Reproduction and Genetics, 2011, 28, 15-21.	1.2	15
435	Imbalanced circulating matrix metalloproteinases in polycystic ovary syndrome. Molecular and Cellular Biochemistry, 2011, 353, 251-257.	1.4	37
436	Common genetic variation in the 3â€²-untranslated region of gonadotropin-releasing hormone receptor regulates gene expression in cella and is associated with thyroid function, insulin secretion as well as insulin sensitivity in polycystic ovary syndrome patients. Human Genetics, 2011, 129, 553-561.	1.8	24
437	Alteration of cardiovascular risk parameters in women with polycystic ovary syndrome who were prescribed to ethinyl estradiolâ€“cyproterone acetate. Archives of Gynecology and Obstetrics, 2011, 284, 923-929.	0.8	20
438	The effect of low dose human chorionic gonadotropin on follicular response and oocyte maturation in PCOS patients undergoing IVF cycles: a randomized clinical trial of efficacy and safety. Archives of Gynecology and Obstetrics, 2011, 284, 1431-1438.	0.8	16
439	Does laparoscopic ovarian diathermy change clomiphene-resistant PCOS into clomiphene-sensitive?. Archives of Gynecology and Obstetrics, 2011, 284, 503-507.	0.8	12
440	Timing of intrauterine insemination: an attempt to unravel the enigma. Archives of Gynecology and Obstetrics, 2011, 284, 1023-1027.	0.8	25
443	Polycystic Ovary Syndrome: A Common Endocrine Disorder and Risk Factor for Vascular Disease. Current Treatment Options in Cardiovascular Medicine, 2011, 13, 289-301.	0.4	37
444	Cardiovascular disease risk characteristics of the main polycystic ovary syndrome phenotypes. Endocrine, 2011, 39, 272-277.	1.1	32
445	Expression and regulation of adipocyte fatty acid binding protein in granulosa cells and its relation with clinical characteristics of polycystic ovary syndrome. Endocrine, 2011, 40, 196-202.	1.1	32
446	Association of metabolic syndrome in polycystic ovarian syndrome: an observational study. Journal of Obstetrics and Gynecology of India, 2011, 61, 176-181.	0.3	11

#	Article	IF	Citations
447	The promoter -1031(T/C) polymorphism in tumor necrosis factor-alpha associated with polycystic ovary syndrome. Reproductive Biology and Endocrinology, 2011, 9, 131.	1.4	33
448	The prevalence of polycystic ovary syndrome in a community sample of Iranian population: Iranian PCOS prevalence study. Reproductive Biology and Endocrinology, 2011, 9, 39.	1.4	204
449	Is interleukin-18 associated with polycystic ovary syndrome?. Reproductive Biology and Endocrinology, 2011, 9, 7.	1.4	57
450	Family association study between INSR gene polymorphisms and PCOS in Han Chinese. Reproductive Biology and Endocrinology, 2011, 9, 76.	1.4	22
451	The impact of endometrioma and laparoscopic cystectomy on serum anti-MÃ¼llerian hormone levels. Reproductive Biology and Endocrinology, 2011, 9, 80.	1.4	104
452	Evaluation of early atherosclerotic findings in women with polycystic ovary syndrome. Journal of Ovarian Research, 2011, 4, 19.	1.3	11
454	Cardiovascular Disease and Primary Ovarian Insufficiency. Seminars in Reproductive Medicine, 2011, 29, 328-341.	0.5	23
455	Endocrinology and Recurrent Early Pregnancy Loss. Seminars in Reproductive Medicine, 2011, 29, 482-490.	0.5	49
456	Diabetes and impaired glucose tolerance in patients with polycystic ovary syndrome--a long term follow-up. Human Reproduction, 2011, 26, 1462-1468.	0.4	49
457	Comparison of MRI-assessed body fat content between lean women with polycystic ovary syndrome (PCOS) and matched controls: less visceral fat with PCOS. Human Reproduction, 2011, 26, 1495-1500.	0.4	52
458	Insulin Resistance in Non-Obese Women with Polycystic Ovary Syndrome: Relation to Byproducts of Oxidative Stress. Experimental and Clinical Endocrinology and Diabetes, 2011, 119, 451-455.	0.6	52
459	Obesity and insulin resistance in women with polycystic ovary syndrome. Gynecological Endocrinology, 2011, 27, 300-306.	0.7	18
460	Analysis of heart rate variability in polycystic ovary syndrome. Gynecological Endocrinology, 2011, 27, 443-447.	0.7	29
461	The effect of a combination therapy with myo-inositol and a combined oral contraceptive pillversusa combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome. Gynecological Endocrinology, 2011, 27, 920-924.	0.7	49
462	Factors Associated With Increased Carotid Intima-Media Thickness and Being Nondipper in Nonobese and Normotensive Young Patients Affected by PCOS. Angiology, 2011, 62, 543-548.	0.8	7
463	MnSOD expression inhibited by electromagnetic pulse radiation in the rat testis. Electromagnetic Biology and Medicine, 2011, 30, 205-218.	0.7	14
464	SNP rs2470152 in CYP19 is correlated to aromatase activity in Chinese polycystic ovary syndrome patients. Molecular Medicine Reports, 2011, 5, 245-9.	1.1	26
465	COMPLICATIONS OF PREGNANCY IN WOMEN WITH POLYCYSTIC OVARIAN SYNDROME. Fetal and Maternal Medicine Review, 2011, 22, 188-206.	0.3	2

#	Article	IF	Citations
466	Plasma apelin levels in patients with polycystic ovary syndrome. Journal of the Turkish German Gynecology Association, 2011, 13, 27-31.	0.2	20
467	Polycystic Ovary Syndrome. Clinical Obstetrics and Gynecology, 2011, 54, 675-684.	0.6	16
468	Menstrual Disorders and Vaginal Discharge. Medical Radiology, 2011, , 145-171.	0.0	0
469	Effect of Obesity on Oocyte and Embryo Quality in Women Undergoing In Vitro Fertilization. Obstetrics and Gynecology, 2011, 118, 63-70.	1.2	202
470	Cholesterol, endocrine and metabolic disturbances in sporadic anovulatory women with regular menstruation. Human Reproduction, 2011, 26, 423-430.	0.4	17
471	First assessment of menstrual cycle function and reproductive endocrine status in Samoan women. Human Reproduction, 2011, 26, 2518-2524.	0.4	15
472	Intra-individual stability over time of standardized anti-Mullerian hormone in FMR1 premutation carriers. Human Reproduction, 2011, 26, 2185-2191.	0.4	34
473	Polycystic ovarian morphology in adolescents with regular menstrual cycles is associated with elevated anti-Mullerian hormone. Human Reproduction, 2011, 26, 2861-2868.	0.4	76
474	Editorial commentary: What's in a number? The polycystic ovary revisited. Human Reproduction, 2011, 26, 3118-3122.	0.4	15
475	Clinical and biochemical presentation of polycystic ovary syndrome in women between the ages of 20 and 40. Human Reproduction, 2011, 26, 3443-3449.	0.4	52
476	Association study of +45G15G(T/G) and +276(G/T) polymorphisms in the adiponectin gene in patients with polycystic ovary syndrome. International Journal of Molecular Medicine, 2011, 27, 283-7.	1.8	20
477	Is having polycystic ovary syndrome a predictor of poor psychological function including anxiety and depression?. Human Reproduction, 2011, 26, 1399-1407.	0.4	140
478	Vascular function in the diagnostic categories of polycystic ovary syndrome. Human Reproduction, 2011, 26, 2192-2199.	0.4	31
479	The Phenotypes of Polycystic Ovary Syndrome Defined by the 1990 Diagnostic Criteria Are Associated with Higher Serum Vaspin Levels than the Phenotypes Introduced by the 2003 Criteria. Obesity Facts, 2011, 4, 145-150.	1.6	16
480	Serum vaspin and C-reactive protein levels in women with polycystic ovaries and polycystic ovary syndrome. Gynecological Endocrinology, 2011, 27, 491-495.	0.7	33
481	Phenotype and metabolic profile of South Asian women with polycystic ovary syndrome (PCOS): results of a large database from a specialist Endocrine Clinic. Human Reproduction, 2011, 26, 202-213.	0.4	114
482	Effect of Short-Term Standard Therapeutic Regimens on Neuropeptide Y and Adipose Tissue Hormones in Overweight Insulinresistant Women with Polycystic Ovary Syndrome. Folia Medica, 2011, 53, 15-24.	0.2	9
483	Metformin or thiazolidinedione therapy in PCOS?. Nature Reviews Endocrinology, 2011, 7, 128-129.	4.3	4

#	Article	IF	Citations
484	Evaluation of asymmetric dimethylarginine, nitric oxide levels and associated independent variables in obese and lean patients with polycystic ovarian syndrome. Gynecological Endocrinology, 2011, 27, 609-614.	0.7	8
485	Genetic polymorphisms of the glucocorticoid receptor may affect the phenotype of women with anovulatory polycystic ovary syndrome. Human Reproduction, 2011, 26, 2902-2911.	0.4	16
486	Anti-MÃ¼llerian Hormone in Women with Polycystic Ovary Syndrome Before and After Therapy with Metformin. Hormone and Metabolic Research, 2011, 43, 723-727.	0.7	23
487	Comparison ofin vitrofertilisation success in patients with polycystic ovary syndrome and tubal factor. Gynecological Endocrinology, 2011, 27, 117-120.	0.7	15
488	Insulin Resistance Variability in Women with Anovulatory and Ovulatory Polycystic Ovary Syndrome, and Normal Controls. Hormone and Metabolic Research, 2011, 43, 141-145.	0.7	10
489	Cyproterone acetate or drospirenone containing combined oral contraceptives plus spironolactone or cyproterone acetate for hirsutism: Randomized comparison of three regimens. Journal of Dermatological Treatment, 2012, 23, 177-183.	1.1	19
490	Diamel Therapy in Polycystic Ovary Syndrome Reduces Hyperinsulinaemia, Insulin Resistance, and Hyperandrogenaemia. International Journal of Endocrinology, 2012, 2012, 1-7.	0.6	6
491	A prospective study of GnRH long agonist versus flexible GnRH antagonist protocol in PCOS: Indian experience. Journal of Human Reproductive Sciences, 2012, 5, 181.	0.4	7
492	Hyperandrogenism sensitizes mononuclear cells to promote glucose-induced inflammation in lean reproductive-age women. American Journal of Physiology - Endocrinology and Metabolism, 2012, 302, E297-E306.	1.8	56
493	Hyperandrogenism Does Not Influence Metabolic Parameters in Adolescent Girls with PCOS. International Journal of Endocrinology, 2012, 2012, 1-5.	0.6	19
494	Obesity Differentially Affects Phenotypes of Polycystic Ovary Syndrome. International Journal of Endocrinology, 2012, 2012, 1-7.	0.6	57
495	Adipokines, Insulin Resistance and Hyperandrogenemia in Obese Patients with Polycystic Ovary Syndrome: Cross-Sectional Correlations and the Effects of Weight Loss. Obesity Facts, 2012, 5, 495-504.	1.6	26
496	The effectiveness of metformin ovulation induction treatment in patients with PCOS: a systematic review and meta-analysis. Gynecological Endocrinology, 2012, 28, 956-960.	0.7	22
497	Hysteroscopic Resection of Uterine Septum and Reproductive Outcome in Women with Unexplained Infertility. Gynecologic and Obstetric Investigation, 2012, 73, 321-325.	0.7	61
498	Prevalence of cervical insufficiency in polycystic ovarian syndrome. Human Reproduction, 2012, 27, 2837-2842.	0.4	24
499	Evaluating the association between endometrial cancer and polycystic ovary syndrome. Human Reproduction, 2012, 27, 1327-1331.	0.4	189
500	Effect of an oral contraceptive on emotional distress, anxiety and depression of women with polycystic ovary syndrome: a prospective study. Human Reproduction, 2012, 27, 1840-1845.	0.4	58
501	Impact of adrenal versus ovarian androgen ratio on signs and symptoms of polycystic ovarian syndrome. Gynecological Endocrinology, 2012, 28, 611-614.	0.7	15

#	Article	IF	Citations
502	Evaluation of endothelial dysfunction, lipid metabolism in women with polycystic ovary syndrome: relationship of paraoxonase 1 activity, malondialdehyde levels, low-density lipoprotein subfractions, and endothelial dysfunction. Gynecological Endocrinology, 2012, 28, 497-501.	0.7	26
503	Infertility Treatment in Polycystic Ovary Syndrome: Lifestyle Interventions, Medications and Surgery. Frontiers of Hormone Research, 2013, 40, 128-141.	1.0	17
504	Risk of preterm delivery in non-diabetic women with polycystic ovarian syndrome. Journal of Perinatology, 2012, 32, 770-776.	0.9	35
506	Ultrasonography in assisted reproduction. , 2012, , 225-241.		0
507	Elevated serum anti-MÃ¼llerian hormone in adolescents with polycystic ovary syndrome: relationship to ultrasound features. Journal of Pediatric Endocrinology and Metabolism, 2012, 25, 983-9.	0.4	32
508	High plasma level of long Pentraxin 3 is associated with insulin resistance in women with polycystic ovary syndrome. Gynecological Endocrinology, 2012, 28, 722-725.	0.7	24
509	High sensitivity C-reactive protein and its relationship with impaired glucose regulation in lean patients with polycystic ovary syndrome. Gynecological Endocrinology, 2012, 28, 259-263.	0.7	22
510	Comparison of assisted reproductive technology outcomes in infertile women with polycystic ovary syndrome:In vitromaturation, GnRH agonist, and GnRH antagonist cycles. Clinical and Experimental Reproductive Medicine, 2012, 39, 166.	0.5	33
511	Insulin, Independent of Serum Androgens of Androgen Receptor CAG Repeat Polymorphism, is Associated with Hirsutism in Polycystic Ovary Syndrome. Acta Endocrinologica, 2012, 8, 413-426.	0.1	1
512	Phenotype and Metabolic Disorders in Polycystic Ovary Syndrome. Isrn Endocrinology, 2012, 2012, 1-7.	2.0	56
513	Management of a adolescent and obese patient who visits Ondokuz MayÄ±s family practice smoking quitance polyclinic. TÃ¼rkiye Aile HekimliÄŸi Dergisi, 2012, 16, 87-92.	0.4	0
514	Development of Obesity and Polycystic Ovary Syndrome in Adolescents. Hormone Research in Paediatrics, 2012, 78, 269-278.	0.8	50
515	Best practices of ASRM and ESHRE: a journey through reproductive medicine. Human Reproduction, 2012, 27, 3365-3379.	0.4	22
516	Number of Antral Follicles, Ovarian Volume, and Vascular Indices in Asymptomatic Women 20 to 39 Years Old as Assessed by 3-Dimensional Sonography. Journal of Ultrasound in Medicine, 2012, 31, 1635-1649.	0.8	31
517	The relationship of epicardial adipose tissue thickness to clinical and biochemical features in women with polycystic ovary syndrome. Endocrine Journal, 2012, 59, 509-516.	0.7	12
518	Two- and Three-Dimensional Sonographic and Color Doppler Techniques for Diagnosis of Polycystic Ovary Syndrome. Journal of Ultrasound in Medicine, 2012, 31, 1015-1024.	0.8	40
519	Endocrinological insights into differentin vitrofertilization treatment aspects. Expert Review of Endocrinology and Metabolism, 2012, 7, 419-432.	1.2	1
520	Polymorphic CAG repeat in the androgen receptor gene in polycystic ovary syndrome patients. Molecular Medicine Reports, 2012, 5, 1330-4.	1.1	17

#	Article	IF	Citations
521	Epidemiology of hirsutism among women of reproductive age in the community: a simplified scoring system. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2012, 163, 165-169.	0.5	38
522	Therapeutic effects of calcium & vitamin D supplementation in women with PCOS. Complementary Therapies in Clinical Practice, 2012, 18, 85-88.	0.7	93
523	Single-cell expression analysis of BMP15 and GDF9 in mature oocytes and BMPR2 in cumulus cells of women with polycystic ovary syndrome undergoing controlled ovarian hyperstimulation. Journal of Assisted Reproduction and Genetics, 2012, 29, 1057-1065.	1.2	36
524	Different diagnostic power of anti-Mullerian hormone in evaluating women with polycystic ovaries with and without hyperandrogenism. Journal of Assisted Reproduction and Genetics, 2012, 29, 1147-1151.	1.2	19
525	Obesity in Polycystic Ovary Syndrome: Insulin Sensitizing Therapy. Current Obesity Reports, 2012, 1, 191-198.	3.5	2
526	Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Annals of Clinical Biochemistry, 2012, 49, 80-85.	0.8	29
527	Determinants of ApoB, ApoA1, and the ApoB/ApoA1 ratio in healthy schoolgirls, prospectively studied from mean ages 10 to 19 years: the Cincinnati National Growth and Health Study. Metabolism: Clinical and Experimental, 2012, 61, 1377-1387.	1.5	10
528	SÃndrome de ovario poliquÃstico en adolescentes. Anales De Pediatria Continuada, 2012, 10, 257-263.	0.0	1
529	Anthropometric indices of central obesity how discriminators of metabolic syndrome in Brazilian women with polycystic ovary syndrome. Gynecological Endocrinology, 2012, 28, 12-15.	0.7	42
530	Is hyperandrogenemia protective for fibrocystic breast disease in PCOS?. Gynecological Endocrinology, 2012, 28, 468-471.	0.7	10
531	The influence of obesity on Androstenedione to Testosterone ratio in women with polycystic ovary syndrome (PCOS) and hyperandrogenemia. Gynecological Endocrinology, 2012, 28, 249-252.	0.7	16
532	Homocysteine metabolism in polycystic ovary syndrome. Gynecological Endocrinology, 2012, 28, 186-189.	0.7	24
533	Consensus on women's health aspects of polycystic ovary syndrome (PCOS). Human Reproduction, 2012, 27, 14-24.	0.4	278
534	Oocyte quality reflected by follicular fluid analysis in poly cystic ovary syndrome (PCOS): A hypothesis based on intermediates of energy metabolism. Medical Hypotheses, 2012, 78, 475-478.	0.8	47
535	Effect of a yoga program on glucose metabolism and blood lipid levels in adolescent girls with polycystic ovary syndrome. International Journal of Gynecology and Obstetrics, 2012, 118, 37-41.	1.0	37
536	Retrieving oocytes from small non-stimulated follicles in polycystic ovary syndrome (PCOS): inÂvitro maturation (IVM) is not indicated inÂthe new GnRH antagonist era. Fertility and Sterility, 2012, 98, 290-293.	0.5	26
537	The effects of oxidative stress on female reproduction: a review. Reproductive Biology and Endocrinology, 2012, 10, 49.	1.4	1,056
538	CONCERN: Does ovary need D-chiro-inositol?. Journal of Ovarian Research, 2012, 5, 14.	1.3	55

#	Article	IF	Citations
539	Adrenocortical steroid response to ACTH in different phenotypes of non-obese polycystic ovary syndrome. Journal of Ovarian Research, 2012, 5, 42.	1.3	8
540	The Link between Polycystic Ovary Syndrome and both Type 1 and Type 2 Diabetes Mellitus: What Do we Know Today?. Women's Health, 2012, 8, 147-154.	0.7	19
541	Nonâ€contraceptive uses and benefits of combined oral contraception. The Obstetrician and Gynaecologist, 2012, 14, 223-228.	0.2	7
542	The prevalence of metabolic syndrome in clomiphene citrate resistant polycystic ovary syndrome. Gynecological Endocrinology, 2012, 28, 365-369.	0.7	5
543	The relationship between retinol-binding protein 4 levels, insulin resistance, androgen hormones and polycystic ovary syndrome. Scandinavian Journal of Clinical and Laboratory Investigation, 2012, 72, 39-44.	0.6	8
544	Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecological Endocrinology, 2012, 28, 509-515.	0.7	143
545	Markers of visceral obesity and cardiovascular risk in patients with polycystic ovarian syndrome. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2012, 164, 161-166.	0.5	17
546	Vitamin D receptor 1a promotor â^'1521 G/C and â^'1012 A/G polymorphisms in polycystic ovary syndrome. Taiwanese Journal of Obstetrics and Gynecology, 2012, 51, 565-571.	0.5	23
547	Genome-wide association study identifies eight new risk loci for polycystic ovary syndrome. Nature Genetics, 2012, 44, 1020-1025.	9.4	505
548	Neopterin: a promising marker for the inflammation in polycystic ovary syndrome. Gynecological Endocrinology, 2012, 28, 879-883.	0.7	7
549	Hormones sexuelles. , 2012, , 19-33.		0
550	Polycystic Ovary Syndrome and Chronic Inflammation: Pharmacotherapeutic Implications. Annals of Pharmacotherapy, 2012, 46, 403-418.	0.9	22
551	Polycystic ovary syndrome: infertility, cardiovascular, metabolic and obstetrical risks, laboratory and clinical outcomesâ€"The PICOLO Study. Gynecological Endocrinology, 2012, 28, 253-258.	0.7	16
552	Effects of Thiazolidinediones on Polycystic Ovary Syndrome: a Meta-analysis of Randomized Placebo-Controlled Trials. Advances in Therapy, 2012, 29, 763-774.	1.3	35
553	Serum Fetuin-A levels in women with polycystic ovary syndrome. Archives of Gynecology and Obstetrics, 2012, 286, 1473-1476.	0.8	15
554	Sequential low-dose step-up and step-down protocols with recombinant follicle-stimulating hormone in polycystic ovary syndrome: prospective comparison with step-down protocol. Archives of Gynecology and Obstetrics, 2012, 286, 1291-1297.	0.8	4
555	A macrophage activation marker chitotriosidase in women with PCOS: does low-grade chronic inflammation in PCOS relate to PCOS itself or obesity?. Archives of Gynecology and Obstetrics, 2012, 286, 1065-1071.	0.8	35
556	Adipocytokine profiles in a putative novel postmenopausal polycystic ovary syndrome (PCOS) phenotype parallel those in premenopausal PCOS: the Rancho Bernardo Study. Metabolism: Clinical and Experimental, 2012, 61, 1238-1241.	1.5	9

#	Article	IF	Citations
557	Endocrine Evaluation of Reproductive Function in Girls during Infancy, Childhood and Adolescence. Endocrine Development, 2012, 22, 24-39.	1.3	17
558	Indications for IVF treatment: From diagnosis to prognosis. , 2012, , 18-30.		0
559	Serum visfatin levels in women with polycystic ovary syndrome. Gynecological Endocrinology, 2012, 28, 619-623.	0.7	18
560	Metabolic profiles characterizing different phenotypes of polycystic ovary syndrome: plasma metabolomics analysis. BMC Medicine, 2012, 10, 153.	2.3	168
561	Polycystic ovary syndrome in Salvador, Brazil: a prevalence study in primary healthcare. Reproductive Biology and Endocrinology, 2012, 10, 96.	1.4	38
562	Heart type fatty acid binding protein response and subsequent development of atherosclerosis in insulin resistant polycystic ovary syndrome patients. Journal of Ovarian Research, 2012, 5, 45.	1.3	11
563	Association of CAPN10 SNPs and Haplotypes with Polycystic Ovary Syndrome among South Indian Women. PLoS ONE, 2012, 7, e32192.	1.1	29
564	Impact of Serum Estradiol on Biomarkers of Oxidative Stress in Polycystic Ovary Syndrome and Ovulatory Women. Clinical Medicine Insights Women's Health, 2012, 5, CMWH.S9721.	0.6	0
565	Evolution and Expectations of Enzymatic Biosensors for Pesticides. , 0, , .		15
566	Effectiveness of GnRH antagonist multiple dose protocol applied during early and late follicular phase compared with GnRH agonist long protocol in non-obese and obese patients with polycystic ovary syndrome undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine, 2012, 39, 22.	0.5	14
568	Plasma Von Willebrand factor antigen levels are elevated in the classic phenotypes of polycystic ovary syndrome. Hormones, 2012, 11, 77-85.	0.9	7
570	Ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women with polycystic ovary syndrome. Ultrasound in Obstetrics and Gynecology, 2012, 39, 341-347.	0.9	47
571	Does day-3 LH/FSH ratio influencein vitrofertilization outcome in PCOS patients undergoing controlled ovarian hyperstimulation with different GnRH-analogue?. Gynecological Endocrinology, 2012, 28, 422-424.	0.7	17
572	Effect of hCG priming on embryonic development of immature oocytes collected from unstimulated women with polycystic ovarian syndrome. Reproductive Biology and Endocrinology, 2012, 10, 40.	1.4	34
573	Association between polymorphisms of the CYP11A1 gene and polycystic ovary syndrome in Chinese women. Molecular Biology Reports, 2012, 39, 8379-8385.	1.0	36
575	Psychological gender of patients with polycystic ovary syndrome. Acta Obstetricia Et Gynecologica Scandinavica, 2012, 91, 710-714.	1.3	16
576	Body composition, bone mineral density and fractures in late postmenopausal women with polycystic ovary syndrome â€“ a longâ€term followâ€up study. Clinical Endocrinology, 2012, 77, 207-214.	1.2	34
577	Protein expression of PKCZ (Protein Kinase C Zeta), Munc18c, and Syntaxin-4 in the insulin pathway in endometria of patients with polycystic ovary syndrome (PCOS). Reproductive Biology and Endocrinology, 2012, 10, 17.	1.4	13

#	Article	IF	Citations
578	Menstrual Irregularity and Poly Cystic Ovarian Syndrome among Adolescent Girlsâ€"A 2 Year Follow-up Study. Indian Journal of Pediatrics, 2012, 79, 69-73.	0.3	37
579	Unilateral or bilateral vagotomy induces ovulation in both ovaries of rats with polycystic ovarian syndrome. Reproductive Biology and Endocrinology, 2013, 11, 68.	1.4	26
580	First intention IVF protocol for polycystic ovaries: does oral contraceptive pill pretreatment influence COH outcome?. Reproductive Biology and Endocrinology, 2013, 11, 54.	1.4	15
581	Epidemiology of polycystic ovary syndrome: a cross sectional study of university students at An-Najah national university-Palestine. Reproductive Biology and Endocrinology, 2013, 11, 47.	1.4	28
582	Endocrinology and physiology of pseudocyesis. Reproductive Biology and Endocrinology, 2013, 11, 39.	1.4	29
583	Changes in Sexual Function among Women with Polycystic Ovary Syndrome: A Pilot Study. Journal of Sexual Medicine, 2013, 10, 467-473.	0.3	32
584	Peroxisome proliferator activated receptor gamma gene variants influence susceptibility and insulin related traits in Indian women with polycystic ovary syndrome. Journal of Assisted Reproduction and Genetics, 2013, 30, 913-921.	1.2	26
585	The haplotype M2 of the ANXA5 gene is not associated with antitrophoblast antibodies. Journal of Assisted Reproduction and Genetics, 2013, 30, 711-716.	1.2	7
586	Association study between FSHR Ala307Thr and Ser680Asn variants and polycystic ovary syndrome (PCOS) in Northern Chinese Han women. Journal of Assisted Reproduction and Genetics, 2013, 30, 717-721.	1.2	27
587	Clinical characteristics, metabolic features, and phenotype of Chinese women with polycystic ovary syndrome: a large-scale caseâ€"control study. Archives of Gynecology and Obstetrics, 2013, 287, 525-531.	0.8	66
588	Office microlaparoscopic ovarian drilling (OMLOD) versus conventional laparoscopic ovarian drilling (LOD) for women with polycystic ovary syndrome. Archives of Gynecology and Obstetrics, 2013, 287, 361-367.	0.8	29
589	Lifestyle intervention and anti-obesity therapies in the polycystic ovary syndrome: impact on metabolism and fertility. Endocrine, 2013, 44, 583-590.	1.1	72
590	Predictors of Insulin Resistance and Metabolic Complications in Polycystic Ovarian Syndrome in an Eastern Indian Population. Indian Journal of Clinical Biochemistry, 2013, 28, 169-176.	0.9	14
591	Effect of Yoga Program on Quality of Life in Adolescent Polycystic Ovarian Syndrome: A Randomized Control Trial. Applied Research in Quality of Life, 2013, 8, 373-383.	1.4	12
592	Ovarian SAHA syndrome is associated with a more insulin-resistant profile and represents an independent risk factor for glucose abnormalities in women with polycystic ovary syndrome: A prospective controlled study. Journal of the American Academy of Dermatology, 2013, 69, 922-930.	0.6	23
593	Using the ovarian sensitivity index to define poor, normal, and high response after controlled ovarian hyperstimulation in the long gonadotropin-releasing hormone-agonist protocol: suggestions for a new principle to solve an old problem. Fertility and Sterility, 2013, 100, 1270-1276.e3.	0.5	78
594	Effectiveness of GnRH antagonist in the treatment of patients with polycystic ovary syndrome undergoing IVF: a systematic review and meta analysis. Gynecological Endocrinology, 2013, 29, 187-191.	0.7	42
595	Birth weight and polycystic ovary syndrome in adult life: a register-based study on 523,757 Danish women born 1973â€"1991. Fertility and Sterility, 2013, 99, 777-782.	0.5	24

#	Article	IF	Citations
596	Subclinical atherosclerosis and hyperandrogenemia are independent risk factors for increased epicardial fat thickness in patients with PCOS and idiopathic hirsutism. Atherosclerosis, 2013, 226, 291-295.	0.4	44
597	Microsatellite polymorphism in the fibrillin 3 gene and susceptibility to PCOS: a caseâ€“control study and meta-analysis. Reproductive BioMedicine Online, 2013, 26, 168-174.	1.1	21
598	Circulating levels and subcutaneous adipose tissue gene expression of pigment epithelium-derived factor in polycystic ovary syndrome and normal women: a case control study. Reproductive Biology and Endocrinology, 2013, 11, 77.	1.4	11
599	An interleukin-6 gene promoter polymorphism is associated with polycystic ovary syndrome in South Indian women. Journal of Assisted Reproduction and Genetics, 2013, 30, 1541-1546.	1.2	43
600	Ovarian imaging by magnetic resonance in adolescent girls with polycystic ovary syndrome and ageâ€matched controls. Journal of Magnetic Resonance Imaging, 2013, 38, 689-693.	1.9	41
601	The clinical characteristics of women with recurrent implantation failure. Journal of Obstetrics and Gynaecology, 2013, 33, 494-498.	0.4	31
602	Transforming growth factor-Î²1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation. Fertility and Sterility, 2013, 100, 538-543.	0.5	41
603	Changes in the reproductive endocrine function in rat following intraovary microinjection of inhba overexpression lentivirus vectors. Gynecological Endocrinology, 2013, 29, 775-778.	0.7	5
604	Correlation between IL-1Î², IL-1Ra gene polymorphism and occurrence of polycystic ovary syndrome infertility. Asian Pacific Journal of Tropical Medicine, 2013, 6, 232-236.	0.4	20
605	Increase in subcutaneous adipose tissue and fat free mass in women with polycystic ovary syndrome is related to impaired insulin sensitivity. Gynecological Endocrinology, 2013, 29, 152-155.	0.7	12
606	Office microlaparoscopic ovarian drilling versus conventional laparoscopic ovarian drilling for women with polycystic ovary syndrome. Gynecological Surgery, 2013, 10, 71-77.	0.9	1
607	Platelet-derived microparticles in overweight/obese women with the polycystic ovary syndrome. Gynecological Endocrinology, 2013, 29, 250-253.	0.7	26
608	The role of cytokines in polycystic ovarian syndrome. Gynecological Endocrinology, 2013, 29, 536-540.	0.7	61
609	Ultrasonographic assessment of skin thickness in patients with PCOS â€“ a case-control study. Gynecological Endocrinology, 2013, 29, 380-383.	0.7	3
610	The effects of opiate consumption on serum reproductive hormone levels, sperm parameters, seminal plasma antioxidant capacity and sperm DNA integrity. Reproductive Toxicology, 2013, 36, 18-23.	1.3	68
611	Twenty years of endocrinologic treatment in transsexualism: analyzing the role of chromosomal analysis and hormonal profiling in the diagnostic work-up. Fertility and Sterility, 2013, 100, 1103-1110.	0.5	34
612	White blood cell differential counts in patients with polycystic ovary syndrome: a pilot study on Chinese women. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2013, 170, 162-164.	0.5	17
613	Age-related normogram for antral follicle count in women with polycystic ovary syndrome. Reproductive BioMedicine Online, 2013, 27, 414-418.	1.1	23

#	Article	IF	Citations
614	Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Human Reproduction, 2013, 28, 777-784.	0.4	539
615	Ethinyl estradiolâ€“drospirenone vs ethinyl estradiolâ€“drospirenone plus metformin in the treatment of lean women with polycystic ovary syndrome. Clinical Endocrinology, 2013, 78, 379-384.	1.2	13
616	Sexual dysfunction assessment and hormonal correlations in patients with polycystic ovary syndrome. International Journal of Impotence Research, 2013, 25, 127-132.	1.0	52
617	Metabolic complications of obesity. Best Practice and Research in Clinical Endocrinology and Metabolism, 2013, 27, 179-193.	2.2	60
618	The visceral adiposity index as a predictor of insulin resistance in young women with polycystic ovary syndrome. Obesity, 2013, 21, 1690-1694.	1.5	109
619	The Relationship Between Insulin Resistance and CpG Island Methylation of LMNA Gene in Polycystic Ovary Syndrome. Cell Biochemistry and Biophysics, 2013, 67, 1041-1047.	0.9	19
620	Anti-Mullerian hormone and insulin resistance in classic phenotype lean PCOS. Archives of Gynecology and Obstetrics, 2013, 288, 905-910.	0.8	33
621	Effects of exercise and group counselling on body composition and <scp>VO</scp>_{2max} in overweight women with polycystic ovary syndrome. Acta Obstetricia Et Gynecologica Scandinavica, 2013, 92, 272-277.	1.3	31
622	Evaluation and treatment of hirsutism. Apollo Medicine, 2013, 10, 138-145.	0.0	0
623	Metformin treatment in different phenotypes of polycystic ovary syndrome. Archives of Gynecology and Obstetrics, 2013, 288, 1131-1136.	0.8	4
624	A prospective, randomised, investigator-blind, controlled, clinical study on the clinical efficacy and tolerability of two highly purified hMG preparations administered subcutaneously in women undergoing IVF. Gynecological Endocrinology, 2013, 29, 695-699.	0.7	8
625	Glucose intolerance states in women with the polycystic ovary syndrome. Journal of Endocrinological Investigation, 2013, 36, 648-653.	1.8	47
626	Dietary intake, glucose metabolism and sex hormones in women with polycystic ovary syndrome (PCOS) compared with women with non-PCOS-related infertility. British Journal of Nutrition, 2013, 109, 2190-2198.	1.2	26
627	Low Plasma Atrial Natriuretic Peptide: A New Piece in the Puzzle of Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4882-4889.	1.8	18
628	Decreased Phosphorylation of Y14Caveolin-1 in Endometrial Tissue of Polycystic Ovary Syndrome Patients may be Related with an Insulin Resistant State in this Tissue. Hormone and Metabolic Research, 2013, 45, 291-296.	0.7	7
629	Can anti-MÃ¼llerian hormone be predictive of spontaneous onset of pregnancy in women with unexplained infertility?. Journal of Obstetrics and Gynaecology, 2013, 33, 857-861.	0.4	21
630	Expression of SET Protein in the Ovaries of Patients with Polycystic Ovary Syndrome. International Journal of Endocrinology, 2013, 2013, 1-5.	0.6	7
631	Pregnancy in polycystic ovary syndrome. Indian Journal of Endocrinology and Metabolism, 2013, 17, 37.	0.2	42

#	Article	IF	Citations
632	Risks for Gestational Diabetes Mellitus and Pregnancy-Induced Hypertension Are Increased in Polycystic Ovary Syndrome. BioMed Research International, 2013, 2013, 1-6.	0.9	35
633	Clinical characteristics of polycystic ovary syndrome in Indian women. Indian Journal of Endocrinology and Metabolism, 2013, 17, 138.	0.2	73
634	Retinol-binding protein 4, leptin, and insulin resistance in idiopathic hirsutism and hirsute women with polycystic ovary syndrome. Journal of the Egyptian Women's Dermatologic Society, 2013, 10, 94-100.	0.2	1
635	Exercise Training in Polycystic Ovarian Syndrome Enhances Flow-Mediated Dilation in the Absence of Changes in Fatness. Medicine and Science in Sports and Exercise, 2013, 45, 2234-2242.	0.2	38
636	The impact of hyperandrogenism in female obesity and cardiometabolic diseases associated with polycystic ovary syndrome. Hormone Molecular Biology and Clinical Investigation, 2013, 15, 91-103.	0.3	10
637	Abdominal Obesity is Associated With a Lower Ankleâ€“Brachial Index in Women With Polycystic Ovary Syndrome. Angiology, 2013, 64, 105-111.	0.8	4
638	Increased Total Renin Levels but Not Angiotensin-Converting Enzyme Activity in Obese Patients with Polycystic Ovary Syndrome. Medical Principles and Practice, 2013, 22, 475-479.	1.1	18
639	Polikistik Over Sendromu olan KadÄ±nlarda Psikiyatrik Belirtiler / Psychiatric Symptoms in Women with Polycystic Ovary Syndrome. Dusunen Adam, 2013, , .	0.0	3
640	Predictors of Postpartum Glucose Tolerance Testing in Italian Women with Gestational Diabetes Mellitus. Isrn Endocrinology, 2013, 2013, 1-6.	2.0	16
641	Management of Pediatric and Adolescent Type 2 Diabetes. International Journal of Pediatrics (United) Tj ETQq1 1 0.784314 rgBT /Ove	0.2	11
642	Longitudinal weight gain in women identified With polycystic ovary syndrome: Results of an observational study in young women. Obesity, 2013, 21, 1526-1532.	1.5	250
643	Pretreatment and coâ€administration of oral antiâ€diabetic agent with clomiphene citrate or <scp>rFSH</scp> for ovulation induction in clomipheneâ€citrateâ€resistant polycystic ovary syndrome. Journal of Obstetrics and Gynaecology Research, 2013, 39, 966-973.	0.6	17
644	Effects of metformin on serum insulin and anti-mullerian hormone levels and on hyperandrogenism in patients with polycystic ovary syndrome. Gynecological Endocrinology, 2013, 29, 246-249.	0.7	27
645	Normal metabolic flexibility despite insulin resistance women with polycystic ovary syndrome. Endocrine Journal, 2013, 60, 1107-1113.	0.7	15
646	The M-OVIN study: does switching treatment to FSH and / or IUI lead to higher pregnancy rates in a subset of women with world health organization type II anovulation not conceiving after six ovulatory cycles with clomiphene citrate â€“ a randomised controlled trial. BMC Women's Health, 2013, 13, 42.	0.8	12
647	Is Insulin Resistance an Intrinsic Defect in Asian Polycystic Ovary Syndrome?. Yonsei Medical Journal, 2013, 54, 609.	0.9	12
648	Effects of insulin-sensitizing agents and insulin resistance in women with polycystic ovary syndrome. Clinical and Experimental Reproductive Medicine, 2013, 40, 100.	0.5	17
649	Cessation of gonadotropin-releasing hormone antagonist on triggering day in flexible multiple-dose protocol: A randomized controlled study. Clinical and Experimental Reproductive Medicine, 2013, 40, 83.	0.5	4

#	Article	IF	Citations
650	Arterial hypertension and metabolic profile in patients with polycystic ovary syndrome. Revista Brasileira De Ginecologia E Obstetricia, 2013, 35, 21-26.	0.3	8
651	Ovarian Volume throughout Life: A Validated Normative Model. PLoS ONE, 2013, 8, e71465.	1.1	72
652	Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clinical Epidemiology, 2013, 6, 1.	1.5	873
653	Association between serum anti-MÃ¼llerian hormone level and ovarian response to mild stimulation in normoovulatory women and anovulatory women with polycystic ovary syndrome. Clinical and Experimental Reproductive Medicine, 2013, 40, 95.	0.5	8
654	Metabolic Disturbance in PCOS: Clinical and Molecular Effects on Skeletal Muscle Tissue. Scientific World Journal, The, 2013, 2013, 1-7.	0.8	13
655	Extended High Frequency Audiometry in Polycystic Ovary Syndrome. Scientific World Journal, The, 2013, 2013, 1-5.	0.8	18
656	Metabolic and other effects of pioglitazone as an add-on therapy to metformin in the treatment of polycystic ovary syndrome (PCOS). Hormones, 2013, 12, 363-378.	0.9	21
657	Primary care treatment of subfertility and what every health professional needs to know about assisted reproductive technology. , 0, , 199-211.		0
658	Chronic anovulation and the polycystic ovary syndrome. , 0, , 151-188.		1
659	A STUDY TO ASSESS THE TFFECTIVENESS OF PLANNED TEACHING PROGRAMME (PTP) ON POLYCYSTIC OVARIAN SYNDROME (PCOS) AMONG ADOLESCENT GIRLS IN SELECTED HIGH SCHOOLS AT MANGALORE. Journal of Health and Allied Sciences NU, 2013, 03, 101-104.	0.1	1
662	Correlation between Expression of Glucose Transporters in Granulosa Cells and Oocyte Quality in Women with Polycystic Ovary Syndrome. Endocrinology and Metabolism, 2014, 29, 40.	1.3	24
663	Power of Proteomics in Linking Oxidative Stress and Female Infertility. BioMed Research International, 2014, 2014, 1-26.	0.9	85
665	Optimal management of subfertility in polycystic ovary syndrome. International Journal of Women's Health, 2014, 6, 613.	1.1	16
666	Polycystic ovary syndrome: implications of metabolic dysfunction. Revista Do Colegio Brasileiro De Cirurgioes, 2014, 41, 106-110.	0.3	9
668	FTOGene Variants Are Associated with PCOS Susceptibility and Hyperandrogenemia in Young Korean Women. Diabetes and Metabolism Journal, 2014, 38, 302.	1.8	31
669	Surgical impact on serum anti-MÃ¼llerian hormone in women with benign ovarian cyst: A prospective study. Obstetrics and Gynecology Science, 2014, 57, 121.	0.6	21
671	Anti-MÃ¼llerian Hormone Levels in the Follicular Fluid of the Preovulatory Follicle: A Predictor for Oocyte Fertilization and Quality of Embryo. Journal of Korean Medical Science, 2014, 29, 1266.	1.1	23
672	Elevated serum androstenedione is associated with a more severe phenotype in women with polycystic ovary syndrome (PCOS). Hormones, 2014, 13, 213-221.	0.9	29

#	Article	IF	Citations
674	Subclinical hypothyroidism diagnosed by thyrotropin-releasing hormone stimulation test in infertile women with basal thyroid-stimulating hormone levels of 2.5 to 5.0 mIU/L. Obstetrics and Gynecology Science, 2014, 57, 507.	0.6	8
675	Clinical and Biochemical Profiles according to Homeostasis Model Assessment-insulin Resistance (HOMA-IR) in Korean Women with Polycystic Ovary Syndrome. Journal of Menopausal Medicine, 2014, 20, 104.	0.3	10
676	Screening for glucose intolerance in polycystic ovary syndrome: hemoglobin A1C, fasting blood glucose or oral glucose tolerance test?. Expert Review of Endocrinology and Metabolism, 2014, 9, 671-683.	1.2	0
677	What do we know about metabolic syndrome in adolescents with PCOS?. Journal of the Turkish German Gynecology Association, 2014, 15, 49-55.	0.2	29
678	The importance of lipid spectrum changes in women with polycystic ovary syndrome(PCOS). Bratislava Medical Journal, 2014, 115, 569-572.	0.4	0
680	The influence of combined oral contraceptives containing drospirenone on hypothalamic-pituitary-adrenocortical axis activity and glucocorticoid receptor expression and function in women with polycystic ovary syndrome. Hormones, 2014, 14, 109-17.	0.9	7
681	Hormonal causes of recurrent pregnancy loss (RPL). Hormones, 2014, 13, 314-322.	0.9	38
682	Improvement in diagnostic performance of the revised total testosterone measuring system in Japanese women with polycystic ovary syndrome. Journal of Medical Investigation, 2014, 61, 65-71.	0.2	8
683	Effect of electroacupuncture on egg quality and tumor necrosis factor -Î± of patients with polycystic ovarian syndrome. World Journal of Acupuncture-moxibustion, 2014, 24, 9-15.	0.1	8
684	Anti-Mullerian hormone may be a useful adjunct in the diagnosis of polycystic ovary syndrome in nonobese adolescents. Journal of Pediatric Endocrinology and Metabolism, 2014, 27, 1175-9.	0.4	35
685	Correlation of visfatin levels and lipoprotein lipid profiles in women with polycystic ovary syndrome undergoing ovarian stimulation. Gynecological Endocrinology, 2014, 30, 516-519.	0.7	19
686	In high responding patients undergoing an initial IVF cycle, elevated estradiol on the day of hCG has no effect on live birth rate. Reproductive Biology and Endocrinology, 2014, 12, 119.	1.4	15
687	Fibroblast growth factor 21 and its relation to metabolic parameters in women with polycystic ovary syndrome. Scandinavian Journal of Clinical and Laboratory Investigation, 2014, 74, 465-469.	0.6	16
688	Comparative evaluation of sonographic ovarian morphology of Indian women with polycystic ovary syndrome versus those of normal women. Indian Journal of Endocrinology and Metabolism, 2014, 18, 180.	0.2	2
689	A cross-sectional study of polycystic ovarian syndrome among adolescent and young girls in Mumbai, India. Indian Journal of Endocrinology and Metabolism, 2014, 18, 317.	0.2	109
690	Correlation between serum adiponectin and clinical characteristics, biochemical parameters in Indian women with polycystic ovary syndrome. Indian Journal of Endocrinology and Metabolism, 2014, 18, 221.	0.2	10
691	Association of -108 C>T PON1 polymorphism with polycystic ovary syndrome. Biomedical Reports, 2014, 2, 255-259.	0.9	7
692	Ovulation induction in polycystic ovary syndrome. Journal of Clinical and Experimental Investigations, 2014, 5, .	0.1	0

#	Article	IF	Citations
693	Does Polycystic Ovary Syndrome Itself Have Additional Effect on Apelin Levels?. Obstetrics and Gynecology International, 2014, 2014, 1-4.	0.5	10
694	Adrenocortical Production Is Associated with Higher Levels of Luteinizing Hormone in Nonobese Women with Polycystic Ovary Syndrome. International Journal of Endocrinology, 2014, 2014, 1-7.	0.6	11
695	Cryptotanshinone Reverses Reproductive and Metabolic Disturbances in PCOS Model Rats via Regulating the Expression of CYP17 and AR. Evidence-based Complementary and Alternative Medicine, 2014, 2014, 1-10.	0.5	24
696	Effects of Acarbose on Polycystic Ovary Syndrome: A Meta-analysis. Experimental and Clinical Endocrinology and Diabetes, 2014, 122, 373-378.	0.6	21
697	Effect of a low-starch/low-dairy diet on fat oxidation in overweight and obese women with polycystic ovary syndrome. Applied Physiology, Nutrition and Metabolism, 2014, 39, 1237-1244.	0.9	19
698	Menstrual cycle influence on cognitive function and emotion processingÃ¢â‚¬â€from a reproductive perspective. Frontiers in Neuroscience, 2014, 8, 380.	1.4	183
699	Comment on trends in onomastics-the case of PCOS by Kalra et al.. Indian Journal of Endocrinology and Metabolism, 2014, 18, 245.	0.2	2
700	Central arterial stiffness and diastolic dysfunction are associated with insulin resistance and abdominal obesity in young women but polycystic ovary syndrome does not confer additional risk. Human Reproduction, 2014, 29, 2041-2049.	0.4	24
701	Polycystic Ovary Syndrome in Young Women: Issues and Consequences. Nestle Nutrition Institute Workshop Series, 2014, , 87-94.	1.5	0
702	Herbal medicine for the management of polycystic ovary syndrome (PCOS) and associated oligo/amenorrhoea and hyperandrogenism; a review of the laboratory evidence for effects with corroborative clinical findings. BMC Complementary and Alternative Medicine, 2014, 14, 511.	3.7	124
703	Comparison of Dietary Intake and Physical Activity between Women with and without Polycystic Ovary Syndrome: A Review. Advances in Nutrition, 2014, 5, 486-496.	2.9	32
704	Postprandial effects of longâ€term niacin/laropiprant use on glucose and lipid metabolism and on cardiovascular risk in patients with polycystic ovary syndrome. Diabetes, Obesity and Metabolism, 2014, 16, 545-552.	2.2	10
705	Hyperinsulinemia Alters Myoinositol to d-chiroinositol Ratio in the Follicular Fluid of Patients With PCOS. Reproductive Sciences, 2014, 21, 854-858.	1.1	85
706	The transcriptome of corona radiata cells from individual MÐ†Ð† oocytes that after ICSI developed to embryos selected for transfer: PCOS women compared to healthy women. Journal of Ovarian Research, 2014, 7, 110.	1.3	15
707	Impact of obesity on intracytoplasmic sperm injection outcome in polycystic ovarian syndrome patients. Evidence Based Women S Health Journal, 2014, 4, 108-111.	0.0	0
708	Studies of cardiovascular risk factors in polycystic ovary syndrome patients combined with subclinical hypothyroidism. Gynecological Endocrinology, 2014, 30, 553-556.	0.7	13
709	Laboratory Assessment. , 2014, , 822-850.e3.		10
710	Managing PCOS-Related Infertility: Ovulation Induction, In Vitro Fertilization, and In Vitro Maturation. , 2014, , 205-221.		1

#	Article	IF	Citations
711	Association between Adiponectin Receptor 1 Gene Polymorphism and Insulin Resistance in Chinese Patients with Polycystic Ovary Syndrome. Gynecologic and Obstetric Investigation, 2014, 77, 45-49.	0.7	7
712	Successful Same-Cycle Blastocyst Transfer following Laparoscopic Ovarian Detorsion: A Report of Two Cases and Literature Review. Case Reports in Obstetrics and Gynecology, 2014, 2014, 1-4.	0.2	0
713	Polycystic Ovarian Syndrome: Pathophysiology and Infertility. World Journal of Laparoscopic Surgery, 2014, 7, 23-27.	0.2	1
714	Plasma visfatin levels and mRNA expression of visfatin in peripheral blood mononuclear cells and peripheral blood monocyte-derived macrophages from normal weight females with polycystic ovary syndrome. Experimental and Therapeutic Medicine, 2014, 7, 1215-1220.	0.8	7
715	Does optimal follicular size in IUI cycles vary between clomiphene citrate and gonadotrophins treatments?. Gynecological Endocrinology, 2014, 30, 107-110.	0.7	26
716	Reciprocal Action of Pentraxin-3 and CRP in Women with Polycystic Ovary Syndrome. European Journal of Inflammation, 2014, 12, 161-166.	0.2	3
717	Copeptin, a surrogate marker for arginine vasopressin, is associated with cardiovascular risk in patients with polycystic ovary syndrome. Journal of Ovarian Research, 2014, 7, 31.	1.3	24
718	Risk of first trimester spontaneous miscarriage among singleton gestations following ICSI and its relation to underlying cause of infertility. Middle East Fertility Society Journal, 2014, 19, 129-134.	0.5	2
719	Assessment of ovarian stromal blood flow after metformin treatment in women with polycystic ovary syndrome. Archives of Gynecology and Obstetrics, 2014, 289, 883-891.	0.8	10
720	Effects of DASH diet on lipid profiles and biomarkers of oxidative stress in overweight and obese women with polycystic ovary syndrome: A randomized clinical trial. Nutrition, 2014, 30, 1287-1293.	1.1	91
721	Women with clomiphene citrate resistant polycystic ovarian disease: predictors of spontaneous ovulation after laparoscopic ovarian drilling. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2014, 175, 178-185.	0.5	8
722	Influence of oral contraceptives on anthropomorphometric, endocrine, and metabolic profiles of anovulatory polycystic ovary syndrome patients. Fertility and Sterility, 2014, 101, 1757-1765.e1.	0.5	25
723	Diagnosis of Polycystic Ovary Syndrome: AMH in combination with clinical symptoms. Journal of Assisted Reproduction and Genetics, 2014, 31, 213-220.	1.2	47
724	Epicardial adipose tissue thickness and NGAL levels in women with polycystic ovary syndrome. Journal of Ovarian Research, 2014, 7, 24.	1.3	8
725	Association between circulating adiponectin levels and polycystic ovarian syndrome. Journal of Ovarian Research, 2014, 7, 18.	1.3	41
726	Definition of insulin resistance using the homeostasis model assessment (HOMA-IR) in IVF patients diagnosed with polycystic ovary syndrome (PCOS) according to the Rotterdam criteria. Endocrine, 2014, 47, 625-630.	1.1	49
727	Endocrine profile following stimulation with recombinant follicle stimulating hormone and luteinizing hormone versus highly purified human menopausal gonadotropin. Reproductive Biology and Endocrinology, 2014, 12, 10.	1.4	25
728	Metabolic heterogeneity of follicular amino acids in polycystic ovary syndrome is affected by obesity and related to pregnancy outcome. BMC Pregnancy and Childbirth, 2014, 14, 11.	0.9	48

#	Article	IF	Citations
729	Occupational exposure to pesticides and consequences on male semen and fertility: A review. Toxicology Letters, 2014, 230, 146-156.	0.4	198
730	Polycystic Ovary Syndrome and Hyperandrogenic States. , 2014, , 485-511.e7.		2
731	Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction Update, 2014, 20, 748-758.	5.2	400
732	Prevalence and impact of hyperandrogenemia in 1,218 women with polycystic ovary syndrome. Endocrine, 2014, 47, 631-638.	1.1	68
733	Gestational Diabetes and Type 2 Diabetes in Reproductive-Aged Women With Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E447-E452.	1.8	110
734	The Pregnancy in Polycystic Ovary Syndrome II study: baseline characteristics and effects of obesity from a multicenter randomized clinical trial. Fertility and Sterility, 2014, 101, 258-269.e8.	0.5	48
736	Association of PCOS and Its Clinical Signs with Sexual Function among Iranian Women Affected by PCOS. Journal of Sexual Medicine, 2014, 11, 2508-2514.	0.3	20
737	Common polymorphisms of calpain-10 and the risk of polycystic ovary syndrome in Tunisian population: a caseâ€“control study. Molecular Biology Reports, 2014, 41, 6569-6574.	1.0	10
738	Retrospective comparison of GnRH agonist trigger with HCG trigger in GnRH antagonist cycles in anticipated high-responders. Reproductive BioMedicine Online, 2014, 29, 552-558.	1.1	14
739	Prevalence of Polycystic Ovary Syndrome Phenotypes Using Updated Criteria for Polycystic Ovarian Morphology: An Assessment of Over 100 Consecutive Women Self-reporting Features of Polycystic Ovary Syndrome. Reproductive Sciences, 2014, 21, 1034-1043.	1.1	74
740	Polycystic ovary syndrome: A review for dermatologists. Journal of the American Academy of Dermatology, 2014, 71, 847.e1-847.e10.	0.6	58
741	25-Hydroxyvitamin D levels are related to hyperinsulinemia in polycystic ovary syndrome. Gynecological Endocrinology, 2014, 30, 557-560.	0.7	10
742	Assessment of atrial conduction time in patients with polycystic ovary syndrome. Journal of Interventional Cardiac Electrophysiology, 2014, 41, 137-143.	0.6	9
743	Evaluation of the Macula, Retinal Nerve Fiber Layer, and Choroid Thickness in Women With Polycystic Ovary Syndrome Using Spectral-Domain Optical Coherence Tomography. Reproductive Sciences, 2014, 21, 1044-1049.	1.1	14
744	Imbalance Between Postprandial Ghrelin and Insulin Responses to an Ad Libitum Meal in Obese Women With Polycystic Ovary Syndrome. Reproductive Sciences, 2014, 21, 1020-1026.	1.1	9
745	Contraception use and pregnancy outcomes in women with polycystic ovary syndrome: data from the Australian Longitudinal Study on Women's Health. Human Reproduction, 2014, 29, 802-808.	0.4	63
746	Brachial-to-ankle pulse wave velocity as an independent prognostic factor for ovulatory response to clomiphene citrate in women with polycystic ovary syndrome. Journal of Ovarian Research, 2014, 7, 74.	1.3	2
747	Two follicle-stimulating hormone receptor polymorphisms and polycystic ovary syndrome risk: a meta-analysis. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2014, 182, 27-32.	0.5	18

#	Article	IF	Citations
748	Genetic variants of the HSD11B1 gene promoter may be protective against polycystic ovary syndrome. Molecular Biology Reports, 2014, 41, 5961-5969.	1.0	5
749	Testosterone treatment increases androgen receptor and aromatase gene expression in myotubes from patients with PCOS and controls, but does not induce insulin resistance. Biochemical and Biophysical Research Communications, 2014, 451, 622-626.	1.0	17
750	The effect of obesity on inflammatory markers in patients with PCOS: a BMI-matched caseâ€“control study. Archives of Gynecology and Obstetrics, 2014, 290, 315-319.	0.8	61
751	Association of the luteinizing hormone/choriogonadotropin receptor gene polymorphism with polycystic ovary syndrome. Gynecological Endocrinology, 2014, 30, 428-430.	0.7	24
752	Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients. Gynecological Endocrinology, 2014, 30, 438-443.	0.7	53
753	Selenium Reduces Oxidative Stress and Calcium Entry Through TRPV1 Channels in the Neutrophils of Patients with Polycystic Ovary Syndrome. Biological Trace Element Research, 2014, 158, 136-142.	1.9	44
754	Zinc and Homocysteine Levels in Polycystic Ovarian Syndrome Patients with Insulin Resistance. Biological Trace Element Research, 2014, 158, 297-304.	1.9	43
756	Physical activity and mental health in women with Polycystic Ovary Syndrome. BMC Women's Health, 2014, 14, 51.	0.8	76
757	Acne and PCOS are less frequent in women with Mayer-Rokitansky-KÃ¼ster-Hauser syndrome despite a high rate of hyperandrogenemia: a cross-sectional study. Reproductive Biology and Endocrinology, 2014, 12, 23.	1.4	9
758	Insulin and body weight but not hyperandrogenism seem involved in seasonal serum 25-OH-vitamin D3 levels in subjects affected by PCOS. Gynecological Endocrinology, 2014, 30, 739-745.	0.7	13
759	Fasting and postâ€prandial glucagon like peptide 1 and oral contraception in polycystic ovary syndrome. Clinical Endocrinology, 2014, 81, 588-592.	1.2	27
760	Gestagen versus oral contraceptive pills to induce withdrawal bleeding before induction of ovulation by clomiphene citrate in polycystic ovary syndrome. Middle East Fertility Society Journal, 2014, 19, 115-123.	0.5	0
761	Progressive Resistance Training in Polycystic Ovary Syndrome: Can Pumping Iron Improve Clinical Outcomes?. Sports Medicine, 2014, 44, 1197-1207.	3.1	17
762	Serum AMH levels in the differential diagnosis of hyperandrogenemic conditions. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2014, 177, 121-125.	0.5	10
763	Clustering of metabolic and cardiovascular risk factors in the polycystic ovary syndrome: a principal component analysis. Metabolism: Clinical and Experimental, 2014, 63, 1071-1077.	1.5	11
764	Combined pioglitazoneâ€“metformin and clomiphene citrate versus metformin and clomiphene citrate in induction of ovulation in women with clomiphene citrate-resistant polycystic ovary syndrome. Middle East Fertility Society Journal, 2014, 19, 27-33.	0.5	3
765	To what extent does the use of the Rotterdam criteria affect the prevalence of polycystic ovary syndrome? A community-based study from the Southwest of Iran. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2014, 174, 100-105.	0.5	42
766	Polycystic ovary syndrome: a common hormonal condition with major metabolic sequelae that physicians should know about. Internal Medicine Journal, 2014, 44, 720-726.	0.5	36

#	Article	IF	Citations
767	Evaluation of ultrasonographic and Anti-MÃ¼llerian Hormone (AMH) changes as predictors for ovarian reserve after laparoscopic ovarian drilling for women with polycystic ovarian syndrome. Middle East Fertility Society Journal, 2014, 19, 314-323.	0.5	6
768	The effects of adipocytokines on the endocrino-metabolic features and obstetric outcome in pregnant obese women with polycystic ovary syndrome. Middle East Fertility Society Journal, 2014, 19, 293-302.	0.5	11
769	33. Hypocaloric diets in overweight and obese patients with polycystic ovary syndrome. Human Health Handbooks, 2014, , 533-552.	0.1	0
770	31. Polycystic ovary syndrome and the metabolic syndrome. Human Health Handbooks, 2014, , 505-520.	0.1	0
771	30. The role of vitamin D for conception, polycystic ovary syndrome, endometriosis and the menstrual cycle. Human Health Handbooks, 2014, , 489-504.	0.1	1
772	Irregular bleeding in a 25-year-old woman. , 0, , 207-210.		0
773	Do we need readjustment of the biochemical parameters in first trimester combined aneuploidy screening test in women with polycystic ovary syndrome?. Prenatal Diagnosis, 2014, 34, 1073-1076.	1.1	5
774	Collection of 125 Oocytes in an In Vitro Maturation Cycle Using a New Oocyte Collection Technique: A Case Report. Journal of Obstetrics and Gynaecology Canada, 2014, 36, 900-903.	0.3	4
775	Follicular phase dexamethazone administration in polycystic ovarian syndrome patients who are clomiphene citrate resistant. Reproducao E Climaterio, 2015, 30, 115-120.	0.1	0
776	Evaluation of insulin resistance and plasma levels for visfatin and resistin in obese and non-obese patients with polycystic ovary syndrome. European Cytokine Network, 2015, 26, 73-78.	1.1	14
778	Study of the association of the T869C polymorphism of the transforming growth factor-Î²1 gene with polycystic ovary syndrome. Molecular Medicine Reports, 2015, 12, 4560-4565.	1.1	4
779	Benefits of short-term structured exercise in non-overweight women with polycystic ovary syndrome: a prospective randomized controlled study. Journal of Physical Therapy Science, 2015, 27, 2293-2297.	0.2	28
780	2015 Meet-The-Professor: Endocrine Case Management. , 2015, , .		0
781	Association between serum levels and pentanucleotide polymorphism in the sex hormone binding globulin gene and cardiovascular risk factors in females with polycystic ovary syndrome. Molecular Medicine Reports, 2015, 11, 3941-3947.	1.1	17
782	Diagnosis and management of polycystic ovary syndrome. Independent Nurse, 2015, 2015, 27-28.	0.0	1
783	Functional microarray analysis of differentially expressed genes in granulosa cells from women with polycystic ovary syndrome related to MAPK/ERK signaling. Scientific Reports, 2015, 5, 14994.	1.6	53
784	Controversies of the assesment and management of polycystic ovary syndrome in adolescents. International Journal of Pediatric Endocrinology (Springer), 2015, 2015, .	1.6	0
786	Altered microRNAs expression profiling in cumulus cells from patients with polycystic ovary syndrome. Journal of Translational Medicine, 2015, 13, 238.	1.8	49

#	Article	IF	Citations
787	The relationship between epicardial fat tissue thickness and visceral adipose tissue in lean patients with polycystic ovary syndrome. Journal of Ovarian Research, 2015, 8, 71.	1.3	17
788	Diagnostic criteria of polycystic ovary syndrome. , 0, , 74-78.		0
789	Polycystic ovary syndrome and cardiovascular risk. , 0, , 89-96.		0
790	History and physical examination of polycystic ovary syndrome: Detecting too much or too little. , 0, , 161-179.		0
791	Ovulation induction in women with polycystic ovary syndrome. , 0, , 226-232.		0
792	Atherogenic index of plasma in nonâ€obese women with androgenetic alopecia. International Journal of Dermatology, 2015, 54, e339-44.	0.5	16
793	Implications of Polycystic Ovary Syndrome for Pregnancy and for the Health of Offspring. Obstetrics and Gynecology, 2015, 125, 1397-1406.	1.2	99
794	Sympathetic activation and endothelial dysfunction in polycystic ovary syndrome are not explained by either obesity or insulin resistance. Clinical Endocrinology, 2015, 83, 812-819.	1.2	60
795	Ocular blood flow in polycystic ovary syndrome. Journal of Obstetrics and Gynaecology Research, 2015, 41, 1080-1086.	0.6	7
796	Ovarian actions of resveratrol. Annals of the New York Academy of Sciences, 2015, 1348, 86-96.	1.8	55
797	Serum antiâ€Mullerian hormone levels across different ethnic groups: a crossâ€sectional study. BJOG: an International Journal of Obstetrics and Gynaecology, 2015, 122, 1625-1629.	1.1	26
798	Value of ultrasonography in the diagnosis of polycystic ovary syndrome â€“ literature review. , 2015, 15, 410-422.		22
799	Efficacy and safety of metformin or oral contraceptives, or both in polycystic ovary syndrome. Therapeutics and Clinical Risk Management, 2015, 11, 1345.	0.9	11
800	Diagnostic Usefulness of Transrectal Ultrasound Compared with Transvaginal Ultrasound Assessment in Young Korean Women with Polycystic Ovary Syndrome. Journal of Menopausal Medicine, 2015, 21, 149.	0.3	17
801	Complications and challenges associated with polycystic ovary syndrome: current perspectives. International Journal of Women's Health, 2015, 7, 745.	1.1	153
802	PREVALENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE IN WOMEN WITH POLYCYSTIC OVARY SYNDROME AND ITS CORRELATION WITH METABOLIC SYNDROME. Arquivos De Gastroenterologia, 2015, 52, 117-123.	0.3	41
803	Hyperandrogenism in female athletes with functional hypothalamic amenorrhea: a distinct phenotype. International Journal of Women's Health, 2015, 7, 103.	1.1	11
804	Evaluation of Para- and Perirenal Fat Thickness and its Association with Metabolic Disorders in Polycystic Ovary Syndrome. Endocrine Practice, 2015, 21, 878-886.	1.1	8

#	Article	IF	Citations
806	Clinical characteristics in Taiwanese women with polycystic ovary syndrome. Clinical and Experimental Reproductive Medicine, 2015, 42, 86.	0.5	17
807	High Prevalence of Vitamin D Deficiency in Infertile Women Referring for Assisted Reproduction. Nutrients, 2015, 7, 9972-9984.	1.7	49
808	N-Acetylcysteine for Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials. Obstetrics and Gynecology International, 2015, 2015, 1-13.	0.5	34
809	Mild-approach ART in a patient with polycystic ovary syndrome. , 0, , 93-96.		0
810	Identification of Differentially Expressed MicroRNAs in the Ovary of Polycystic Ovary Syndrome with Hyperandrogenism and Insulin Resistance. Chinese Medical Journal, 2015, 128, 169-174.	0.9	44
811	Polycystic ovary syndrome woman with heterozygous androgen receptor gene mutation who gave birth to a child with androgen insensitivity syndrome. Obstetrics and Gynecology Science, 2015, 58, 179.	0.6	10
812	Unaltered timing of embryo development in women with polycystic ovarian syndrome (PCOS): a time-lapse study. Journal of Assisted Reproduction and Genetics, 2015, 32, 1031-1042.	1.2	26
813	PCOS Therapy. , 2015, , 89-137.		3
814	Confocal Microscopic Analysis of the Spindle and Chromosome Configurations of in vitro-Matured Oocytes from Different Types of Polycystic Ovary Syndrome Patients. Gynecologic and Obstetric Investigation, 2015, 80, 179-186.	0.7	7
815	Lipidomic analysis of plasma samples from women with polycystic ovary syndrome. Metabolomics, 2015, 11, 657-666.	1.4	44
816	Triggering ovulation with gonadotropin-releasing hormone agonist versus human chorionic gonadotropin in polycystic ovarian syndrome. A randomized trial. Middle East Fertility Society Journal, 2015, 20, 217-223.	0.5	6
817	The association between follicular size at the time of spontaneous rupture and pregnancy rates in clomiphene citrate treated PCOS patients in coit cycles. Gynecological Endocrinology, 2015, 31, 392-395.	0.7	3
818	A caseâ€“control observational study of insulin resistance and metabolic syndrome among the four phenotypes of polycystic ovary syndrome based on Rotterdam criteria. Reproductive Health, 2015, 12, 7.	1.2	49
819	Metabolic profile of Diane-35 versus Diane-35 plus metformin in Chinese PCOS women under standardized life-style changes. Gynecological Endocrinology, 2015, 31, 548-551.	0.7	18
820	PCOS and Insulin Resistance (IR): From Lifestyle to Insulin Sensitizers. ISGE Series, 2015, , 11-23.	0.2	0
821	Fertility biomarkers to estimate metabolic risks in women with polycystic ovary syndrome. Journal of Assisted Reproduction and Genetics, 2015, 32, 1749-1756.	1.2	8
822	Treatment Strategies for the Infertile Polycystic Ovary Syndrome Patient. Women's Health, 2015, 11, 901-912.	0.7	14
823	Risk of cancer among women with polycystic ovary syndrome: A Danish cohort study. Gynecologic Oncology, 2015, 136, 99-103.	0.6	132

#	Article	IF	Citations
824	Prevalence of Infertility and Use of Fertility Treatment in Women with Polycystic Ovary Syndrome: Data from a Large Community-Based Cohort Study. Journal of Women's Health, 2015, 24, 299-307.	1.5	161
825	Metabolic risk in PCOS: phenotype and adiposity impact. Trends in Endocrinology and Metabolism, 2015, 26, 136-143.	3.1	181
826	Recurrent pregnancy loss and obesity. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2015, 29, 489-497.	1.4	39
827	Hypertension in Reproductive-Aged Women With Polycystic Ovary Syndrome and Association With Obesity. American Journal of Hypertension, 2015, 28, 847-851.	1.0	76
828	FTO gene variants are not associated with polycystic ovary syndrome in women from Southern Brazil. Gene, 2015, 560, 25-29.	1.0	25
829	A higher anti-MÃ¼llerian hormone level is associated with an increased chance of pregnancy in patients undergoing controlled ovarian stimulation and intrauterine insemination. Journal of Obstetrics and Gynaecology, 2015, 35, 64-68.	0.4	13
830	Predictors of success of laparoscopic ovarian drilling in women with polycystic ovary syndrome: an evidence-based approach. Archives of Gynecology and Obstetrics, 2015, 291, 11-18.	0.8	35
831	Mental Health and Physical Activity in Women with Polycystic Ovary Syndrome: A Brief Review. Sports Medicine, 2015, 45, 497-504.	3.1	42
832	N-acetyl cysteine reduces oxidative toxicity, apoptosis, and calcium entry through TRPV1 channels in the neutrophils of patients with polycystic ovary syndrome. Free Radical Research, 2015, 49, 338-346.	1.5	31
833	DASH Diet, Insulin Resistance, and Serum hs-CRP in Polycystic Ovary Syndrome: A Randomized Controlled Clinical Trial. Hormone and Metabolic Research, 2015, 47, 232-238.	0.7	91
834	Identification and replication of prediction models for ovulation, pregnancy and live birth in infertile women with polycystic ovary syndrome. Human Reproduction, 2015, 30, 2222-2233.	0.4	19
835	A systematic review and meta-analysis of metformin among patients with polycystic ovary syndrome undergoing assisted reproductive technology procedures. International Journal of Gynecology and Obstetrics, 2015, 131, 111-116.	1.0	26
836	Phenotypic Characterization of Polycystic Ovary Syndrome in Adolescents Based on Menstrual Irregularity. Hormone Research in Paediatrics, 2015, 84, 223-230.	0.8	4
837	Preliminary study of blood methylmercury effects on reproductive hormones and relevant factors among infertile and pregnant women in Taiwan. Chemosphere, 2015, 135, 411-417.	4.2	13
838	Large, comparative, randomized double-blind trial confirming noninferiority of pregnancy rates for corifollitropin alfa compared with recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist controlled ovarian stimulation protocol in older patients undergoing inÂvitro fertilization. Fertility and Sterility, 2015, 104, 94-103.e1.	0.5	48
839	The Diagnosis of Polycystic Ovary Syndrome during Adolescence. Hormone Research in Paediatrics, 2015, 83, 376-389.	0.8	2,130
840	Investigation of the Annexin A5 M2 haplotype in 500 white European couples who have experienced recurrent spontaneous abortion. Reproductive BioMedicine Online, 2015, 31, 681-688.	1.1	17
841	Detection of urine metabolites in polycystic ovary syndrome by UPLC triple-TOF-MS. Clinica Chimica Acta, 2015, 448, 39-47.	0.5	26

#	Article	IF	Citations
842	Irisin plasma concentration in PCOS and healthy subjects is related to body fat content and android fat distribution. Gynecological Endocrinology, 2015, 31, 907-911.	0.7	20
843	Increased body mass index negatively impacts blastocyst formation rate in normal responders undergoing in vitro fertilization. Journal of Assisted Reproduction and Genetics, 2015, 32, 1299-1304.	1.2	49
844	Adolescent Oligomenorrhea (Age 14â€“19) Tracks Into the Third Decade of Life (Age 20â€“28) and Predicts Increased Cardiovascular Risk Factors and Metabolic Syndrome. Metabolism: Clinical and Experimental, 2015, 64, 539-553.	1.5	27
845	Association ofCYP17A1gene -34T/C polymorphism with polycystic ovary syndrome in Han Chinese population. Gynecological Endocrinology, 2015, 31, 40-43.	0.7	18
846	Frequency of nodular goiter and autoimmune thyroid disease in patients with polycystic ovary syndrome. Endocrine, 2015, 49, 464-469.	1.1	21
847	The correlation of aromatase activity and obesity in women with or without polycystic ovary syndrome. Journal of Ovarian Research, 2015, 8, 11.	1.3	81
848	OvAge: a new methodology to quantify ovarian reserve combining clinical, biochemical and 3D-ultrasonographic parameters. Journal of Ovarian Research, 2015, 8, 21.	1.3	26
849	PON1 polymorphisms are associated with polycystic ovary syndrome susceptibility, related traits, and PON1 activity in Indian women with the syndrome. Fertility and Sterility, 2015, 104, 207-216.	0.5	18
850	Calcium plus vitamin D supplementation affects glucose metabolism and lipid concentrations in overweight and obese vitamin D deficient women with polycystic ovary syndrome. Clinical Nutrition, 2015, 34, 586-592.	2.3	107
851	Metabolic Aspects of PCOS. , 2015, , .		6
852	Polycystic Ovary Syndrome: Special Diagnostic and Therapeutic Considerations for Children. Pediatric Dermatology, 2015, 32, 571-578.	0.5	12
853	Polycystic Ovary Syndrome and Insulin: Our Understanding in the Past, Present and Future. Women's Health, 2015, 11, 137-149.	0.7	29
854	The effectiveness and safety of treatments used for polycystic ovarian syndrome management in adolescents: a systematic review and network meta-analysis protocol. Systematic Reviews, 2015, 4, 125.	2.5	12
855	Association of Calpain (CAPN) 10 (UCSNP-43, rs3792267) gene polymorphism with elevated serum androgens in young women with the most severe phenotype of polycystic ovary syndrome (PCOS). Gynecological Endocrinology, 2015, 31, 630-634.	0.7	9
856	Affect-regulated exercise: an alternative approach for lifestyle modification in overweight/obese women with polycystic ovary syndrome. Gynecological Endocrinology, 2015, 31, 971-975.	0.7	9
857	Genetic Predisposition to Polycystic Ovary Syndrome, Postpartum Weight Reduction, and Glycemic Changes: A Longitudinal Study in Women With Prior Gestational Diabetes. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E1560-E1567.	1.8	2
859	Androgen levels in women with various forms of ovarian dysfunction: associations with cardiometabolic features. Human Reproduction, 2015, 30, 2376-2386.	0.4	58
860	Paternal history of diabetes mellitus and hypertension affects the prevalence and phenotype of PCOS. Journal of Assisted Reproduction and Genetics, 2015, 32, 1731-1739.	1.2	9

#	Article	IF	Citations
861	Monofollicular Stimulation in PCOS Patients. , 2015, , 57-66.		0
862	Vitamin D Supplementation Decreases TGF-Î²1 Bioavailability in PCOS: A Randomized Placebo-Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 4307-4314.	1.8	77
863	Increased serum chemerin concentrations in patients with polycystic ovary syndrome: Relationship between insulin resistance and ovarian volume. Clinica Chimica Acta, 2015, 450, 366-369.	0.5	32
864	Increased chromosome 16 disomy rates in human spermatozoa and recurrent spontaneous abortions. Fertility and Sterility, 2015, 104, 1130-1137.e10.	0.5	26
866	Expression and localisation of c-kit and KITL in the adult human ovary. Journal of Ovarian Research, 2015, 8, 31.	1.3	22
867	Chromium Supplementation and the Effects on Metabolic Status in Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Annals of Nutrition and Metabolism, 2015, 67, 42-48.	1.0	26
868	Randomized Controlled Trial of Preconception Interventions in Infertile Women With Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 4048-4058.	1.8	180
869	1-h Postprandial glucose level is related to the serum anti-MÃ¼llerian hormone level in women with polycystic ovary syndrome. Gynecological Endocrinology, 2015, 31, 815-818.	0.7	11
870	Pregnancy in Polycystic Ovary Syndrome I: Lessons from a Pragmatic Explanatory with Repository Clinical Trial. Seminars in Reproductive Medicine, 2015, 33, 213-219.	0.5	0
871	A Novel Letrozole Model Recapitulates Both the Reproductive and Metabolic Phenotypes of Polycystic Ovary Syndrome in Female Mice1. Biology of Reproduction, 2015, 93, 69.	1.2	145
872	M2/ANXA5 haplotype as a predisposition factor in Malay women and couples experiencing recurrent spontaneous abortion: a pilot study. Reproductive BioMedicine Online, 2015, 30, 434-439.	1.1	14
873	Efficacy of metformin on pregnancy complications in women with polycystic ovary syndrome: a meta-analysis. Gynecological Endocrinology, 2015, 31, 833-839.	0.7	39
874	Attention deficit-hyperactivity disorder symptoms in women with polycystic ovary syndrome. International Journal of Psychiatry in Medicine, 2015, 50, 317-325.	0.8	23
875	Android fat distribution affects some hemostatic parameters in women with polycystic ovary syndrome compared with healthy control subjects matched for age and body mass index. Fertility and Sterility, 2015, 104, 467-473.	0.5	8
876	Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations. Nature Communications, 2015, 6, 7502.	5.8	314
877	Reproductive System Outcome Among Patients with Polycystic Ovarian Syndrome. Endocrinology and Metabolism Clinics of North America, 2015, 44, 787-797.	1.2	11
878	Putative role for insulin resistance in depression risk in polycystic ovary syndrome. Fertility and Sterility, 2015, 104, 707-714.e1.	0.5	46
879	The Diagnosis of Polycystic Ovary Syndrome in Adolescents. Pediatrics, 2015, 136, 1154-1165.	1.0	151

#	Article	IF	Citations
880	Adipokines in human reproduction. Hormone Molecular Biology and Clinical Investigation, 2015, 24, 11-24.	0.3	51
881	Polymorphism of CAG and GGN repeats of androgen receptor gene in women with polycystic ovary syndrome. Reproductive BioMedicine Online, 2015, 31, 790-798.	1.1	11
882	Does obesity have detrimental effects on IVF treatment outcomes?. BMC Women's Health, 2015, 15, 61.	0.8	48
883	Serum sirtuin 1 levels in patients with polycystic ovary syndrome. Journal of Obstetrics and Gynaecology, 2015, 35, 608-611.	0.4	14
884	Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with d-Chiro-Inositol. Archives of Gynecology and Obstetrics, 2015, 291, 1181-1186.	0.8	64
885	Women with polycystic ovary syndrome have greater muscle strength irrespective of body composition. Gynecological Endocrinology, 2015, 31, 237-242.	0.7	30
886	CYP51A1 Induced by Growth Differentiation Factor 9 and Follicle-Stimulating Hormone in Granulosa Cells Is a Possible Predictor for Unfertilization. Reproductive Sciences, 2015, 22, 377-384.	1.1	17
887	Association of plasma GDF-9 or GDF-15 levels with bone parameters in polycystic ovary syndrome. Journal of Bone and Mineral Metabolism, 2015, 33, 101-108.	1.3	21
888	The influence of body weight on sexual function and quality of life in women with polycystic ovary syndrome. Archives of Gynecology and Obstetrics, 2015, 291, 451-455.	0.8	53
889	Mouse GDF9 decreases KITL gene expression in human granulosa cells. Endocrine, 2015, 48, 686-695.	1.1	6
890	Therapeutic effects of metformin and laparoscopic ovarian drilling in treatment of clomiphene and insulin-resistant polycystic ovary syndrome. Archives of Gynecology and Obstetrics, 2015, 291, 1089-1094.	0.8	6
891	Impact of letrozole on ultrasonographic markers of endometrial receptivity in polycystic ovary syndrome women with poor endometrial response to clomiphene citrate despite adequate ovulation. Middle East Fertility Society Journal, 2015, 20, 182-187.	0.5	6
892	Pathophysiology, risk factors, and screening methods for prediabetes in women with polycystic ovary syndrome. International Journal of Women's Health, 2016, Volume 8, 381-387.	1.1	6
893	Epigenetic modification of long interspersed elements-1 in cumulus cells of mature and immature oocytes from patients with polycystic ovary syndrome. Clinical and Experimental Reproductive Medicine, 2016, 43, 82.	0.5	21
894	http://www.omicsgroup.org/journals/effects-of-borax-and-sleeve-gastrectomy-on-mrna-expression-ofantioxidant-genes-in-substantia-nigra Journal of Obesity & Weight Loss Therapy, 2016, 06, .	0.1	2
895	Risk for Gestational Diabetes Mellitus and Adverse Birth Outcomes in Chinese Women with Polycystic Ovary Syndrome. International Journal of Endocrinology, 2016, 2016, 1-6.	0.6	21
896	Inositol Treatment and ART Outcomes in Women with PCOS. International Journal of Endocrinology, 2016, 2016, 1-9.	0.6	25
897	From Placenta to Polycystic Ovarian Syndrome: The Role of Adipokines. Mediators of Inflammation, 2016, 2016, 1-14.	1.4	26

#	Article	IF	Citations
898	Bariatric Surgery, Polycystic Ovary Syndrome, and Infertility. Journal of Obesity, 2016, 2016, 1-6.	1.1	56
899	A Combined Therapy with Myo-Inositol and D-Chiro-Inositol Improves Endocrine Parameters and Insulin Resistance in PCOS Young Overweight Women. International Journal of Endocrinology, 2016, 2016, 1-5.	0.6	67
900	Different Effects of Myoinositol plus Folic Acid versus Combined Oral Treatment on Androgen Levels in PCOS Women. International Journal of Endocrinology, 2016, 2016, 1-8.	0.6	25
901	Correlation between ovarian morphology and biochemical and hormonal parameters in polycystic ovary syndrome. Pakistan Journal of Medical Sciences, 2016, 32, 742-5.	0.3	3
902	Insulin-Sensitizers, Polycystic Ovary Syndrome and Gynaecological Cancer Risk. International Journal of Endocrinology, 2016, 2016, 1-17.	0.6	23
903	Associations of Vitamin D with Inter- and Intra-Muscular Adipose Tissue and Insulin Resistance in Women with and without Polycystic Ovary Syndrome. Nutrients, 2016, 8, 774.	1.7	10
904	Insulin Resistance in PCOS Patients Enhances Oxidative Stress and Leukocyte Adhesion: Role of Myeloperoxidase. PLoS ONE, 2016, 11, e0151960.	1.1	76
905	To Assess the Association between Glucose Metabolism and Ectopic Lipid Content in Different Clinical Classifications of PCOS. PLoS ONE, 2016, 11, e0160571.	1.1	13
906	The Association of -429T>C and -374T>A Polymorphisms in the RAGE Gene with Polycystic Ovary Syndrome. International Journal of Medical Sciences, 2016, 13, 451-456.	1.1	6
907	Prospective Randomized Study on the Influence of Myoinositol in PCOS Women Undergoing IVF in the Improvement of Oocyte Quality, Fertilization Rate, and Embryo Quality. International Journal of Endocrinology, 2016, 2016, 1-5.	0.6	77
908	Association between serum gonadotropin level and insulin resistance-related parameters in Korean women with polycystic ovary syndrome. Obstetrics and Gynecology Science, 2016, 59, 498.	0.6	14
909	Hypothyroidism in polycystic ovarian syndrome: a comparative study of clinical characteristics, metabolic and hormonal parameters in euthyroid and hypothyroid polycystic ovarian syndrome women. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 2016, , 3181-3185.	0.0	1
911	SERUM IRISIN AND LEPTIN LEVELS IN OBESE AND NON-OBESE WOMEN WITH POLYCYSTIC OVARY SYNDROME WITH REFERENCE TO GLUCOSE HOMEOSTASIS. International Journal of Pharmacy and Pharmaceutical Sciences, 2016, 8, 276.	0.3	6
912	The role of antimullerian hormone in the hormonal workup of women with persistent acne. Journal of Cosmetic Dermatology, 2016, 15, 343-349.	0.8	8
913	Evaluation of the role of soluble receptors for advanced glycosylated end-products in polycystic ovarian syndrome. Evidence Based Women S Health Journal, 2016, 6, 26-31.	0.0	0
914	Relationship between pelvic floor muscle and hormone levels in polycystic ovary syndrome. Neurourology and Urodynamics, 2016, 35, 780-785.	0.8	7
915	17-Hydroxyprogesterone responses to human chorionic gonadotropin are not associated with serum anti-Mullerian hormone levels among adolescent girls with polycystic ovary syndrome. Journal of Pediatric Endocrinology and Metabolism, 2016, 29, 835-40.	0.4	4
916	Avoiding OHSS: Controlled Ovarian Low-Dose Stimulation in Women with PCOS. Geburtshilfe Und Frauenheilkunde, 2016, 76, 718-726.	0.8	24

#	Article	IF	Citations
917	The association of thiol/disulphide homeostasis and lipid accumulation index with cardiovascular risk factors in overweight adolescents with polycystic ovary syndrome. Clinical Endocrinology, 2016, 84, 516-523.	1.2	23
918	Diagnosis and management of polycystic ovary syndrome in the UK (2004â€“2014): a retrospective cohort study. BMJ Open, 2016, 6, e012461.	0.8	29
919	Effect of acupoint catgut embedding therapy combined with Chinese medicine for nourishing the kidneys and promoting blood circulation and improving blood glucose and lipid levels as well as the pregnancy rate in obese PCOS patients with infertility. Experimental and Therapeutic Medicine, 2016, 12, 2909-2914.	0.8	23
920	Amh Measurement Versus Ovarian Ultrasound In The Diagnosis Of Polycystic Ovary Syndrome In Different Phenotypes. Endocrine Practice, 2016, 22, 287-293.	1.1	38
921	Point mutation in mitochondrial tRNA gene is associated with polycystic ovary syndrome and insulin resistance. Molecular Medicine Reports, 2016, 13, 3169-3172.	1.1	25
922	Single-cell analysis of differences in transcriptomic profiles of oocytes and cumulus cells at GV, MI, MII stages from PCOS patients. Scientific Reports, 2016, 6, 39638.	1.6	56
924	FADS1-FADS2 gene cluster confers risk to polycystic ovary syndrome. Scientific Reports, 2016, 6, 21195.	1.6	9
925	Circulating Zinc-Î±2-glycoprotein levels and Insulin Resistance in Polycystic Ovary Syndrome. Scientific Reports, 2016, 6, 25934.	1.6	28
926	Co-morbidity of cervical incompetence with polycystic ovarian syndrome (PCOS) negatively impacts prognosis: A retrospective analysis of 178 patients. BMC Pregnancy and Childbirth, 2016, 16, 308.	0.9	12
927	Polycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: a systematic review. Fertility Research and Practice, 2016, 2, 14.	4.1	99
930	Polycystic Ovary Syndrome in Adolescents. Endocrinology and Metabolism Clinics of North America, 2016, 45, 329-344.	1.2	19
931	Impact of dexamethasone on pregnancy outcome in PCOs women candidate for IVF/ICSI, a single-blind randomized clinical trial study. Middle East Fertility Society Journal, 2016, 21, 184-188.	0.5	3
932	Acupuncture for treating polycystic ovary syndrome: guidance for future randomized controlled trials. Journal of Zhejiang University: Science B, 2016, 17, 169-180.	1.3	19
933	Genetic determinants ofÂpolycystic ovary syndrome: progress and future directions. Fertility and Sterility, 2016, 106, 25-32.	0.5	103
934	Ovarian Physiology and GWAS: Biobanks, Biology, and Beyond. Trends in Endocrinology and Metabolism, 2016, 27, 516-528.	3.1	9
935	Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertility and Sterility, 2016, 106, 6-15.	0.5	741
936	Genetics of Common Endocrine Disease: The Present and the Future. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 787-794.	1.8	12
937	Is cystatin C level altered in women with polycystic ovary syndrome?. Clinical Chemistry and Laboratory Medicine, 2016, 54, e265-e267.	1.4	0

#	Article	IF	Citations
938	Inositolâ€™s and other nutraceuticalsâ€™ synergistic actions counteract insulin resistance in polycystic ovarian syndrome and metabolic syndrome: state-of-the-art and future perspectives. Gynecological Endocrinology, 2016, 32, 431-438.	0.7	82
939	Developmental Programming: Prenatal Testosterone Excess and Insulin Signaling Disruptions in Female Sheep1. Biology of Reproduction, 2016, 94, 113.	1.2	33
940	Diet-Induced Weight Loss Reduces DNA Damage and Cardiometabolic Risk Factors in Overweight/Obese Women with Polycystic Ovary Syndrome. Annals of Nutrition and Metabolism, 2016, 68, 220-227.	1.0	21
941	In Estimated Good Prognosis Patients Could Unexpected â€œHyporesponseâ€• to Controlled Ovarian Stimulation be Related to Genetic Polymorphisms of FSH Receptor?. Reproductive Sciences, 2016, 23, 1103-1108.	1.1	38
942	Effect of sleeve gastrectomy bariatric surgery-induced weight loss on serum AMH levels in reproductive aged women. Gynecological Endocrinology, 2016, 32, 799-802.	0.7	33
943	Spironolactone and intermenstrual bleeding in polycystic ovary syndrome with normal BMI. Journal of Endocrinological Investigation, 2016, 39, 1015-1021.	1.8	16
944	The Effects of Vitamin D-K-Calcium Co-Supplementation on Endocrine, Inflammation, and Oxidative Stress Biomarkers in Vitamin D-Deficient Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Hormone and Metabolic Research, 2016, 48, 446-451.	0.7	66
945	The impact of insulin resistance on clinical, hormonal and metabolic parameters in lean women with polycystic ovary syndrome. Journal of Obstetrics and Gynaecology, 2016, 36, 893-896.	0.4	14
946	The role of AMH in the pathophysiology of polycystic ovarian syndrome. Reproductive BioMedicine Online, 2016, 33, 15-28.	1.1	93
947	Peroxisome proliferator activated receptor gamma polymorphism Pro12Ala in polycystic ovary syndrome (PCOS) of South Indian Population. Asian Pacific Journal of Reproduction, 2016, 5, 210-213.	0.2	5
948	The Role of Physical Activity in Preconception, Pregnancy and Postpartum Health. Seminars in Reproductive Medicine, 2016, 34, e28-e37.	0.5	76
949	The feasibility of progressive resistance training in women with polycystic ovary syndrome: a pilot randomized controlled trial. BMC Sports Science, Medicine and Rehabilitation, 2016, 8, 14.	0.7	40
950	Inositol and human reproduction. From cellular metabolism to clinical use. Gynecological Endocrinology, 2016, 32, 690-695.	0.7	47
951	An evidence based approach for diagnosis of adolescent polycystic ovarian syndrome. Middle East Fertility Society Journal, 2016, 21, 194-195.	0.5	3
952	Interleukin 10 (â^' 1082 G/A) and (â^' 819 C/T) gene polymorphisms in Egyptian women with polycystic ovary syndrome (PCOS). Meta Gene, 2016, 9, 254-258.	0.3	23
953	The evaluation of endothelial function and structure in hirsute patients in reproductive age. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2016, 206, 208-212.	0.5	4
954	Is elective single-embryo transfer a viable treatment policy in inÂvitro maturation cycles?. Fertility and Sterility, 2016, 106, 1691-1695.	0.5	16
955	Spironolactone in the treatment of polycystic ovary syndrome. Expert Opinion on Pharmacotherapy, 2016, 17, 1713-1715.	0.9	27

#	Article	IF	Citations
956	Polycystic ovary syndrome and psychiatric disorders: Co-morbidity and heritability in a nationwide Swedish cohort. Psychoneuroendocrinology, 2016, 73, 196-203.	1.3	155
957	The Effects of Soy Isoflavones on Metabolic Status of Patients With Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3386-3394.	1.8	59
958	Anti-MÃ¼llerian hormone for prediction of ovarian response in Chinese infertile women undergoing IVF/ICSI cycles: a prospective, multi-centre, observational study. Reproductive BioMedicine Online, 2016, 33, 506-512.	1.1	24
959	Steroid Metabolomic Disease Signature of Nonsyndromic Childhood Obesity. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4329-4337.	1.8	30
960	Genome-Wide Association Studies for Polycystic Ovary Syndrome. Seminars in Reproductive Medicine, 2016, 34, 224-229.	0.5	30
961	Raising threshold for diagnosis of polycystic ovary syndrome excludes population of patients with metabolic risk. Fertility and Sterility, 2016, 106, 1244-1251.	0.5	15
962	The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocrine Reviews, 2016, 37, 467-520.	8.9	863
963	What does a diagnostic label of â€˜polycystic ovary syndromeâ€™ really mean in adolescence? a review of current practice recommendations. Clinical Obesity, 2016, 6, 1-18.	1.1	14
964	Neurokinin B Receptor Antagonism in Women With Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4313-4321.	1.8	103
965	Proinflammatory environment and role of TNF-Î± in endometrial function of obese women having polycystic ovarian syndrome. International Journal of Obesity, 2016, 40, 1715-1722.	1.6	63
966	Definitions and reporting of placental insufficiency in biomedical journals: a review of the literature. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2016, 205, 146-149.	0.5	23
967	The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Human Reproduction Update, 2016, 22, 687-708.	5.2	440
968	Obesity, type 2 diabetes mellitus and cardiovascular disease risk: an uptodate in the management of polycystic ovary syndrome. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2016, 207, 214-219.	0.5	88
969	Phenotypes and body mass in women with polycystic ovary syndrome identified in referral versus unselected populations: systematic review and meta-analysis. Fertility and Sterility, 2016, 106, 1510-1520.e2.	0.5	112
970	Serum irisin and its regulation by hyperinsulinemia in women with polycystic ovary syndrome. Endocrine Journal, 2016, 63, 1107-1112.	0.7	23
971	Abnormally activated one-carbon metabolic pathway is associated with mtDNA hypermethylation and mitochondrial malfunction in the oocytes of polycystic gilt ovaries. Scientific Reports, 2016, 6, 19436.	1.6	63
972	Developmental programming: rescuing disruptions in preovulatory follicle growth and steroidogenesis from prenatal testosterone disruption. Journal of Ovarian Research, 2016, 9, 39.	1.3	12
973	Outcomes of in vitro fertilization cycles among patients with polycystic ovary syndrome following ovarian puncture for in vitro maturation. International Journal of Gynecology and Obstetrics, 2016, 135, 319-323.	1.0	5

#	Article	IF	Citations
974	Refining diagnostic features in PCOS to optimize health outcomes. Nature Reviews Endocrinology, 2016, 12, 630-631.	4.3	21
975	Cardiovascular Disease and 10-Year Mortality in Postmenopausal Women with Clinical Features of Polycystic Ovary Syndrome. Journal of Women's Health, 2016, 25, 875-881.	1.5	65
976	Helicobacter pylori infection and polycystic ovary syndrome in adolescent and young adult patients. Journal of Obstetrics and Gynaecology Research, 2016, 42, 1768-1772.	0.6	1
977	Prostate specific antigen (PSA) in diagnosis of polycystic ovarian syndrome â€“ a new insight. Gynecological Endocrinology, 2016, 32, 931-935.	0.7	9
978	Polycystic ovary syndrome. Nature Reviews Disease Primers, 2016, 2, 16057.	18.1	1,004
979	Vascular endothelial growth factor (VEGFA) gene variation in polycystic ovary syndrome in a Tunisian women population. BMC Genomics, 2016, 17, 748.	1.2	29
980	Relationship between Advanced Glycation End Products and Steroidogenesis in PCOS. Reproductive Biology and Endocrinology, 2016, 14, 71.	1.4	38
981	A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human Reproduction, 2016, 31, 2756-2764.	0.4	31
982	Treatment of polycystic ovarian syndrome in primary care. The Prescriber, 2016, 27, 36-45.	0.1	5
984	Outpatient infertility management. , 0, , 297-310.		0
986	Role of ghrelin and adiponectin in pathogenesis of polycystic ovary syndrome, effect of metformin. Evidence Based Women S Health Journal, 2016, 6, 153-159.	0.0	1
987	The impact of using gonadotropin-releasing hormone agonist for triggering final oocyte maturation in antagonist-treated intracytoplasmic sperm injection cycles on women at high risk of developing ovarian hyperstimulation syndrome. Evidence Based Women S Health Journal, 2016, 6, 85-89.	0.0	0
988	Reproductive Endocrinology in Recurrent Pregnancy Loss. Clinical Obstetrics and Gynecology, 2016, 59, 474-486.	0.6	14
989	Weight Loss and Lowering Androgens Predict Improvements in Health-Related Quality of Life in Women With PCOS. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2966-2974.	1.8	107
990	Randomized controlled trial of letrozole, berberine, or a combination for infertility in the polycystic ovary syndrome. Fertility and Sterility, 2016, 106, 757-765.e1.	0.5	35
991	Predictors of Gestational Diabetes Mellitus in Chinese Women with Polycystic Ovary Syndrome: A Cross-Sectional Study. Gynecologic and Obstetric Investigation, 2016, 81, 220-224.	0.7	9
992	Adipokines and soluble cell adhesion molecules in insulin resistant and non-insulin resistant women with polycystic ovary syndrome. Archives of Physiology and Biochemistry, 2016, 122, 223-227.	1.0	5
993	Effect of polycystic ovaries on inÂvitro fertilization and intra-cytoplasmic sperm injection treatment outcome. Asian Pacific Journal of Reproduction, 2016, 5, 182-187.	0.2	3

#	Article	IF	Citations
994	A new predictive tool for the early risk assessment of gestational diabetes mellitus. Primary Care Diabetes, 2016, 10, 315-323.	0.9	22
995	Physiological Aspects of Female Fertility: Role of the Environment, Modern Lifestyle, and Genetics. Physiological Reviews, 2016, 96, 873-909.	13.1	143
996	Circulating anti-mullerian hormone as predictor of ovarian response to clomiphene citrate in women with polycystic ovary syndrome. Journal of Ovarian Research, 2016, 9, 3.	1.3	26
997	A caseâ€“control study on reduced HDL2b in patients with polycystic ovarian syndrome. Gynecological Endocrinology, 2016, 32, 848-851.	0.7	1
998	Association between anti-Mullerian hormone and insulin resistance in non-obese adolescent females with polycystic ovary syndrome. Gynecological Endocrinology, 2016, 32, 926-930.	0.7	17
999	Is Xanthine oxidase activity in polycystic ovary syndrome associated with inflammatory and cardiovascular risk factors?. Journal of Reproductive Immunology, 2016, 116, 98-103.	0.8	27
1000	N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin. Reproduction, Fertility and Development, 2016, 28, 723.	0.1	39
1001	Higher circulating leukocytes in women with PCOS is reversed by aerobic exercise. Biochimie, 2016, 124, 27-33.	1.3	37
1002	Evidence-Based Management of Infertility in Women With Polycystic Ovary Syndrome. JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing, 2016, 45, 111-122.	0.2	15
1003	Vigorous exercise is associated with superior metabolic profiles in polycystic ovary syndrome independent of total exercise expenditure. Fertility and Sterility, 2016, 105, 486-493.	0.5	39
1004	What is the best treatment for women with polycystic ovarian syndrome and high LH/FSH ratio? A comparison among in vitro fertilization with GnRH agonist, GnRH antagonist and in vitro maturation. Journal of Endocrinological Investigation, 2016, 39, 799-803.	1.8	11
1005	Cystatin C, a novel cardiometabolic risk marker in women with polycystic ovary syndrome. Gynecological Endocrinology, 2016, 32, 457-459.	0.7	5
1006	A Nonrandomized Trial of Progressive Resistance Training Intervention in Women With Polycystic Ovary Syndrome and Its Implications in Telomere Content. Reproductive Sciences, 2016, 23, 644-654.	1.1	44
1007	Effects of selenium supplementation on glucose homeostasis and free androgen index in women with polycystic ovary syndrome: A randomized, double blinded, placebo controlled clinical trial. Journal of Trace Elements in Medicine and Biology, 2016, 34, 56-61.	1.5	39
1008	UHPLC/Q-TOFMS-based plasma metabolomics of polycystic ovary syndrome patients with and without insulin resistance. Journal of Pharmaceutical and Biomedical Analysis, 2016, 121, 141-150.	1.4	33
1009	Weight Gain and Dyslipidemia in Early Adulthood Associate With Polycystic Ovary Syndrome: Prospective Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 739-747.	1.8	114
1010	Measures of body adiposity and visceral adiposity index as predictors of metabolic syndrome among Thai women with PCOS. Gynecological Endocrinology, 2016, 32, 276-280.	0.7	24
1011	Association of single-nucleotide polymorphisms rs2197076 and rs2241883 of FABP1 gene with polycystic ovary syndrome. Journal of Assisted Reproduction and Genetics, 2016, 33, 75-83.	1.2	10

#	Article	IF	Citations
1012	Pregnancy outcomes in women withÂpolycystic ovary syndrome undergoing inÂvitro fertilization. Fertility and Sterility, 2016, 105, 791-797.e2.	0.5	68
1013	The inflammatory markers in polycystic ovary syndrome: association with obesity and IVF outcomes. Journal of Endocrinological Investigation, 2016, 39, 899-907.	1.8	73
1014	Role of kisspeptin in polycystic ovary syndrome (PCOS). Gynecological Endocrinology, 2016, 32, 718-722.	0.7	37
1015	Polycystic Ovary Syndrome, Obesity, and Pregnancy. Seminars in Reproductive Medicine, 2016, 34, 093-101.	0.5	70
1016	Metabolic syndrome, diet and exercise. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2016, 37, 140-151.	1.4	45
1017	Type of gonadotropin during controlled ovarian stimulation affects the endocrine profile in follicular fluid and apoptosis rate in cumulus cells. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2016, 197, 142-146.	0.5	7
1018	The effects of acupuncture on polycystic ovary syndrome: A systematic review and meta-analysis. European Journal of Integrative Medicine, 2016, 8, 12-18.	0.8	23
1019	Cardiovascular disease risk in first-degree relatives of women with polycystic ovary syndrome. Fertility and Sterility, 2016, 105, 1338-1344.e3.	0.5	12
1020	Body Mass Index below Obesity Threshold Implies Similar Cardiovascular Risk among Various Polycystic Ovary Syndrome Phenotypes. Medical Principles and Practice, 2016, 25, 61-66.	1.1	11
1021	Relationship between hyperandrogenism, obesity, inflammation and polycystic ovary syndrome. Gynecological Endocrinology, 2016, 32, 709-713.	0.7	59
1022	Antiâ€MÃ¼llerian hormone as a marker of ovarian reserve: What have we learned, and what should we know?. Reproductive Medicine and Biology, 2016, 15, 127-136.	1.0	52
1023	Single-Nucleotide Polymorphism on Exon 17 of Insulin Receptor Gene Influences Insulin Resistance in PCOS: A Pilot Study on North Indian Women. Biochemical Genetics, 2016, 54, 158-168.	0.8	12
1024	Impact of unilateral versus bilateral laparoscopic ovarian drilling on ovarian reserve and pregnancy rate: a randomized clinical trial. Gynecological Endocrinology, 2016, 32, 399-402.	0.7	20
1025	The Role of Anti-MÃ¼llerian Hormone in the Characterization of the Different Polycystic Ovary Syndrome Phenotypes. Reproductive Sciences, 2016, 23, 655-661.	1.1	21
1026	A randomized controlled trial of clomifene citrate, metformin, and pioglitazone versus letrozole, metformin, and pioglitazone for clomifeneâ€citrateâ€resistant polycystic ovary syndrome. International Journal of Gynecology and Obstetrics, 2016, 132, 206-209.	1.0	15
1027	White Matter Microstructure and Cognitive Function in Young Women With Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 314-323.	1.8	40
1028	Low 25 (OH) vitamin D levels are associated with autoimmune thyroid disease in polycystic ovary syndrome. Endocrine, 2016, 53, 538-542.	1.1	26
1029	Advantages of Recombinant Follicle-Stimulating Hormone over Human Menopausal Gonadotropin in Intrauterine Insemination: A Randomized Clinical Trial in Polycystic Ovary Syndrome-Associated Infertility. Gynecologic and Obstetric Investigation, 2016, 81, 118-123.	0.7	3

#	Article	IF	Citations
1030	Comparison of clinical and hormonal characteristics among four phenotypes of polycystic ovary syndrome based on the Rotterdam criteria. Archives of Gynecology and Obstetrics, 2016, 293, 447-456.	0.8	44
1031	The amount and duration of smoking is associated with aggravation of hormone and biochemical profile in women with PCOS. Gynecological Endocrinology, 2016, 32, 143-146.	0.7	13
1032	Selenium Supplementation and the Effects on Reproductive Outcomes, Biomarkers of Inflammation, and Oxidative Stress in Women with Polycystic Ovary Syndrome. Hormone and Metabolic Research, 2016, 48, 185-190.	0.7	60
1033	Increased circulating urocortin-3 levels is associated with polycystic ovary syndrome. Gynecological Endocrinology, 2016, 32, 218-222.	0.7	12
1034	The impact of follicular fluid adiponectin and ghrelin levels based on BMI on IVF outcomes in PCOS. Journal of Endocrinological Investigation, 2016, 39, 431-437.	1.8	16
1035	Clitoral and labial sizes in women wÄ±th PCOS. Journal of Obstetrics and Gynaecology, 2016, 36, 97-101.	0.4	7
1036	Levels of Regulatory Proteins Associated With Cell Proliferation in Endometria From Untreated Patients Having Polycystic Ovarian Syndrome With and Without Endometrial Hyperplasia. Reproductive Sciences, 2016, 23, 211-218.	1.1	11
1037	The mean platelet volume and neutrophil to lymphocyte ratio in obese and lean patients with polycystic ovary syndrome. Journal of Endocrinological Investigation, 2016, 39, 45-53.	1.8	32
1038	Are serum chemerin levels different between obese and non-obese polycystic ovary syndrome women?. Gynecological Endocrinology, 2016, 32, 38-41.	0.7	18
1039	Hyperandrogenism, Hirsutism, and Polycystic Ovary Syndrome. , 2016, , 2275-2296.e6.		2
1040	Blood Trace Element Concentrations in Polycystic Ovary Syndrome: Systematic Review and Meta-analysis. Biological Trace Element Research, 2017, 175, 254-262.	1.9	29
1041	Caring for women with polycystic ovary syndrome. Nurse Practitioner, 2017, 42, 39-47.	0.2	1
1042	Anti-MÃ¼llerian Hormone in Obese Adolescent Girls With Polycystic Ovary Syndrome. Journal of Adolescent Health, 2017, 60, 333-339.	1.2	33
1043	Effectiveness of Acupuncture in Women with Polycystic Ovarian Syndrome Undergoing in Vitro Fertilisation Or Intracytoplasmic Sperm Injection: A Systematic Review and Meta-Analysis. Acupuncture in Medicine, 2017, 35, 162-170.	0.4	33
1044	Genetic analysis of the M2/ANXA5 haplotype as recurrent pregnancy loss predisposition in the Malay population. Journal of Assisted Reproduction and Genetics, 2017, 34, 517-524.	1.2	12
1045	An inverse association between serum soluble receptor of advanced glycation end products and hyperandrogenism and potential implication in polycystic ovary syndrome patients. Reproductive Biology and Endocrinology, 2017, 15, 9.	1.4	14
1046	Evaluation of tumor necrosis factor alpha serum level in obese and lean women with clomiphene citrate resistant polycystic ovary disease. Middle East Fertility Society Journal, 2017, 22, 193-200.	0.5	0
1047	Circulating androgens and SHBG during the normal menstrual cycle in two ethnic populations. Scandinavian Journal of Clinical and Laboratory Investigation, 2017, 77, 184-189.	0.6	8

#	Article	IF	Citations
1048	Expression of AKT1 along with AKT2 in granulosa-lutein cells of hyperandrogenic PCOS patients. Archives of Gynecology and Obstetrics, 2017, 295, 1041-1050.	0.8	28
1049	Effect of metformin and oral contraceptives on polycystic ovary syndrome and IVF cycles. Journal of Endocrinological Investigation, 2017, 40, 745-752.	1.8	14
1050	Oral carnitine supplementation influences mental health parameters and biomarkers of oxidative stress in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Gynecological Endocrinology, 2017, 33, 442-447.	0.7	44
1051	Association of IL-1Î², IL-1Ra and FABP1 gene polymorphisms with the metabolic features of polycystic ovary syndrome. Inflammation Research, 2017, 66, 621-636.	1.6	16
1052	Racial and ethnic differences in the prevalence of metabolicÂsyndrome and its components of metabolic syndrome in women with polycystic ovary syndrome: aÂregional cross-sectional study. American Journal of Obstetrics and Gynecology, 2017, 217, 189.e1-189.e8.	0.7	62
1053	The Effects of Omega-3 Fatty Acids and Vitamin E Co-Supplementation on Indices of Insulin Resistance and Hormonal Parameters in Patients with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Experimental and Clinical Endocrinology and Diabetes, 2017, 125, 353-359.	0.6	44
1054	The Effects of Calcium, Vitamins D and K co-Supplementation on Markers of Insulin Metabolism and Lipid Profiles in Vitamin D-Deficient Women with Polycystic Ovary Syndrome. Experimental and Clinical Endocrinology and Diabetes, 2017, 125, 316-321.	0.6	22
1055	Inter-observer variability in the assessment of ultrasound features of polycystic ovaries. Middle East Fertility Society Journal, 2017, 22, 226-232.	0.5	0
1056	Polycystic Ovary Syndrome and Increased Soluble Tumor Necrosis Factor Like Weak Inducer of Apoptosis Levels Are Independent Predictors of Dyslipidemia in Youth. Gynecologic and Obstetric Investigation, 2017, 82, 200-204.	0.7	1
1057	Autonomic nervous system activation mediates the increase in wholeâ€body glucose uptake in response to electroacupuncture. FASEB Journal, 2017, 31, 3288-3297.	0.2	38
1058	Antiâ€MÃ¼llerian hormone exhibits a great variation in infertile women with different ovarian reserve patterns. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2017, 57, 464-468.	0.4	8
1059	Metabolic Outcomes, Bone Health, and Risk of Polycystic Ovary Syndrome in Girls with Idiopathic Central Precocious Puberty Treated with Gonadotropin-Releasing Hormone Analogues. Hormone Research in Paediatrics, 2017, 87, 162-169.	0.8	25
1060	Obesity contributes more to increasing ApoB/ApoA1 ratio than hyperandrogenism in PCOS women aged 20â€“38 years in China. Experimental and Therapeutic Medicine, 2017, 13, 1337-1342.	0.8	10
1061	Cardiovascular autonomic dysfunction in women with polycystic ovary syndrome: a systematic review and meta-analysis. Reproductive BioMedicine Online, 2017, 35, 113-120.	1.1	10
1063	Paratubal Cyst Size Correlates With Obesity and Dysregulation of the Wnt Signaling Pathway. Journal of Pediatric and Adolescent Gynecology, 2017, 30, 571-577.	0.3	6
1064	Anti-MÃ¼llerian hormone, follicle stimulating hormone, antral follicle count, and risk of menopause within 5 years. Maturitas, 2017, 102, 18-25.	1.0	51
1065	Hyperandrogenism in adolescent girls: relationship with the somatotrophic axis. Journal of Pediatric Endocrinology and Metabolism, 2017, 30, 561-568.	0.4	6
1066	Phenotypic variation in anti-Mullerian hormone (AMH) production per follicle in women with polycystic ovary syndrome (PCOS) and isolated polycystic ovarian morphology (PCOM): an observational cross-sectional study. Gynecological Endocrinology, 2017, 33, 801-806.	0.7	9

#	Article	IF	Citations
1067	The role of stress in PCOS. Expert Review of Endocrinology and Metabolism, 2017, 12, 87-95.	1.2	25
1068	Persistent amenorrhea and decreased DHEAS to cortisol ratio after recovery from anorexia nervosa. Gynecological Endocrinology, 2017, 33, 311-314.	0.7	6
1070	Nuclear factor-Î¹B expression in the endometrium of normal and overweight women with polycystic ovary syndrome. Journal of Obstetrics and Gynaecology, 2017, 37, 924-930.	0.4	20
1071	Elevated antiâ€Mullerian hormone in lean women may not indicate polycystic ovarian syndrome. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2017, 57, 552-557.	0.4	12
1072	Biochemical and Imaging Diagnostics in Endocrinology. Endocrinology and Metabolism Clinics of North America, 2017, 46, 679-689.	1.2	2
1073	New biomarkers for diagnosis and management of polycystic ovary syndrome. Clinica Chimica Acta, 2017, 471, 248-253.	0.5	56
1074	Phoenixin-14 concentrations are increased in association with luteinizing hormone and nesfatin-1 concentrations in women with polycystic ovary syndrome. Clinica Chimica Acta, 2017, 471, 243-247.	0.5	41
1075	An epidemiological survey: Effect of predisposing factors for PCOS in Indian urban and rural population. Middle East Fertility Society Journal, 2017, 22, 313-316.	0.5	71
1076	GnRH antagonist for patients with polycystic ovary syndrome undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer in fresh cycles. Experimental and Therapeutic Medicine, 2017, 13, 3097-3102.	0.8	2
1077	Which origin for polycystic ovaries syndrome: Genetic, environmental or both?. Annales D'Endocrinologie, 2017, 78, 176-185.	0.6	34
1078	Demographic analysis of a low resource, socioculturally diverse urban community presenting for infertility care in a United States public hospital. Contraception and Reproductive Medicine, 2017, 2, 17.	0.7	11
1079	Polycystic ovary morphology is associated with insulin resistance in women with polycystic ovary syndrome. Clinical Endocrinology, 2017, 87, 375-380.	1.2	12
1080	Genetics of polycystic ovary syndrome. Expert Review of Molecular Diagnostics, 2017, 17, 723-733.	1.5	71
1081	LINE1 CpG-DNA Hypomethylation in Granulosa Cells and Blood Leukocytes Is Associated With PCOS and Related Traits. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1396-1405.	1.8	23
1082	Rotterdam criteriaâ€“based diagnostic subtype is not a strong predictor of cutaneous phenotype in patients with polycystic ovary syndrome: A cross-sectional study. Journal of the American Academy of Dermatology, 2017, 77, 174-176.	0.6	3
1083	Risk of Alzheimer's disease is not increased among patients with hidradenitis suppurativa: A retrospective population-based cohort analysis. Journal of the American Academy of Dermatology, 2017, 77, 176-177.	0.6	11
1084	Phospholipase C-related but catalytically inactive proteins regulate ovarian follicle development. Journal of Biological Chemistry, 2017, 292, 8369-8380.	1.6	3
1085	Dietary patterns and the phenotype of polycystic ovary syndrome: the chance of ongoing pregnancy. Reproductive BioMedicine Online, 2017, 34, 668-676.	1.1	11

#	Article	IF	Citations
1086	Polycystic ovary syndrome: analysis of the global research architecture using density equalizing mapping. Reproductive BioMedicine Online, 2017, 34, 627-638.	1.1	13
1087	Association of ethnicity, Fitzpatrick skin type, and hirsutism: A retrospective cross-sectional study of women with polycystic ovarian syndrome. International Journal of Women's Dermatology, 2017, 3, 37-43.	1.1	46
1088	Valuable predictors of gestational diabetes mellitus in infertile Chinese women with polycystic ovary syndrome: a prospective cohort study. Gynecological Endocrinology, 2017, 33, 448-451.	0.7	8
1089	Serum visfatin, vascular endothelial growth factor and matrix metalloproteinase-9 in women with polycystic ovary syndrome. Gynecological Endocrinology, 2017, 33, 529-533.	0.7	17
1090	Serum Level of Zinc and Copper in Sudanese Women with Polycystic Ovarian Syndrome. Biological Trace Element Research, 2017, 180, 23-27.	1.9	17
1091	Does an increased body mass index affect endometrial gene expression patterns in infertile patients? AÂfunctional genomics analysis. Fertility and Sterility, 2017, 107, 740-748.e2.	0.5	60
1092	Risk factors for preeclampsia in infertile Chinese women with polycystic ovary syndrome: A prospective cohort study. Journal of Clinical Hypertension, 2017, 19, 504-509.	1.0	16
1093	Are CRH & NGF as psychoneuroimmune regulators in women with polycystic ovary syndrome?. Gynecological Endocrinology, 2017, 33, 227-233.	0.7	8
1094	Determinants of low bone mineral density in premenopausal polycystic ovary syndrome patients. Gynecological Endocrinology, 2017, 33, 234-237.	0.7	22
1095	Polycystic ovary syndrome: early diagnosis and intervention are necessary for fertility preservation in young women with endometrial cancer under 35Âyears of age. Reproductive Medicine and Biology, 2017, 16, 67-71.	1.0	28
1096	Luteal phase HCG support for unexplained recurrent pregnancy loss â€“ a low hanging fruit?. Reproductive BioMedicine Online, 2017, 34, 319-324.	1.1	12
1097	Elevated serum interferon Î³-inducible protein-10 in women with polycystic ovary syndrome. Gynecological Endocrinology, 2017, 33, 363-367.	0.7	5
1098	Association of betatrophin with metabolic characteristics in overweight/obese and lean women with PCOS. Gynecological Endocrinology, 2017, 33, 238-243.	0.7	13
1099	Selenium status parameters in patients with polycystic ovary syndrome. Journal of Trace Elements in Medicine and Biology, 2017, 44, 241-246.	1.5	17
1100	Coping in Women With Polycystic Ovary Syndrome: Implications for Practitioners. Journal for Nurse Practitioners, 2017, 13, 700-707.	0.4	9
1101	Effects of metformin treatment on serum levels of C-reactive protein and interleukin-6 in women with polycystic ovary syndrome. Medicine (United States), 2017, 96, e8183.	0.4	26
1102	No. 350-Hirsutism: Evaluation and Treatment. Journal of Obstetrics and Gynaecology Canada, 2017, 39, 1054-1068.	0.3	5
1103	Contraception and Conception After Bariatric Surgery. Obstetrics and Gynecology, 2017, 130, 979-987.	1.2	31

#	Article	IF	Citations
1104	New Diagnostic Criteria of Polycystic Ovarian Morphology for Adolescents: Impact on Prevalence and Hormonal Profile. Hormone Research in Paediatrics, 2017, 88, 401-407.	0.8	18
1105	The prevalence of Type 2 diabetes is not increased in normal-weight women with PCOS. Human Reproduction, 2017, 32, 2279-2286.	0.4	40
1106	Long Noncoding RNAs: Potential Regulators Involved in the Pathogenesis of Polycystic Ovary Syndrome. Endocrinology, 2017, 158, 3890-3899.	1.4	66
1107	Insulin resistance in a large cohort of women with polycystic ovary syndrome: a comparison between euglycaemic-hyperinsulinaemic clamp and surrogate indexes. Human Reproduction, 2017, 32, 2515-2521.	0.4	90
1108	Bone markers in polycystic ovary syndrome: A multicentre study. Clinical Endocrinology, 2017, 87, 673-679.	1.2	16
1109	Gonadal soma controls ovarian follicle proliferation through Gsdf in zebrafish. Developmental Dynamics, 2017, 246, 925-945.	0.8	68
1110	A Machine Learning Algorithm for Identifying Atopic Dermatitis in Adults from Electronic Health Records. , 2017, 2017, 83-90.		42
1111	Polycystic Ovary Syndrome (PCOS) in Juvenile and Adult Type 1 Diabetes in a German/Austrian Cohort. Experimental and Clinical Endocrinology and Diabetes, 2017, 125, 661-668.	0.6	3
1112	Activation of Endoplasmic Reticulum Stress in Granulosa Cells from Patients with Polycystic Ovary Syndrome Contributes to Ovarian Fibrosis. Scientific Reports, 2017, 7, 10824.	1.6	70
1113	Insulin resistance and obesity among infertile women with different polycystic ovary syndrome phenotypes. Scientific Reports, 2017, 7, 5339.	1.6	46
1114	Ageâ€stratified thresholds of antiâ€MÃ¼llerian hormone improve prediction of polycystic ovary syndrome over a populationâ€based threshold. Clinical Endocrinology, 2017, 87, 733-740.	1.2	26
1115	Combined Lifestyle and Herbal Medicine in Overweight Women with Polycystic Ovary Syndrome (<scp>PCOS</scp>): A Randomized Controlled Trial. Phytotherapy Research, 2017, 31, 1330-1340.	2.8	66
1117	Identification of reference genes for qRT-PCR in granulosa cells of healthy women and polycystic ovarian syndrome patients. Scientific Reports, 2017, 7, 6961.	1.6	23
1118	Inositol supplementation in women with polycystic ovary syndrome undergoing intracytoplasmic sperm injection: a systematic review and meta-analysis of randomized controlled trials. Reproductive BioMedicine Online, 2017, 35, 529-535.	1.1	25
1119	Weight reduction by using a formula diet recovers menstruation in obese patients with an ovulatory disorder. Reproductive Medicine and Biology, 2017, 16, 268-275.	1.0	2
1120	GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial. Journal of Assisted Reproduction and Genetics, 2017, 34, 1537-1545.	1.2	24
1121	Conception and Assisted Reproduction. , 0, , 213-225.		0
1122	Insulin resistance in pregnant women with and without polycystic ovary syndrome, and measures of body composition in offspring at birth and three years of age. Acta Obstetricia Et Gynecologica Scandinavica, 2017, 96, 1307-1314.	1.3	20

#	Article	IF	Citations
1123	Effect of Preconception Impaired Glucose Tolerance on Pregnancy Outcomes in Women With Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3822-3829.	1.8	18
1124	Polycystic ovary syndrome, personality, and depression: A twin study. Psychoneuroendocrinology, 2017, 85, 63-68.	1.3	26
1125	Saturated Fat Intake Is Related to Heart Rate Variability in Women with Polycystic OvaryÂSyndrome. Annals of Nutrition and Metabolism, 2017, 71, 224-233.	1.0	8
1126	An International Consortium Update: Pathophysiology, Diagnosis, and Treatment of Polycystic Ovarian Syndrome in Adolescence. Hormone Research in Paediatrics, 2017, 88, 371-395.	0.8	282
1128	Fasting as possible complementary approach for polycystic ovary syndrome: Hope or hype?. Medical Hypotheses, 2017, 105, 1-3.	0.8	48
1129	Salivary testosterone measurement in women with and without polycystic ovary syndrome. Scientific Reports, 2017, 7, 3589.	1.6	10
1130	Polycystic ovarian morphology and the diagnosis of polycystic ovary syndrome: redefining threshold levels for follicle count and serum anti-MÃ¼llerian hormone using cluster analysis. Human Reproduction, 2017, 32, 1723-1731.	0.4	62
1131	Short term monotherapy with exenatide is superior to metformin in weight loss, improving insulin resistance and inflammation in Chinese overweight/obese PCOS women. Obesity Medicine, 2017, 7, 15-20.	0.5	18
1132	Effect of Acupuncture and Clomiphene in Chinese Women With Polycystic Ovary Syndrome. JAMA - Journal of the American Medical Association, 2017, 317, 2502.	3.8	136
1133	Successful treatment with Korean herbal medicine and lifestyle management in an obese woman with polycystic ovarian syndrome. Integrative Medicine Research, 2017, 6, 325-328.	0.7	11
1134	Premature ovarian failure/dysfunction following surgical treatment of polycystic ovarian syndrome: A case series. Middle East Fertility Society Journal, 2017, 22, 233-235.	0.5	4
1135	Association between polycystic ovary syndrome and the risk of stroke and all-cause mortality: insights from a meta-analysis. Gynecological Endocrinology, 2017, 33, 904-910.	0.7	47
1136	Plasmatic and Intracellular Markers of Oxidative Stress in Normal Weight and Obese Patients with Polycystic Ovary Syndrome. Experimental and Clinical Endocrinology and Diabetes, 2017, 125, 506-513.	0.6	14
1137	The Effects of Vitamin D Supplementation on Metabolic Status of Patients with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Hormone and Metabolic Research, 2017, 49, 493-498.	0.7	46
1138	Effect of Two Different Doses of Vitamin D Supplementation on Metabolic Profiles of Insulin-Resistant Patients with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Hormone and Metabolic Research, 2017, 49, 612-617.	0.7	24
1139	Polycystic Ovarian Syndrome: Long-Term Health Consequences. Seminars in Reproductive Medicine, 2017, 35, 271-281.	0.5	38
1140	Can the source of hyperandrogenism in adolescents with polycystic ovary syndrome predict metabolic phenotype?. Gynecological Endocrinology, 2017, 33, 882-887.	0.7	3
1141	5Î±-reductase activity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Reproductive Biology and Endocrinology, 2017, 15, 21.	1.4	22

#	Article	IF	Citations
1142	Ovarian morphology is associated with insulin resistance in women with polycystic ovary syndrome: a cross sectional study. Fertility Research and Practice, 2017, 3, 8.	4.1	20
1143	Comparison of 25-hydroxyvitamin D and metabolic parameters between women with and without polycystic ovarian syndrome. Hormone Molecular Biology and Clinical Investigation, 2017, 31, .	0.3	2
1144	A Canary in the Coal Mine: Reproductive Health and Cardiovascular Disease in Women. Seminars in Reproductive Medicine, 2017, 35, 250-255.	0.5	4
1145	Use of the serum anti-MÃ¼llerian hormone assay as a surrogate for polycystic ovarian morphology: impact on diagnosis and phenotypic classification of polycystic ovary syndrome. Human Reproduction, 2017, 32, 1716-1722.	0.4	57
1146	Subclinical hypothyroidism does not influence the metabolic and hormonal profile of women with PCOS. Hormone Molecular Biology and Clinical Investigation, 2017, 31, .	0.3	8
1147	Impact of the opioid system onÂtheÂreproductive axis. Fertility and Sterility, 2017, 108, 207-213.	0.5	44
1148	Acupuncture for polycystic ovarian syndrome. Medicine (United States), 2017, 96, e7066.	0.4	38
1150	Leptin Levels in Women With Polycystic Ovary Syndrome: A Systematic Review and a Meta-Analysis. Reproductive Sciences, 2017, 24, 656-670.	1.1	45
1151	Ovarian morphology in polycystic ovary syndrome: estimates from 2D and 3D ultrasound and magnetic resonance imaging and their correlation to anti-MÃ¼llerian hormone. Acta Radiologica, 2017, 58, 997-1004.	0.5	16
1152	Visceral adiposity index levels in overweight and/or obese, and non-obese patients with polycystic ovary syndrome and its relationship with metabolic and inflammatory parameters. Journal of Endocrinological Investigation, 2017, 40, 487-497.	1.8	58
1153	AntimÃ¼llerian hormone levels and cardiometabolic risk in young women with polycystic ovary syndrome. Fertility and Sterility, 2017, 107, 276-281.	0.5	30
1154	The relationship of urocortin-2 with insulin resistance patients having PCOS. Gynecological Endocrinology, 2017, 33, 124-127.	0.7	8
1155	The Rotterdam criteria for polycystic ovary syndrome: evidence-based criteria?. Human Reproduction, 2017, 32, 261-264.	0.4	80
1156	Habitual physical activity is associated with improved anthropometric and androgenic profile in PCOS: a cross-sectional study. Journal of Endocrinological Investigation, 2017, 40, 377-384.	1.8	30
1157	Apparent diffusion coefficient measurement of ovarian stroma: A potential tool for the diagnosis of polycystic ovary syndrome. Diagnostic and Interventional Imaging, 2017, 98, 57-61.	1.8	5
1158	Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS). Gynecological Endocrinology, 2017, 33, 39-42.	0.7	79
1159	Endocrine and cardiometabolic cord blood characteristics of offspring born to mothers with and without polycystic ovary syndrome. Fertility and Sterility, 2017, 107, 261-268.e3.	0.5	40
1160	The role of AMH and its receptor SNP in the pathogenesis of PCOS. Molecular and Cellular Endocrinology, 2017, 439, 363-368.	1.6	20

#	Article	IF	Citations
1161	Does intrauterine insemination timing matter for achieving pregnancy during ovulation induction using gonadotropins? A retrospective cohort study. Journal of the Chinese Medical Association, 2017, 80, 366-370.	0.6	8
1162	Novel adipokines WISP1 and betatrophin in PCOS: relationship to AMH levels, atherogenic and metabolic profile. Gynecological Endocrinology, 2017, 33, 119-123.	0.7	23
1163	Association of Prooxidantâ€“Antioxidant Balance with Clinical and Laboratory Parameters and Its Relation to Different Drug Regimens in Polycystic Ovary Syndrome Women with Normal BMI. Indian Journal of Clinical Biochemistry, 2017, 32, 315-322.	0.9	5
1164	Effect of omega-3 fatty acids supplementation on insulin resistance in women with polycystic ovary syndrome: Meta-analysis of randomized controlled trials. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2017, 11, 157-162.	1.8	37
1165	Epigenetic regulation of an adverse metabolic phenotype in polycystic ovary syndrome: the impact of the leukocyte methylation of PPARGC1A promoter. Fertility and Sterility, 2017, 107, 467-474.e5.	0.5	38
1166	Pulsatile gonadotropin-releasing hormone therapy in persistent amenorrheic weight-recovered anorexia nervosa patients. Fertility and Sterility, 2017, 107, 502-509.	0.5	9
1167	The effects of omega-3 fatty acids and vitamin E co-supplementation on gene expression of lipoprotein(a) and oxidized low-density lipoprotein, lipid profiles and biomarkers of oxidative stress in patients with polycystic ovary syndrome. Molecular and Cellular Endocrinology, 2017, 439, 247-255.	1.6	59
1168	Differential Effects on Haemostatic Markers by Metformin and the Contraceptive Pill: A Randomized Comparative Trial in PCOS. Thrombosis and Haemostasis, 2017, 117, 2053-2062.	1.8	7
1169	Improvement in quality of oocytes in polycystic ovarian syndrome in programs of in vitro fertilization. Gynecological Endocrinology, 2017, 33, 8-11.	0.7	14
1170	N o 350-Hirsutisme : Ã©valuation et traitement. Journal of Obstetrics and Gynaecology Canada, 2017, 39, 1069-1084.	0.3	1
1171	Polycystic Ovary Syndrome: Management of a Long-Term Condition in Primary Care. , 0, , 111-118.		2
1172	A Missense Variant rs4645843 in <i>TNF-</i><i>Î±</i> Gene Is a Risk Factor of Polycystic Ovary Syndrome in the Uygur Population. Tohoku Journal of Experimental Medicine, 2017, 243, 95-100.	0.5	11
1173	Role of osteocalcin, tumor necrosis factor-alpha and adiponectin in polycystic ovary syndrome patients with insulin resistance. TâˆšÂºrk Jinekoloji Ve Obstetrik Dernei Dergisi, 2017, 14, 89-93.	0.3	0
1174	Access to medicines: the plot thickens in 24 Season 2 (Indian series). Journal of Intellectual Property Law and Practice, 2017, 12, 619-620.	0.2	0
1175	Association of Exon 10A and 10B inactivating mutation of follicle stimulating hormone receptor gene (FSHR) and Polycystic Ovarian Syndrome in Vellore cohort. IOP Conference Series: Materials Science and Engineering, 2017, 263, 022036.	0.3	1
1176	Vitamin D and Female Reproduction. , 0, , .		0
1178	The prevalence of polycystic ovary syndrome in reproductive-aged women of different ethnicity: a systematic review and meta-analysis. Oncotarget, 2017, 8, 96351-96358.	0.8	203
1179	Polycystic ovary syndrome in adolescence: diagnostic and therapeutic strategies. Translational Pediatrics, 2017, 6, 248-255.	0.5	41

#	Article	IF	Citations
1180	Investigation of Demodex folliculorum frequency in patients with polycystic ovary syndrome. Anais Brasileiros De Dermatologia, 2017, 92, 807-810.	0.5	10
1181	Effect of Two Different Doses of Vitamin D Supplementation on Metabolic Profiles of Insulin-Resistant Patients with Polycystic Ovary Syndrome. Nutrients, 2017, 9, 1280.	1.7	59
1182	Expression of the genes for peroxisome proliferator-activated receptor-Î³, cyclooxygenase-2, and proinflammatory cytokines in granulosa cells from women with polycystic ovary syndrome. Clinical and Experimental Reproductive Medicine, 2017, 44, 146.	0.5	16
1183	The Contribution of New Areas to the Total Hirsutism Scores in Basrah Hirsute Women. Diseases (Basel, Switzerland), 2017, 5, 32.	1.0	6
1184	The Distribution of Stroma and Antral Follicles Differs between Insulin-Resistance and Hyperandrogenism-Related Polycystic Ovarian Syndrome. Frontiers in Endocrinology, 2017, 8, 117.	1.5	36
1185	Intrauterine Reprogramming of the Polycystic Ovary Syndrome: Evidence from a Pilot Study of Cord Blood Global Methylation Analysis. Frontiers in Endocrinology, 2017, 8, 352.	1.5	35
1186	Dysbiosis of Gut Microbiota Associated with Clinical Parameters in Polycystic Ovary Syndrome. Frontiers in Microbiology, 2017, 8, 324.	1.5	224
1187	Risk of Type 2 Diabetes Mellitus following Gestational Diabetes Pregnancy in Women with Polycystic Ovary Syndrome. Journal of Diabetes Research, 2017, 2017, 1-5.	1.0	20
1188	Serum Concentrations of Betatrophin and Its Association with Indirect Indices of Insulin Resistance and Beta Cell Function in Women with Polycystic Ovary Syndrome. International Journal of Endocrinology, 2017, 2017, 1-6.	0.6	8
1189	Therapeutic effects of metformin and clomiphene in combination with lifestyle intervention on infertility in women with obese polycystic ovary syndrome. Pakistan Journal of Medical Sciences, 2017, 33, 8-12.	0.3	18
1190	Gynecological Morbidity. , 2017, , 342-353.		1
1191	Association between fat mass and obesity associated (FTO) gene rs9939609 A/T polymorphism and polycystic ovary syndrome: a systematic review and meta-analysis. BMC Medical Genetics, 2017, 18, 89.	2.1	63
1192	Relationship between serum anti-Mullerian hormone and clinical parameters in polycystic ovary syndrome. Endocrine Journal, 2017, 64, 531-541.	0.7	25
1193	Visfatin and resistin in gonadotroph cells: expression, regulation of LH secretion and signalling pathways. Reproduction, Fertility and Development, 2017, 29, 2479.	0.1	18
1194	Use of letrozole versus clomiphene citrate combined with gonadotropins for ovulation induction in infertile women with polycystic ovary syndrome: a pilot study. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 2017, 6, 4098.	0.0	2
1195	Evaluation of vitamin D3 in patients of polycystic ovary syndrome and their correlation. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 2017, 6, 2010.	0.0	0
1196	PCOSBase: a manually curated database of polycystic ovarian syndrome. Database: the Journal of Biological Databases and Curation, 2017, 2017, .	1.4	10
1197	Thyroid function/antibodies in sudanese women with polycystic ovarian disease. Obstetrics and Gynecology Science, 2017, 60, 187.	0.6	9

#	Article	IF	Citations
1198	Follicular fluid cerebellin and betatrophin regulate the metabolic functions of growing follicles in polycystic ovary syndrome. Clinical and Experimental Reproductive Medicine, 2017, 44, 33.	0.5	5
1199	The effects of combined therapy of myo-inositol and D-chiro inositol in reduction of the individual components of metabolic syndrome in overweight PCOS patients compared to myo-inositol supplementation alone: a prospective randomised controlled trial. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 2017, 6, 2939.	0.0	3
1200	Heart rate variability in normal-weight patients with polycystic ovary syndrome. Anatolian Journal of Cardiology, 2017, 17, 404-409.	0.5	8
1201	Impact of metformin on C-reactive protein levels in women with polycystic ovary syndrome: a meta-analysis. Oncotarget, 2017, 8, 35425-35434.	0.8	7
1202	Laparoscopic ovarian drilling-plus: a one-stop management approach for PCO-associated infertility. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 2017, 6, 4771.	0.0	0
1203	Low-dose gonadotropin induction of ovulation in anovulatory women: still needed in the age of IVF. Reproduction, 2018, 156, F1-F10.	1.1	24
1204	Management of women with PCOS using myo-inositol and folic acid. New clinical data and review of the literature. Hormone Molecular Biology and Clinical Investigation, 2018, 34, .	0.3	32
1205	Dehydroepiandrosterone enhances decidualization in women of advanced reproductive age. Fertility and Sterility, 2018, 109, 728-734.e2.	0.5	37
1206	The Effects of Vitamin D Supplementation on Biomarkers of Inflammation and Oxidative Stress Among Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Hormone and Metabolic Research, 2018, 50, 271-279.	0.7	59
1207	Impact of diet and bariatric surgery on anti-MÃ¼llerian hormone levels. Human Reproduction, 2018, 33, 690-693.	0.4	31
1208	Salivary and serum androgens with anti-MÃ¼llerian hormone measurement for the diagnosis of polycystic ovary syndrome. Scientific Reports, 2018, 8, 3795.	1.6	10
1209	Maternal carriers of the ANXA5 M2 haplotype are exposed to a greater risk for placenta-mediated pregnancy complications. Journal of Assisted Reproduction and Genetics, 2018, 35, 921-928.	1.2	11
1210	Inhibition of microRNA-19b promotes ovarian granulosa cell proliferation by targeting IGF-1 in polycystic ovary syndrome. Molecular Medicine Reports, 2018, 17, 4889-4898.	1.1	28
1211	Correlation of platelet to lymphocyte and neutrophil to lymphocyte ratio with hormonal and metabolic parameters in women with PCOS. Hormone Molecular Biology and Clinical Investigation, 2018, 34, .	0.3	12
1212	Elevated levels of the circulatory ischemia-modified albumin in patients with polycystic ovary syndrome: a meta-analysis. Gynecological Endocrinology, 2018, 34, 868-874.	0.7	6
1213	Subclinical hypothyroidism is not a risk factor for polycystic ovary syndrome in obese women of reproductive age. Gynecological Endocrinology, 2018, 34, 875-879.	0.7	10
1214	The effects of synbiotic supplementation on hormonal status, biomarkers of inflammation and oxidative stress in subjects with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. BMC Endocrine Disorders, 2018, 18, 21.	0.9	47
1215	Does Metformin Treatment During Pregnancy Modify the Future Metabolic Profile in Women With PCOS?. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2408-2413.	1.8	15

#	Article	IF	Citations
1216	Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy. Journal of Steroid Biochemistry and Molecular Biology, 2018, 182, 27-36.	1.2	305
1217	Reproductive health, obesity, and cardiometabolic risk factors among Samoan women. American Journal of Human Biology, 2018, 30, e23106.	0.8	1
1218	Alterations of polyunsaturated fatty acid metabolism in ovarian tissues of polycystic ovary syndrome rats. Journal of Cellular and Molecular Medicine, 2018, 22, 3388-3396.	1.6	12
1219	Local Cortisol Elevation Contributes to Endometrial Insulin Resistance in Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2457-2467.	1.8	22
1220	FSHB â˜211 G>T is a major genetic modulator of reproductive physiology and health in childbearing age women. Human Reproduction, 2018, 33, 954-966.	0.4	28
1221	Association between Th1/Th2 immune imbalance and obesity in women with or without polycystic ovary syndrome. Gynecological Endocrinology, 2018, 34, 709-714.	0.7	28
1222	The PCOS Patients differ in Lipid Profile According to their Phenotypes. Experimental and Clinical Endocrinology and Diabetes, 2018, 126, 437-444.	0.6	16
1223	Tumor necrosis factor alpha versus LH and androstendione as a reliable predictor of spontaneous ovulation after laparoscopic ovarian drilling for women with clomiphene citrate resistance polycystic ovarian disease. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2018, 222, 126-133.	0.5	7
1224	Differential rate in decline in ovarian reserve markers in women with polycystic ovary syndrome compared with control subjects: results of a longitudinal study. Fertility and Sterility, 2018, 109, 526-531.	0.5	18
1225	Steroid-depleted polycystic ovarian syndrome serum promotesin vitrooocyte maturation and embryo development. Gynecological Endocrinology, 2018, 34, 698-703.	0.7	3
1226	Unilateral or bilateral laparoscopic ovarian drilling in polycystic ovary syndrome: a meta-analysis of randomized trials. Archives of Gynecology and Obstetrics, 2018, 297, 859-870.	0.8	25
1227	Serum irisin concentrations in lean adolescents with polycystic ovary syndrome. Clinical Endocrinology, 2018, 88, 585-591.	1.2	6
1228	A Single Bout of Electroacupuncture Remodels Epigenetic and Transcriptional Changes in Adipose Tissue in Polycystic Ovary Syndrome. Scientific Reports, 2018, 8, 1878.	1.6	40
1229	Serum miRNAs in women affected by hyperandrogenic polycystic ovary syndrome: the potential role of miR-155 as a biomarker for monitoring the estroprogestinic treatment. Gynecological Endocrinology, 2018, 34, 704-708.	0.7	25
1230	Wilmsâ€™ Tumor 1 Overexpression in Granulosa Cells Is Associated with Polycystic Ovaries in Polycystic Ovary Syndrome Patients. Gynecologic and Obstetric Investigation, 2018, 83, 241-246.	0.7	4
1231	Controlled Ovarian Stimulation for In Vitro Fertilisation Cycles. , 2018, , 259-270.		1
1232	Diagnostic Criteria for PCOS. , 2018, , 11-21.		0
1233	The effects of fish oil on gene expression in patients with polycystic ovary syndrome. European Journal of Clinical Investigation, 2018, 48, e12893.	1.7	12

#	Article	IF	Citations
1234	Obesity in Pregnancy. Medical Clinics of North America, 2018, 102, 87-106.	1.1	51
1235	What is adolescent polycystic ovary syndrome?. Journal of Paediatrics and Child Health, 2018, 54, 351-355.	0.4	16
1236	Health-related quality of life in patients with polycystic ovary syndrome: validation of the German PCOSQ-G. Archives of Gynecology and Obstetrics, 2018, 297, 1027-1035.	0.8	19
1237	Metabolic syndrome, hypertension, and hyperlipidemia in mothers, fathers, sisters, and brothers of women with polycystic ovary syndrome: a systematic review and meta-analysis. Fertility and Sterility, 2018, 109, 356-364.e32.	0.5	69
1238	The Influences of Chromium Supplementation on Glycemic Control, Markers of Cardio-Metabolic Risk, and Oxidative Stress in Infertile Polycystic ovary Syndrome Women Candidate for In vitro Fertilization: a Randomized, Double-Blind, Placebo-Controlled Trial. Biological Trace Element Research, 2018, 185, 48-55.	1.9	29
1239	Pediatric obesity: Current concepts. Disease-a-Month, 2018, 64, 98-156.	0.4	48
1240	Differential association of DENND1A genetic variants with polycystic ovary syndrome in Tunisian but not Bahraini Arab women. Gene, 2018, 647, 79-84.	1.0	17
1241	Health-related knowledge, beliefs and self-efficacy in women with polycystic ovary syndrome. Human Reproduction, 2018, 33, 91-100.	0.4	31
1242	Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome. Cardiovascular Diabetology, 2018, 17, 37.	2.7	133
1243	Apa-I polymorphism in VDR gene is related to metabolic syndrome in polycystic ovary syndrome: a cross-sectional study. Reproductive Biology and Endocrinology, 2018, 16, 38.	1.4	21
1245	Polycystic ovary syndrome: possible involvement of androgen-induced, chemerin-mediated ovarian recruitment of monocytes/macrophagesâ€. Biology of Reproduction, 2018, 99, 838-852.	1.2	71
1246	Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study. European Journal of Endocrinology, 2018, 179, 1-11.	1.9	127
1247	Polycystic ovarian syndrome: an under-recognised problem?. British Journal of General Practice, 2018, 68, 244-244.	0.7	8
1248	Polycystic ovarian syndrome: overdiagnosed and overtreated?. British Journal of General Practice, 2018, 68, 243-243.	0.7	0
1249	Ethnicity, obesity and the prevalence of impaired glucose tolerance and type 2 diabetes in PCOS: a systematic review and meta-regression. Human Reproduction Update, 2018, 24, 455-467.	5.2	229
1250	Cardiotrophin-1 as a new metabolic biomarker in women with PCOS. Gynecological Endocrinology, 2018, 34, 781-783.	0.7	1
1251	The impact of mild hypercholesterolemia on glycemic and hormonal profiles, menstrual characteristics and the ovarian morphology of women with polycystic ovarian syndrome. Hormone Molecular Biology and Clinical Investigation, 2018, 34, .	0.3	6
1252	Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients. Archives of Gynecology and Obstetrics, 2018, 297, 1557-1563.	0.8	24

#	Article	IF	Citations
1253	PON1 promoter polymorphisms contribute to PCOS susceptibility and phenotypic outcomes in Indian women. Gene, 2018, 661, 34-44.	1.0	6
1254	Genetic association study from North India to analyze association of CYP19A1 and CYP17A1 with polycystic ovary syndrome. Journal of Assisted Reproduction and Genetics, 2018, 35, 1123-1129.	1.2	30
1255	Serum AMH levels and insulin resistance in women with PCOS. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2018, 224, 159-164.	0.5	38
1256	Fertility and infertility: Definition and epidemiology. Clinical Biochemistry, 2018, 62, 2-10.	0.8	1,074
1257	Operative transvaginal hydrolaparoscopy improve ovulation rate after clomiphene failure in polycystic ovary syndrome. Gynecological Endocrinology, 2018, 34, 32-35.	0.7	11
1259	Psychological distress, anger and quality of life in polycystic ovary syndrome: associations with biochemical, phenotypical andsocio-demographic factors. Journal of Psychosomatic Obstetrics and Gynaecology, 2018, 39, 128-137.	1.1	45
1260	The Effect of Tamoxifen on Thin Endometrium in Patients Undergoing Frozenâ€“Thawed Embryo Transfer. Reproductive Sciences, 2018, 25, 861-866.	1.1	12
1262	Polycystic ovarian syndrome: Prevalence and impactÂon the wellbeing of Australian women aged 16â€“29Âyears. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2018, 58, 222-233.	0.4	25
1263	Early menarche and blood pressure in adulthood: systematic review and meta-analysis. Journal of Public Health, 2018, 40, 476-484.	1.0	38
1264	The role of serum ADAMTS-1 and aggrecan on polycystic ovary syndrome in adolescents and younger-aged females. Archives of Gynecology and Obstetrics, 2018, 297, 487-493.	0.8	7
1265	Heterogenous origins of hyperandrogenism in the polycystic ovary syndrome in relation to body mass index and insulin resistance. Gynecological Endocrinology, 2018, 34, 238-242.	0.7	9
1266	Treatment strategies for women with polycystic ovary syndrome. Gynecological Endocrinology, 2018, 34, 272-277.	0.7	86
1267	Polycystic ovarian syndrome (PCOS): Long-term metabolic consequences. Metabolism: Clinical and Experimental, 2018, 86, 33-43.	1.5	217
1269	The cardiometabolic effect of current management of polycystic ovary syndrome: strategies of prevention and treatment. Gynecological Endocrinology, 2018, 34, 87-91.	0.7	12
1270	Adropin levels in women with polycystic ovaries undergoing ovarian stimulation: correlation with lipoprotein lipid profiles. Gynecological Endocrinology, 2018, 34, 153-156.	0.7	14
1272	Polycystic ovary syndrome in adolescents. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2018, 48, 103-114.	1.4	48
1273	Vitamin D receptor gene polymorphisms and risk of polycystic ovary syndrome in South Indian women. Gynecological Endocrinology, 2018, 34, 161-165.	0.7	26
1274	Methylprednisolone for prevention of ovarian hyperstimulation syndrome in patients with polycystic ovarian syndrome undergoingin-vitrofertilisation: a randomised controlled trial. Journal of Obstetrics and Gynaecology, 2018, 38, 241-246.	0.4	8

#	Article	IF	Citations
1275	Alopecia and the metabolic syndrome. Clinics in Dermatology, 2018, 36, 54-61.	0.8	34
1276	Assessment of M2/ANXA5 haplotype as a risk factor in couples with placenta-mediated pregnancy complications. Journal of Assisted Reproduction and Genetics, 2018, 35, 157-163.	1.2	7
1277	The Effects of Selenium Supplementation on Gene Expression Related to Insulin and Lipid in Infertile Polycystic Ovary Syndrome Women Candidate for In Vitro Fertilization: a Randomized, Double-Blind, Placebo-Controlled Trial. Biological Trace Element Research, 2018, 183, 218-225.	1.9	27
1278	Effects of vitamin D supplementation on insulin sensitivity and androgen levels in vitaminâ€Dâ€deficient polycystic ovary syndrome patients. Journal of Obstetrics and Gynaecology Research, 2018, 44, 270-277.	0.6	35
1279	Expression of miR-15a, miR-145, and miR-182 in granulosa-lutein cells, follicular fluid, and serum of women with polycystic ovary syndrome (PCOS). Archives of Gynecology and Obstetrics, 2018, 297, 221-231.	0.8	36
1280	Circulating irisin in patients with polycystic ovary syndrome: a meta-analysis. Reproductive BioMedicine Online, 2018, 36, 172-180.	1.1	21
1281	Sexual function in women with polycystic ovary syndrome and their hormonal and clinical correlations. International Journal of Impotence Research, 2018, 30, 54-61.	1.0	15
1282	Evaluation of PCSK9 levels and its genetic polymorphisms in women with polycystic ovary syndrome. Gene, 2018, 644, 129-136.	1.0	17
1283	The Effects of Flaxseed Oil Omega-3 Fatty Acids Supplementation on Metabolic Status of Patients with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Experimental and Clinical Endocrinology and Diabetes, 2018, 126, 222-228.	0.6	33
1284	Family-based analysis of GGT1 and HNF1A gene polymorphisms in patients with polycystic ovary syndrome. Reproductive BioMedicine Online, 2018, 36, 115-119.	1.1	6
1285	The Effects of Magnesium and Zinc Co-Supplementation on Biomarkers of Inflammation and Oxidative Stress, and Gene Expression Related to Inflammation in Polycystic Ovary Syndrome: a Randomized Controlled Clinical Trial. Biological Trace Element Research, 2018, 184, 300-307.	1.9	46
1286	Impact of variants on type-2 diabetes risk genes identified through genomewide association studies in polycystic ovary syndrome: a caseâ€“control study. Journal of Genetics, 2018, 97, 1213-1223.	0.4	2
1287	Managing polycystic ovary syndrome in primary care. Singapore Medical Journal, 2018, 59, 567-571.	0.3	17
1288	PREGNANCY RATE FOLLOWING LUTEAL PHASE SUPPORT IN POLYCYSTIC OVARY WOMEN USING LETROZOLE WITH OR WITHOUT GONADOTROPIN AS OVULATION INDUCTION. Asian Journal of Pharmaceutical and Clinical Research, 2018, 11, 321.	0.3	1
1289	Lean polycystic ovary syndrome (PCOS): an evidence-based practical approach. Journal of Diabetes and Metabolic Disorders, 2018, 17, 277-285.	0.8	68
1290	Anxiety, Depression, and Quality of Life in Women with Polycystic Ovarian Syndrome. Indian Journal of Psychological Medicine, 2018, 40, 239-246.	0.6	73
1291	Serum Preptin and Amylin Levels with Respect to Body Mass Index in Polycystic Ovary Syndrome Patients. Medical Science Monitor, 2018, 24, 7517-7523.	0.5	5
1293	Physiological roles of activins in the human ovary. Journal of Bio-X Research, 2018, 1, 111-119.	0.3	4

#	Article	IF	Citations
1294	Oriental herbal medicine and moxibustion for polycystic ovary syndrome. Medicine (United States), 2018, 97, e12942.	0.4	17
1295	Sport, doping and female fertility. Reproductive Biology and Endocrinology, 2018, 16, 108.	1.4	21
1296	Letrozole for patients with polycystic ovary syndrome. Medicine (United States), 2018, 97, e13038.	0.4	10
1297	Polycystic Ovary Syndrome, Pathophysiology, and Reproductive Health Implications. , 0, , .		1
1298	Polycystic ovarian syndrome is linked to increased oxidative stress in Omani women. International Journal of Women's Health, 2018, Volume 10, 763-771.	1.1	51
1299	Identification of selected genetic polymorphisms in polycystic ovary syndrome in Sri Lankan women using low cost genotyping techniques. PLoS ONE, 2018, 13, e0209830.	1.1	27
1300	Large-scale genome-wide meta-analysis of polycystic ovary syndrome suggests shared genetic architecture for different diagnosis criteria. PLoS Genetics, 2018, 14, e1007813.	1.5	341
1301	The Effects of Chromium Supplementation on Gene Expression of Insulin, Lipid, and Inflammatory Markers in Infertile Women With Polycystic Ovary Syndrome Candidate for in vitro Fertilization: A Randomized, Double-Blinded, Placebo-Controlled Trial. Frontiers in Endocrinology, 2018, 9, 726.	1.5	13
1302	Current Management of Polycystic Ovary Syndrome: From Bench to Bedside. International Journal of Endocrinology, 2018, 2018, 1-2.	0.6	15
1303	Spontaneous ovulation and pregnancy in women with polycystic ovarian disease; a cross sectional study. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 2018, 7, 359.	0.0	0
1304	UPLC/Qâ€TOFâ€MS based plasma metabolomics and clinical characteristics of polycystic ovarian syndrome. Molecular Medicine Reports, 2019, 19, 280-292.	1.1	10
1305	Effect of microecological preparation supplementation on woman with polycystic ovary syndrome. Medicine (United States), 2018, 97, e13040.	0.4	4
1306	Testosterone Levels in Third Trimester in Polycystic Ovary Syndrome: Odense Child Cohort. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3819-3827.	1.8	29
1307	Effects of body mass index on the outcomes of in vitro fertilization in Chinese patients with polycystic ovary syndrome: a retrospective cohort study. Journal of Zhejiang University: Science B, 2018, 19, 490-496.	1.3	13
1308	Intrafollicular fibroblast growth factor 13 in polycystic ovary syndrome: relationship with androgen levels and oocyte developmental competence. Journal of Ovarian Research, 2018, 11, 87.	1.3	9
1309	A new evidenceâ€based guideline for assessment and management of polycystic ovary syndrome. Medical Journal of Australia, 2018, 209, 299-300.	0.8	18
1310	The effects of vitamin D supplementation on metabolic profiles and gene expression of insulin and lipid metabolism in infertile polycystic ovary syndrome candidates for in vitro fertilization. Reproductive Biology and Endocrinology, 2018, 16, 94.	1.4	53
1311	Cross-method comparison of serum androstenedione measurement with respect to the validation of a new fully automated chemiluminescence immunoassay. Clinical Biochemistry, 2018, 62, 32-38.	0.8	8

#	Article	IF	Citations
1312	Methodological and reporting quality evaluation of systematic reviews on acupuncture in women with polycystic ovarian syndrome: A systematic review. Complementary Therapies in Clinical Practice, 2018, 33, 197-203.	0.7	12
1313	Endometrial injury for patients with endometriosis and polycystic ovary syndrome undergoing medically assisted reproduction: current data and a protocol. Hormone Molecular Biology and Clinical Investigation, 2018, 35, .	0.3	4
1314	Dynamic Change in Insulin Resistance Induced by Free Fatty Acids Is Unchanged Though Insulin Sensitivity Improves Following Endurance Exercise in PCOS. Frontiers in Endocrinology, 2018, 9, 592.	1.5	11
1315	A cross-sectional comparison of clinical and endocrine parameters among phenotypes of polycystic ovarian syndrome in iranian population. Middle East Fertility Society Journal, 2018, 23, 425-430.	0.5	5
1316	Bone Mineral Density is Unaltered in Women with Polycystic Ovary Syndrome. Hormone and Metabolic Research, 2018, 50, 754-760.	0.7	14
1317	How to choose the suitable animal model of polycystic ovary syndrome?. Traditional Medicine and Modern Medicine, 2018, 01, 95-113.	0.2	6
1318	Undetectable Serum Levels of Anti-MÃ¼llerian Hormone in Women with Ovarian Hyperstimulation Syndrome during In Vitro Fertilization and Successful Pregnancy Outcome: Case Report. Acta Clinica Croatica, 2018, 57, 177-180.	0.1	3
1319	Assessing C reactive protein/albumin ratio as a new biomarker for polycystic ovary syndrome: a caseâ€“control study of women from Bahraini medical clinics. BMJ Open, 2018, 8, e021860.	0.8	26
1320	Environmental exposure to triclosan and polycystic ovary syndrome: a cross-sectional study in China. BMJ Open, 2018, 8, e019707.	0.8	19
1321	The association of hs-CRP and fibrinogen with anthropometric and lipid parameters in non-obese adolescent girls with polycystic ovary syndrome. Journal of Pediatric Endocrinology and Metabolism, 2018, 31, 1213-1220.	0.4	12
1322	Serum and follicular fluid concentration of stem cell factor in PCOS. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 2018, 7, 3467.	0.0	0
1323	Hormonal and Metabolic Effects of Coenzyme Q10 and/or Vitamin E in Patients with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 319-327.	1.8	45
1324	A Summary on Polycystic Ovary Syndrome: Diagnostic Criteria, Prevalence, Clinical Manifestations, and Management According to the Latest International Guidelines. Seminars in Reproductive Medicine, 2018, 36, 005-012.	0.5	115
1325	The Needs of Women and Healthcare Providers regarding Polycystic Ovary Syndrome Information, Resources, and Education: A Systematic Search and Narrative Review. Seminars in Reproductive Medicine, 2018, 36, 035-041.	0.5	27
1326	The effects of probiotic and selenium co-supplementation on parameters of mental health, hormonal profiles, and biomarkers of inflammation and oxidative stress in women with polycystic ovary syndrome. Journal of Ovarian Research, 2018, 11, 80.	1.3	94
1327	The effect of serum and follicular fluid secreted frizzle-related protein-5 on in vitro fertilization outcomes in patients with polycystic ovary syndrome. Molecular Biology Reports, 2018, 45, 2037-2044.	1.0	7
1328	Profiles for long non-coding RNAs in ovarian granulosa cells from women with PCOS with or without hyperandrogenism. Reproductive BioMedicine Online, 2018, 37, 613-623.	1.1	17
1329	Introductory Chapter: Polycystic Ovarian Disease: The Rainbow Without Color (SPECTRUM). , 0, , .		0

#	Article	IF	Citations
1330	Associations of serum fetuin-A and oxidative stress parameters with polycystic ovary syndrome. Clinical and Experimental Reproductive Medicine, 2018, 45, 116-121.	0.5	17
1331	Early gonadotropin-releasing hormone antagonist protocol in women with polycystic ovary syndrome: A preliminary randomized trial. Clinical and Experimental Reproductive Medicine, 2018, 45, 135-142.	0.5	9
1332	Can resistance training improve the symptoms of polycystic ovary syndrome?. BMJ Open Sport and Exercise Medicine, 2018, 4, e000372.	1.4	7
1333	Assisted reproductive technology in Beijing, 2013â€“2015. Reproductive BioMedicine Online, 2018, 37, 521-532.	1.1	13
1334	Long-Term Effects of Oral Antidiabetic Drugs During Pregnancy on Offspring: A Systematic Review and Meta-analysis of Follow-up Studies of RCTs. Diabetes Therapy, 2018, 9, 1811-1829.	1.2	37
1335	Influence of peroxisome proliferator-activated receptor-Î³ exon 2 and exon 6 and insulin receptor substrate (IRS)-1 Gly972Arg polymorphisms on insulin resistance and beta-cell function in southern mediterranean women with polycystic ovary syndrome. Journal of Clinical and Translational Endocrinology, 2018, 13, 1-8.	1.0	10
1336	Benign Conditions of the Ovary. , 2018, , 761-799.		1
1337	Does the Pituitary Gland Volume Change in Polycystic Ovary Syndrome?. Gynecologic and Obstetric Investigation, 2018, 83, 515-519.	0.7	9
1338	American, European, and Chinese practice guidelines or consensuses of polycystic ovary syndrome: a comparative analysis. Journal of Zhejiang University: Science B, 2018, 19, 354-363.	1.3	18
1339	The association between circulating irisin levels and different phenotypes of polycystic ovary syndrome. Journal of Endocrinological Investigation, 2018, 41, 1401-1407.	1.8	25
1340	Hyperhomocysteinemia in polycystic ovary syndrome: decreased betaine-homocysteine methyltransferase and cystathionine Î²-synthase-mediated homocysteine metabolism. Reproductive BioMedicine Online, 2018, 37, 234-241.	1.1	15
1341	The diagnosis of PCOS in young infertile women according to different diagnostic criteria: the role of serum anti-MÃ¼llerian hormone. Archives of Gynecology and Obstetrics, 2018, 298, 207-215.	0.8	13
1342	Role of A-kinase anchoring protein 95 in the regulation of cytochrome P450 family 19 subfamily A member 1 (CYP19A1) in human ovarian granulosa cells. Reproduction, Fertility and Development, 2018, 30, 1128.	0.1	9
1343	Metabolic syndrome in Iran: A review. Translational Metabolic Syndrome Research, 2018, 1, 10-22.	0.2	6
1344	Chicken Is a Useful Model to Investigate the Role of Adipokines in Metabolic and Reproductive Diseases. International Journal of Endocrinology, 2018, 2018, 1-19.	0.6	47
1345	Diabetes mellitus and insulin resistance in mothers, fathers, sisters, and brothers of women with polycystic ovary syndrome: a systematic review and meta-analysis. Fertility and Sterility, 2018, 110, 523-533.e14.	0.5	37
1346	Follicle-Stimulating Hormone Receptor: Advances and Remaining Challenges. International Review of Cell and Molecular Biology, 2018, 338, 1-58.	1.6	23
1347	Adult-onset acne: prevalence, impact, and management challenges. Clinical, Cosmetic and Investigational Dermatology, 2018, Volume 11, 59-69.	0.8	57

#	Article	IF	Citations
1348	Surface-enhanced Raman scattering for the detection of polycystic ovary syndrome. Biomedical Optics Express, 2018, 9, 801.	1.5	11
1349	Myo-inositol supplementation reduces the amount of gonadotropins and length of ovarian stimulation in women undergoing IVF: a systematic review and meta-analysis of randomized controlled trials. Archives of Gynecology and Obstetrics, 2018, 298, 675-684.	0.8	56
1350	Perfluorinated alkyl acids in the serum and follicular fluid of UK women with and without polycystic ovarian syndrome undergoing fertility treatment and associations with hormonal and metabolic parameters. International Journal of Hygiene and Environmental Health, 2018, 221, 1068-1075.	2.1	52
1351	A Cohort Study Comparing Women with Autism Spectrum Disorder with and without Generalized Joint Hypermobility. Behavioral Sciences (Basel, Switzerland), 2018, 8, 35.	1.0	12
1352	Polycystic Ovary Syndrome. Nursing Clinics of North America, 2018, 53, 407-420.	0.7	103
1353	The obesogen tributyltin induces features of polycystic ovary syndrome (PCOS): a review. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2018, 21, 181-206.	2.9	19
1354	MicroRNA-16 Promotes Ovarian Granulosa Cell Proliferation and Suppresses Apoptosis Through Targeting PDCD4 in Polycystic Ovarian Syndrome. Cellular Physiology and Biochemistry, 2018, 48, 670-682.	1.1	49
1355	Predictive factors of gestational diabetes in pregnancies following assisted reproductive technology: a nested caseâ€“control study. Archives of Gynecology and Obstetrics, 2018, 298, 199-206.	0.8	21
1356	C-type natriuretic peptide: a link between hyperandrogenism and anovulation in a mouse model of polycystic ovary syndrome. Clinical Science, 2018, 132, 905-908.	1.8	9
1357	Evaluation of biochemical, endocrine, and metabolic biomarkers for the early diagnosis of polycystic ovary syndrome among nonâ€obese Saudi women. International Journal of Gynecology and Obstetrics, 2018, 142, 162-169.	1.0	22
1358	Hippo signaling in the ovary and polycystic ovarian syndrome. Journal of Assisted Reproduction and Genetics, 2018, 35, 1763-1771.	1.2	32
1359	New Biomarkers to Evaluate Hyperandrogenemic Women and Hypogonadal Men. Advances in Clinical Chemistry, 2018, 86, 71-125.	1.8	17
1360	The Polycystic Ovary Syndrome and the Metabolic Syndrome: A Possible Chronobiotic-Cytoprotective Adjuvant Therapy. International Journal of Endocrinology, 2018, 2018, 1-12.	0.6	29
1361	A study of ghrelin and leptin levels and their relationship to metabolic profiles in obese and lean Saudi women with polycystic ovary syndrome (PCOS). Lipids in Health and Disease, 2018, 17, 195.	1.2	24
1362	Preliminary study showing no association between G238A (rs361525) tumor necrosis factor-Î± (TNF-Î±) gene polymorphism and its serum level, hormonal and biochemical aspects of polycystic ovary syndrome. BMC Medical Genetics, 2018, 19, 149.	2.1	7
1363	Assessment of oxytocin level, glucose metabolism components and cutoff values for oxytocin and anti-mullerian hormone in infertile PCOS women. Taiwanese Journal of Obstetrics and Gynecology, 2018, 57, 555-559.	0.5	15
1364	Ontogeny and reversal of brain circuit abnormalities in a preclinical model of PCOS. JCI Insight, 2018, 3, .	2.3	65
1365	Sleep disturbances in women with polycystic ovary syndrome: prevalence, pathophysiology, impact and management strategies. Nature and Science of Sleep, 2018, Volume 10, 45-64.	1.4	74

#	Article	IF	Citations
1366	Anxiety and depression states of adolescents with polycystic ovary syndrome. Turkish Journal of Medical Sciences, 2018, 48, 531-536.	0.4	21
1367	Killer-cell immunoglobulin-like receptors associated with polycystic ovary syndrome. Journal of Reproductive Immunology, 2018, 130, 1-6.	0.8	9
1368	Pilot study of the optimal protocol of low dose stepâ€up follicle stimulating hormone therapy for infertile women. Reproductive Medicine and Biology, 2018, 17, 315-324.	1.0	4
1369	Comparison of Metformin and N Acetylcysteine on Clinical, Metabolic Parameter and Hormonal Profile in Women with Polycystic Ovarian Syndrome. Journal of Obstetrics and Gynecology of India, 2019, 69, 77-81.	0.3	9
1370	The role of anti-MÃ¼llerian hormone in predicting clomiphene citrate resistance in women with polycystic ovarian syndrome. Gynecological Endocrinology, 2019, 35, 86-89.	0.7	14
1371	The Effect of Metformin on the Endometrium of Women with Polycystic Ovary Syndrome. Gynecologic and Obstetric Investigation, 2019, 84, 35-44.	0.7	9
1372	Evaluation of Hormonal Status. , 2019, , 887-915.e4.		8
1373	Comparison of Serum A Disintegrin and Metalloproteinase with Thrombospondin Motifs-19 Levels in Different Fertility Situations: Could It Be a Serum Marker of Ovarian Function and Oocyte Pool?. Gynecologic and Obstetric Investigation, 2019, 84, 6-11.	0.7	4
1374	Assessing the variability and predictability of adipokines (adiponectin, leptin, resistin and their ratios) in non-obese and obese women with anovulatory polycystic ovary syndrome. BMC Research Notes, 2019, 12, 513.	0.6	11
1375	Body-image distress is increased in women with polycystic ovary syndrome and mediates depression and anxiety. Fertility and Sterility, 2019, 112, 930-938.e1.	0.5	64
1376	Nitric oxide (NO) levels in patients with polycystic ovary syndrome (PCOS): a meta-analysis. Journal of International Medical Research, 2019, 47, 4083-4094.	0.4	13
1377	Association of measures of central fat accumulation indices with body fat distribution and metabolic, hormonal, and inflammatory parameters in women with polycystic ovary syndrome. Archives of Endocrinology and Metabolism, 2019, 63, 417-426.	0.3	12
1378	Analysis of VEGF gene polymorphisms and serum VEGF protein levels contribution in polycystic ovary syndrome of patients. Molecular Biology Reports, 2019, 46, 5821-5829.	1.0	15
1379	Polycystic Ovary Syndrome (PCOS) and Sexual Dysfunctions. Journal of Psychosexual Health, 2019, 1, 154-158.	0.2	3
1380	Is There a Relationship Between Vitamin D Deficiency Status and PCOS in Infertile Women?. Geburtshilfe Und Frauenheilkunde, 2019, 79, 723-730.	0.8	12
1381	Ultrasound Imaging in Reproductive Medicine. , 2019, , .		0
1382	Elevated chemerin induces insulin resistance in human granulosaâ€lutein cells from polycystic ovary syndrome patients. FASEB Journal, 2019, 33, 11303-11313.	0.2	28
1383	Association of occupational exposure on semen density in male industrial workers undergoing infertility treatment at tertiary care hospital. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 2019, 8, 2453.	0.0	0

#	Article	IF	Citations
1384	Polyzystisches Ovarsyndrom (PCOS). Springer Reference Medizin, 2019, , 1-12.	0.0	0
1385	Pentraxin 3 as a marker of endothelial dysfunction in young women with polycystic ovary syndrome (PCOS). Scandinavian Journal of Clinical and Laboratory Investigation, 2019, 79, 419-423.	0.6	6
1386	Ultrasound and Ovarian Hyperstimulation Syndrome. , 2019, , 321-333.		0
1387	PCOS. , 2019, , 91-109.		0
1388	Comparison of the Uroflowmetry Parameter Results Between Transgender Males Undergoing Gender-Affirming Hormone Therapy and Age-Matched Cisgender Females: Preliminary Data. Transgender Health, 2019, 4, 152-156.	1.2	8
1389	Polycystic ovary syndrome dependency on mtDNA mutation; copy Number and its association with insulin resistance. BMC Research Notes, 2019, 12, 455.	0.6	24
1390	Epidemiology of infertility and characteristics of infertile couples requesting assisted reproduction in a low-resource setting in Africa, Sudan. Fertility Research and Practice, 2019, 5, 7.	4.1	46
1391	Analysis of ovarian volume of Korean children and adolescents at magnetic resonance imaging. Pediatric Radiology, 2019, 49, 1320-1326.	1.1	2
1392	Polycystic ovary syndrome (PCOS) and genetic predisposition: A review article. European Journal of Obstetrics and Gynecology and Reproductive Biology: X, 2019, 3, 100060.	0.6	114
1393	Effect of Calcium and Vitamin D Supplements as an Adjuvant Therapy to Metformin on Menstrual Cycle Abnormalities, Hormonal Profile, and IGF-1 System in Polycystic Ovary Syndrome Patients: A Randomized, Placebo-Controlled Clinical Trial. Advances in Pharmacological Sciences, 2019, 2019, 1-10.	3.7	15
1394	MicroRNA-125b controls growth of ovarian granulosa cells in polycystic ovarian syndrome by modulating cyclin B1 expression. Archives of Medical Science, 2019, 18, 746-752.	0.4	2
1395	The effects of curcumin supplementation on glycemic status, lipid profile and hs-CRP levels in overweight/obese women with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled clinical trial. Complementary Therapies in Medicine, 2019, 47, 102201.	1.3	63
1396	Ultrasonographic Evaluation of Femoral Cartilage Thickness in Patients with Polycystic Ovary Syndrome. Acta Clinica Croatica, 2019, 58, 103-106.	0.1	1
1397	Diffuse idiopathic skeletal hyperostosis in a 33-year-old woman with PCOS and metabolic syndrome: a rare scenario. BMJ Case Reports, 2019, 12, e223740.	0.2	5
1398	Investigation of soluble anti-MÃ¼llerian hormone receptor type 2 as a biomarker for diagnosis of female fertility disorders. Reproductive BioMedicine Online, 2019, 39, 1017-1025.	1.1	2
1399	The rs16944 SNP in IL-1B and risk of polycystic ovarian syndrome. Gene Reports, 2019, 17, 100547.	0.4	0
1400	Unexplained recurrent pregnancy loss and unexplained infertility: twins in disguise. Human Reproduction Open, 2020, 2020, .	2.3	6
1401	The effects of di(2-ethylhexyl) phthalate exposure in women with polycystic ovary syndrome undergoing in vitro fertilization. Journal of International Medical Research, 2019, 47, 6278-6293.	0.4	30

#	Article	IF	Citations
1402	Inflammatory Stimuli Trigger Increased Androgen Production and Shifts in Gene Expression in Theca-Interstitial Cells. Endocrinology, 2019, 160, 2946-2958.	1.4	38
1403	Ultrasound Evaluation in Female Infertility. Obstetrics and Gynecology Clinics of North America, 2019, 46, 683-696.	0.7	8
1404	Epigenetic Reprogramming of Immune Cells in Women With PCOS Impact Genes Controlling Reproductive Function. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 6155-6170.	1.8	22
1405	A Higher Estradiol Rise After Dual Trigger in Progestin-Primed Ovarian Stimulation Is Associated With a Lower Oocyte and Mature Oocyte Yield in Normal Responders. Frontiers in Endocrinology, 2019, 10, 696.	1.5	4
1406	Prevalence of polycystic ovary syndrome in women with severe obesity â€“ Effects of a structured weight loss programme. Clinical Endocrinology, 2019, 91, 750-758.	1.2	20
1407	The effect of myoinositol on ovarian blood flows in women with polycystic ovary syndrome. Gynecological Endocrinology, 2019, 35, 237-241.	0.7	5
1408	Effect of phlebotomy versus oral contraceptives containing cyproterone acetate on the clinical and biochemical parameters in women with polycystic ovary syndrome: a randomized controlled trial. Journal of Ovarian Research, 2019, 12, 78.	1.3	8
1409	Neuroendocrine Impairments of Polycystic Ovary Syndrome. Endocrinology, 2019, 160, 2230-2242.	1.4	56
1410	Lipidomics biomarkers in women with polycystic ovary syndrome (PCOS) using ultra-high performance liquid chromatographyâ€“quadrupole time of flight electrospray in a positive ionization mode mass spectrometry. Scandinavian Journal of Clinical and Laboratory Investigation, 2019, 79, 437-442.	0.6	17
1411	Negative impact of polycystic ovary syndrome on bone health: a systematic review and meta-analysis. Human Reproduction Update, 2019, 25, 634-646.	5.2	30
1412	Continuous versus intermittent aerobic exercise in the improvement of quality of life for women with polycystic ovary syndrome: A randomized controlled trial. Journal of Health Psychology, 2019, 26, 135910531986980.	1.3	14
1413	Mesenchymal Stem Cells Alleviate DHEA-Induced Polycystic Ovary Syndrome (PCOS) by Inhibiting Inflammation in Mice. Stem Cells International, 2019, 2019, 1-12.	1.2	56
1414	Developmental Programming: Contribution of Epigenetic Enzymes to Antral Follicular Defects in the Sheep Model of PCOS. Endocrinology, 2019, 160, 2471-2484.	1.4	16
1415	Anogenital distance in children born of mothers with polycystic ovary syndrome: the Odense Child Cohort. Human Reproduction, 2019, 34, 2061-2070.	0.4	21
1416	A Narrative Review of Placental Contribution to Adverse Pregnancy Outcomes in Women With Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5299-5315.	1.8	44
1417	A randomized controlled trial of combination letrozole and clomiphene citrate or letrozole alone for ovulation induction in women with polycystic ovary syndrome. Fertility and Sterility, 2019, 111, 571-578.e1.	0.5	48
1418	Vitamin D and probiotic co-supplementation affects mental health, hormonal, inflammatory and oxidative stress parameters in women with polycystic ovary syndrome. Journal of Ovarian Research, 2019, 12, 5.	1.3	87
1419	The influence of the rs1137101 genotypes of leptin receptor gene on the demographic and metabolic profile of normal Saudi females and those suffering from polycystic ovarian syndrome. BMC Women's Health, 2019, 19, 10.	0.8	8

#	Article	IF	Citations
1420	Obesity Does not Compromise Ovarian Reserve Markers in Infertile Women. Geburtshilfe Und Frauenheilkunde, 2019, 79, 79-85.	0.8	8
1421	Pre-Conception Characteristics Predict Obstetrical and Neonatal Outcomes in Women With Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 809-818.	1.8	34
1422	Early onset of cabergoline therapy for prophylaxis from ovarian hyperstimulation syndrome (OHSS): A potentially safer and more effective protocol. Reproductive Biology, 2019, 19, 145-148.	0.9	8
1423	Binge eating in patients with polycystic ovary syndrome: prevalence, causes, and management strategies . Neuropsychiatric Disease and Treatment, 2019, Volume 15, 1273-1285.	1.0	15
1424	Independent and Additive Effects of Coenzyme Q10 and Vitamin E on Cardiometabolic Outcomes and Visceral Adiposity in Women With Polycystic Ovary Syndrome. Archives of Medical Research, 2019, 50, 1-10.	1.5	25
1425	Association between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2019, 48, 822-830.	0.9	22
1426	Effect of hyperinsulinaemia and insulin resistance on endocrine, metabolic and fertility outcomes in women with polycystic ovary syndrome undergoing ovulation induction. Clinical Endocrinology, 2019, 91, 440-448.	1.2	25
1427	AMH in combination with SHBG for the diagnosis of polycystic ovary syndrome. Journal of Obstetrics and Gynaecology, 2019, 39, 1130-1136.	0.4	18
1428	Quality of life among infertile PCOS patients. Archives of Gynecology and Obstetrics, 2019, 300, 461-467.	0.8	22
1429	Altered miR-186 and miR-135a contribute to granulosa cell dysfunction by targeting ESR2: A possible role in polycystic ovary syndrome. Molecular and Cellular Endocrinology, 2019, 494, 110478.	1.6	21
1430	Evaluating exercise challenge to validate cardiac autonomic dysfunction in lean PCOS phenotype. Journal of Basic and Clinical Physiology and Pharmacology, 2019, 30, .	0.7	1
1431	Chronic low-grade inflammation in polycystic ovary syndrome: is there a (patho)-physiological role for interleukin-1?. Seminars in Immunopathology, 2019, 41, 447-459.	2.8	37
1432	Depression Over the Lifespan in a Population-Based Cohort of Women With Polycystic Ovary Syndrome: Longitudinal Analysis. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2809-2819.	1.8	43
1433	Renal resistive index in patients with polycystic ovary syndrome. Archives of Endocrinology and Metabolism, 2019, 63, 288-292.	0.3	0
1434	Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2875-2891.	1.8	67
1435	Exercise Recommendations for Women with Polycystic Ovary Syndrome: Is the Evidence Enough?. Sports Medicine, 2019, 49, 1143-1157.	3.1	36
1436	Endometrial Flushing Tumor Necrosis Factor Alpha and Interleukin 2 Levels in Women with Polycystic Ovary Syndrome, Leiomyoma and Endometrioma: Comparison with Healthy Controls. Geburtshilfe Und Frauenheilkunde, 2019, 79, 517-523.	0.8	6
1437	Gonadotropin-Releasing Hormone Agonist Versus Human Chorionic Gonadotropin for Ovulation Induction in Polycystic Ovary Syndrome Patients Undergoing Intrauterine Insemination: A Randomised Controlled Trial. Fertility & Reproduction, 2019, 01, 88-92.	0.0	0

#	Article	IF	Citations
1438	PCOS diagnosis in adolescents: the timeline of a controversy in a systematic review. Journal of Pediatric Endocrinology and Metabolism, 2019, 32, 549-559.	0.4	9
1439	Identification of potential metabolic biomarkers of polycystic ovary syndrome in follicular fluid by SWATH mass spectrometry. Reproductive Biology and Endocrinology, 2019, 17, 45.	1.4	37
1440	Selenium and Polycystic Ovary Syndrome; Current Knowledge and Future Directions: A Systematic Review. Hormone and Metabolic Research, 2019, 51, 279-287.	0.7	20
1441	The effects of exercise on cardiometabolic outcomes in women with polycystic ovary syndrome not taking the oral contraceptive pill: protocol for a systematic review and meta-analysis. Systematic Reviews, 2019, 8, 116.	2.5	6
1442	Endogenous sex hormones and risk of venous thromboembolism in young women. Journal of Thrombosis and Haemostasis, 2019, 17, 1297-1304.	1.9	17
1443	Body image and its relationships with sexual functioning, anxiety, and depression in women with polycystic ovary syndrome. Journal of Affective Disorders, 2019, 253, 385-393.	2.0	57
1444	Correlation of body mass index (BMI), anti-mullerian hormone (AMH), and insulin resistance among different polycystic ovary syndrome (PCOS) phenotypes â€“ a cross-sectional study. Gynecological Endocrinology, 2019, 35, 970-973.	0.7	31
1445	Recent advances in the understanding and management of polycystic ovary syndrome. F1000Research, 2019, 8, 565.	0.8	63
1446	A mutation in Siteâ€‹1 Protease is associated with a complex phenotype that includes episodic hyperCKemia and focal myoedema. Molecular Genetics & Genomic Medicine, 2019, 7, e00733.	0.6	13
1447	PGC-1Î± protects against oxidized low-density lipoprotein and luteinizing hormone-induced granulosa cells injury through ROS-p38 pathway. Human Cell, 2019, 32, 285-296.	1.2	20
1448	Androgens and Cardiovascular Diseases in Women. , 2019, , 3-12.		0
1449	Effects of bariatric surgery on obese polycystic ovary syndrome: aÂsystematic review and meta-analysis. Surgery for Obesity and Related Diseases, 2019, 15, 942-950.	1.0	42
1450	Serum and follicular fluid irisin levels in women with polycystic ovaries undergoing ovarian stimulation: correlation with insulin resistance and lipoprotein lipid profiles. Gynecological Endocrinology, 2019, 35, 803-806.	0.7	9
1451	Improvement of embryonic development and clinical outcomes of germinal vesicle stage oocytes using a microvibration culture system. Systems Biology in Reproductive Medicine, 2019, 65, 333-341.	1.0	3
1452	Association of Kiss1 and GPR54 Gene Polymorphisms with Polycystic Ovary Syndrome among Sri Lankan Women. BioMed Research International, 2019, 2019, 1-10.	0.9	14
1453	HSD3B1 gene polymorphism and female pattern hair loss in women with polycystic ovary syndrome. Journal of the Formosan Medical Association, 2019, 118, 1225-1231.	0.8	9
1454	Haplotype analysis ofVEGFgene polymorphisms in polycystic ovary syndrome. Gynecological Endocrinology, 2019, 35, 847-850.	0.7	5
1455	Blood anti-MÃ¼llerian hormone is a possible determinant of recurrent early miscarriage, yet not conclusive in predicting a further miscarriage. Reproductive BioMedicine Online, 2019, 39, 304-311.	1.1	4

#	Article	IF	Citations
1456	Age-specific values of Access anti-MÃ¼llerian hormone immunoassay carried out on Japanese patients with infertility: a retrospective large-scale study. BMC Women's Health, 2019, 19, 57.	0.8	14
1457	Evaluation of antioxidant defense markers in relation to hormonal and insulin parameters in women with polycystic ovary syndrome (PCOS): A case-control study. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2019, 13, 1957-1961.	1.8	29
1458	Detection of T lymphocyte subsets and related functional molecules in follicular fluid of patients with polycystic ovary syndrome. Scientific Reports, 2019, 9, 6040.	1.6	21
1459	Do serum androgens influence blastocysts ploidy in karyotypically normal women?. Systems Biology in Reproductive Medicine, 2019, 65, 281-287.	1.0	0
1460	Comparison of the effect of two combinations of myo-inositol and <scp>D</scp>-chiro-inositol in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial. Gynecological Endocrinology, 2019, 35, 695-700.	0.7	25
1461	Carnitine and chromium co-supplementation affects mental health, hormonal, inflammatory, genetic, and oxidative stress parameters in women with polycystic ovary syndrome. Journal of Psychosomatic Obstetrics and Gynaecology, 2019, , 1-9.	1.1	18
1462	The resting metabolic rate in women with polycystic ovary syndrome and its relation to the hormonal milieu, insulin metabolism, and body fat distribution: a cohort study. Journal of Endocrinological Investigation, 2019, 42, 1089-1097.	1.8	12
1463	Polycystic Ovary Syndrome in Active Duty Service Women: A Retrospective Analysis. Military Medicine, 2019, 184, 440-446.	0.4	5
1464	Polycystic ovary syndrome. Nurse Practitioner, 2019, 44, 30-35.	0.2	11
1465	Metabolomic change due to combined treatment with myo-inositol, D-chiro-inositol and glucomannan in polycystic ovarian syndrome patients: a pilot study. Journal of Ovarian Research, 2019, 12, 25.	1.3	21
1466	Age at Onset of Metabolic Syndrome Among Women With and Without Polycystic Ovary Syndromeâ€“Like Status. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1429-1439.	1.8	9
1467	Effect of low-dose aspirin on the development of ovarian hyperstimulation syndrome and outcomes of assisted reproductive techniques in the women with PCOS, a randomized double-blinded clinical trial. Taiwanese Journal of Obstetrics and Gynecology, 2019, 58, 255-260.	0.5	12
1468	Polycystic ovary syndrome in adult women. Medicina ClÃnica (English Edition), 2019, 152, 450-457.	0.1	12
1469	How to Evaluate Acne in Reproductive-Age Women: An Epidemiological Study in Chinese Communities. BioMed Research International, 2019, 2019, 1-5.	0.9	6
1470	Dysregulated miR-142, -33b and -423 in granulosa cells target TGFBR1 and SMAD7: a possible role in polycystic ovary syndrome. Molecular Human Reproduction, 2019, 25, 638-646.	1.3	34
1471	Follicular fluid concentrations of phthalate metabolites are associated with altered intrafollicular reproductive hormones in women undergoing inÂvitro fertilization. Fertility and Sterility, 2019, 111, 953-961.	0.5	37
1472	Peroxiredoxin 4 levels in patients with PCOS and/or obesity. Journal of Gynecology Obstetrics and Human Reproduction, 2019, 48, 739-743.	0.6	4
1473	Levels of circulating insulin cell-free DNA in women with polycystic ovary syndrome â€“ a longitudinal cohort study. Reproductive Biology and Endocrinology, 2019, 17, 34.	1.4	8

#	Article	IF	Citations
1474	DNA methylome profiling of granulosa cells reveals altered methylation in genes regulating vital ovarian functions in polycystic ovary syndrome. Clinical Epigenetics, 2019, 11, 61.	1.8	63
1475	Comparison of 2-Hour Oral Glucose Tolerance Test and Hemoglobin A1C in the Identification of Pre-Diabetes in Women with Infertility and Recurrent Pregnancy Loss. Clinical Medicine Insights Reproductive Health, 2019, 13, 117955811983128.	3.9	2
1476	Lower prevalence of nonâ€“cavity-distorting uterine fibroids in patients with polycystic ovary syndrome than in those with unexplained infertility. Fertility and Sterility, 2019, 111, 1011-1019.e1.	0.5	6
1477	Circular RNA expression profiling of granulosa cells in women of reproductive age with polycystic ovary syndrome. Archives of Gynecology and Obstetrics, 2019, 300, 431-440.	0.8	40
1478	Novel circular RNA expression in the cumulus cells of patients with polycystic ovary syndrome. Archives of Gynecology and Obstetrics, 2019, 299, 1715-1725.	0.8	32
1479	Association between the vascular endothelial growth factor gene polymorphisms and the risk of polycystic ovary syndrome in Northern Chinese women. Gynecological Endocrinology, 2019, 35, 706-709.	0.7	4
1480	Quantitative mass spectrometric analysis to unravel glycoproteomic signature of follicular fluid in women with polycystic ovary syndrome. PLoS ONE, 2019, 14, e0214742.	1.1	19
1481	Association of paraoxonase-1 L55M and Q192R polymorphisms with PCOS risk and potential risk factors for atherosclerosis. Biomarkers in Medicine, 2019, 13, 279-289.	0.6	4
1482	MicroRNA-9 affects isolated ovarian granulosa cells proliferation and apoptosis via targeting vitamin D receptor. Molecular and Cellular Endocrinology, 2019, 486, 18-24.	1.6	15
1483	Differential activity of the corticosteroidogenic enzymes in normal cycling women and women with polycystic ovary syndrome. Reviews in Endocrine and Metabolic Disorders, 2019, 20, 3-13.	2.6	4
1484	Expression of genes controlling steroid metabolism and action in granulosa-lutein cells of women with polycystic ovaries. Molecular and Cellular Endocrinology, 2019, 486, 47-54.	1.6	17
1485	Letrozole versus laparoscopic ovarian drilling in clomiphene citrate-resistant women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reproductive Biology and Endocrinology, 2019, 17, 17.	1.4	15
1486	The HMGA2-IMP2 Pathway Promotes Granulosa Cell Proliferation in Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1049-1059.	1.8	38
1487	Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 256-266.	5.5	106
1488	Effect of polycystic ovary syndrome on cardiac autonomic function at a late fertile age: a prospective Northern Finland Birth Cohort 1966 study. BMJ Open, 2019, 9, e033780.	0.8	6
1489	QUALITY OF LIFE IN WOMEN WITH POLYCYSTIC OVARIAN SYNDROME: REQUISITE OF CLINICAL PHARMACIST INTERVENTION. Asian Journal of Pharmaceutical and Clinical Research, 2019, , 100-105.	0.3	1
1490	Quantitative Differences in TGF-Î² Family Members Measured in Small Antral Follicle Fluids From Women With or Without PCO. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 6371-6384.	1.8	24
1491	A comprehensive review of clinical studies with herbal medicine on polycystic ovary syndrome (PCOS). DARU, Journal of Pharmaceutical Sciences, 2019, 27, 863-877.	0.9	73

#	Article	IF	Citations
1492	The regulation and signalling of anti-MÃ¼llerian hormone in human granulosa cells: relevance to polycystic ovary syndrome. Human Reproduction, 2019, 34, 2467-2479.	0.4	28
1493	Baicalin ameliorates polycystic ovary syndrome through AMP-activated protein kinase. Journal of Ovarian Research, 2019, 12, 109.	1.3	25
1494	Polycystic Ovary Syndrome: Impact of Lipotoxicity on Metabolic and Reproductive Health. Obstetrical and Gynecological Survey, 2019, 74, 223-231.	0.2	20
1495	Triglycerides as a Metabolic Target in Afrocaribbean Infertile Women with Polycystic Ovary Syndrome. Metabolic Syndrome and Related Disorders, 2019, 17, 500-504.	0.5	3
1496	Polycystic ovary syndrome. Nursing, 2019, 49, 34-40.	0.2	17
1498	The Effect of Berberine on Reproduction and Metabolism in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomized Control Trials. Evidence-based Complementary and Alternative Medicine, 2019, 2019, 1-14.	0.5	19
1499	No evidence for a major effect of three common polymorphisms of the GPx1 , MnSOD , and CAT genes on PCOS susceptibility. Journal of Cellular Biochemistry, 2019, 120, 2362-2369.	1.2	8
1500	Endoplasmic Reticulum Stress Activated by Androgen Enhances Apoptosis of Granulosa Cells via Induction of Death Receptor 5 in PCOS. Endocrinology, 2019, 160, 119-132.	1.4	58
1501	PCOS: diagnosis and management of related infertility. Obstetrics, Gynaecology and Reproductive Medicine, 2019, 29, 1-5.	0.1	4
1502	Cardiometabolic risks in PCOS: a review of the current state of knowledge. Expert Review of Endocrinology and Metabolism, 2019, 14, 23-33.	1.2	34
1503	Increased Expression of KISS1 and KISS1 Receptor in Human Granulosa Lutein Cellsâ€"Potential Pathogenesis of Polycystic Ovary Syndrome. Reproductive Sciences, 2019, 26, 1429-1438.	1.1	22
1504	The Effects of Magnesium and Vitamin E Co-Supplementation on Hormonal Status and Biomarkers of Inflammation and Oxidative Stress in Women with Polycystic Ovary Syndrome. Biological Trace Element Research, 2019, 191, 54-60.	1.9	35
1505	Assisted reproductive outcomes in women with different polycystic ovary syndrome phenotypes. International Journal of Gynecology and Obstetrics, 2019, 144, 147-152.	1.0	5
1506	Body image, personality profiles and alexithymia in patients with polycystic ovary syndrome (PCOS). Journal of Psychosomatic Obstetrics and Gynaecology, 2019, 40, 294-303.	1.1	24
1507	Elevation of antimÃ¼llerian hormone in women with polycystic ovary syndrome undergoing assisted reproduction: effect of insulin. Fertility and Sterility, 2019, 111, 157-167.	0.5	20
1508	Dietary intake, body composition and metabolic parameters in women with polycystic ovary syndrome. Clinical Nutrition, 2019, 38, 2342-2348.	2.3	10
1509	Overview of systematic reviews of non-pharmacological interventions in women with polycystic ovary syndrome. Human Reproduction Update, 2019, 25, 243-256.	5.2	32
1510	Comparison of myo-inositol and metformin on glycemic control, lipid profiles, and gene expression related to insulin and lipid metabolism in women with polycystic ovary syndrome: a randomized controlled clinical trial. Gynecological Endocrinology, 2019, 35, 406-411.	0.7	31

#	Article	IF	Citations
1511	Correlation Between Physiologic and Osteopathic Measures of Sympathetic Activity in Women With Polycystic Ovary Syndrome. Journal of Osteopathic Medicine, 2019, 119, 7-17.	0.4	8
1512	Perinatal exposure to di-ethyl-hexyl phthalate via parenteral route induced polycystic ovarian syndrome-like genetic and pathologic changes in F1 offspring mice. Molecular and Cellular Toxicology, 2019, 15, 19-30.	0.8	4
1513	Circulating antimÃ¼llerian hormone and steroid hormone levels remain high in pregnant women with polycystic ovary syndrome at term. Fertility and Sterility, 2019, 111, 588-596.e1.	0.5	42
1514	Circulating Angiopoietin-like 8 protein (ANGPTL8/Betatrophin) in patients with polycystic ovary syndrome: a systematic review and multi effect size meta-analysis. Gynecological Endocrinology, 2019, 35, 190-197.	0.7	9
1515	Treatment with <scp>d</scp>-chiro-inositol and alpha lipoic acid in the management of polycystic ovary syndrome. Gynecological Endocrinology, 2019, 35, 506-510.	0.7	16
1516	Nonpharmacologic Management of Symptoms in Females With Polycystic Ovary Syndrome: A Narrative Review. Journal of Osteopathic Medicine, 2019, 119, 25-39.	0.4	4
1517	Altered expression of the kisspeptin/KISS1R and neurokinin B/NK3R systems in mural granulosa and cumulus cells of patients with polycystic ovarian syndrome. Journal of Assisted Reproduction and Genetics, 2019, 36, 113-120.	1.2	29
1518	Anti-MÃ¼llerian hormone serum levels in systemic lupus erythematosus patients: Influence of the disease severity and therapy on the ovarian reserve. Endocrine, 2019, 63, 369-375.	1.1	23
1519	Sympathovagal imbalance and neurophysiologic cognitive assessment using evoked potentials in polycystic ovary syndrome in young adolescents â€“ a cross-sectional study. Journal of Basic and Clinical Physiology and Pharmacology, 2019, 30, 233-237.	0.7	6
1520	The impact of lipid accumulation product (LAP) and visceral adiposity index (VAI) on clinical, hormonal and metabolic parameters in lean women with polycystic ovary syndrome. Gynecological Endocrinology, 2019, 35, 233-236.	0.7	13
1521	Serum betatrophin levels are reduced in patients with full-blown polycystic ovary syndrome. Gynecological Endocrinology, 2019, 35, 224-227.	0.7	7
1522	The relationship between anti-MÃ¼llerian hormone serum level and body mass index in a large cohort of infertile patients. Endocrine, 2019, 63, 157-163.	1.1	20
1523	The Effect of Magnesium and Vitamin E Co-Supplementation on Glycemic Control and Markers of Cardio-Metabolic Risk in Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Hormone and Metabolic Research, 2019, 51, 100-105.	0.7	24
1524	Correlation of Vitamin D3 (Calcitriol) Serum Concentrations with Vitamin B12 and Folic Acid in Women Undergoing in vitro Fertilisation/Intracytoplasmatic Sperm Injection. Ginekologia and Obstetric Investigation, 2019, 84, 128-135.	0.7	8
1525	Genetics of Polycystic Ovary Syndrome. , 2019, , 447-461.		0
1526	Urinary concentration of personal care products and polycystic ovary syndrome: A case-control study. Environmental Research, 2019, 168, 48-53.	3.7	33
1527	Metabolic syndrome in Iranian adolescents with polycystic ovary syndrome. International Journal of Adolescent Medicine and Health, 2019, 31, .	0.6	4
1528	The Effects of Synbiotic Supplementation on Metabolic Status in Women With Polycystic Ovary Syndrome: a Randomized Double-Blind Clinical Trial. Probiotics and Antimicrobial Proteins, 2019, 11, 1355-1361.	1.9	40

#	Article	IF	Citations
1529	Impact of mitochondrial DNA copy number and displacement loop alterations on polycystic ovary syndrome risk in south Indian women. Mitochondrion, 2019, 44, 35-40.	1.6	35
1530	The prevalence of obstructive sleep apnoea in women with polycystic ovary syndrome: a systematic review and meta-analysis. Sleep and Breathing, 2020, 24, 339-350.	0.9	55
1531	Evaluation of serum level of omentinâ€1 in females with hirsutism. Journal of Cosmetic Dermatology, 2020, 19, 535-539.	0.8	4
1532	Cardiovascular evaluation and serum paraoxonase-1 levels in adolescents with polycystic ovary syndrome. Journal of Obstetrics and Gynaecology, 2020, 40, 90-95.	0.4	6
1533	The effects of chronic oxytocin administration on body weight and food intake in DHT-induced PCOS model rats. Gynecological Endocrinology, 2020, 36, 55-60.	0.7	12
1534	The Effects of Selenium Supplementation on Clinical Symptoms and Gene Expression Related to Inflammation and Vascular Endothelial Growth Factor in Infertile Women Candidate for In Vitro Fertilization. Biological Trace Element Research, 2020, 193, 319-325.	1.9	11
1535	Maternal polycystic ovary syndrome and risk of neuropsychiatric disorders in offspring: prenatal androgen exposure or genetic confounding?. Psychological Medicine, 2020, 50, 616-624.	2.7	61
1536	The prevalence of heterozygous CYP21A2 deficiency in patients with idiopathic acne, hirsutism, or both. Endocrine, 2020, 67, 665-672.	1.1	11
1537	Hyperandrogen enhances apoptosis of human ovarian granulosa cells via up-regulation and demethylation of PDCD4. Gynecological Endocrinology, 2020, 36, 333-337.	0.7	12
1538	Hypertension in Polycystic Ovary Syndrome: Novel Insights. Current Hypertension Reviews, 2020, 16, 55-60.	0.5	19
1539	The effect of probiotics, prebiotics, and synbiotics on hormonal and inflammatory indices in women with polycystic ovary syndrome: a systematic review and meta-analysis. European Journal of Nutrition, 2020, 59, 433-450.	1.8	50
1540	The association between dietary antioxidants, oxidative stress markers, abdominal obesity and poly-cystic ovary syndrome: A case control study. Journal of Obstetrics and Gynaecology, 2020, 40, 77-82.	0.4	12
1541	High level of visfatin and the activation of Akt and ERK1/2 signaling pathways are associated with endometrium malignant transformation in polycystic ovary syndrome. Gynecological Endocrinology, 2020, 36, 156-161.	0.7	9
1542	Association between Biomarkers of Low-grade Inflammation and Sex Hormones in Women with Polycystic Ovary Syndrome. Experimental and Clinical Endocrinology and Diabetes, 2020, 128, 723-730.	0.6	22
1543	Impact of Bariatric Surgery on Female Reproductive Health and Maternal Outcomes. Obesity Surgery, 2020, 30, 383-390.	1.1	13
1544	The effects of aerobic physical exercises on body image among women with polycystic ovary syndrome. Journal of Affective Disorders, 2020, 262, 350-358.	2.0	25
1545	Coadministration of metformin or spironolactone enhances efficacy of rosiglitazone in management of PCOS. Gynecological Endocrinology, 2020, 36, 308-312.	0.7	3
1546	Curtailing PCOS. Pediatric Research, 2020, 87, 353-361.	1.1	53

#	Article	IF	Citations
1547	Outcomes of Patients with Central Precocious Puberty Due to Loss-of-Function Mutations in the MKRN3 Gene after Treatment with Gonadotropin-Releasing Hormone Analog. Neuroendocrinology, 2020, 110, 705-713.	1.2	17
1548	Levonorgestrel IUD: is there a long-lasting effect on return to fertility?. Journal of Assisted Reproduction and Genetics, 2020, 37, 45-52.	1.2	20
1549	High dose of <scp>d</scp>-chiro-inositol improves oocyte quality in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial. Gynecological Endocrinology, 2020, 36, 398-401.	0.7	12
1550	The Correlation between Hormonal Disturbance in PCOS Women and Serum Level of Kisspeptin. International Journal of Endocrinology, 2020, 2020, 1-8.	0.6	14
1551	Impaired heat shock protein 72 expression in women with polycystic ovary syndrome following a supervised exercise programme. Cell Stress and Chaperones, 2020, 25, 73-80.	1.2	2
1552	Disparate Relationship of Sexual Satisfaction, Self-Esteem, Anxiety, and Depression with Endocrine Profiles of Women With or Without PCOS. Reproductive Sciences, 2020, 27, 432-442.	1.1	11
1553	Discriminating hypothalamic oligomenorrhea/amenorrhea from hyperandrogenic oligomenorrhea/amenorrhea in exercising women. Applied Physiology, Nutrition and Metabolism, 2020, 45, 707-714.	0.9	13
1554	Metabolic alterations associated with polycystic ovary syndrome: A UPLC Q-Exactive based metabolomic study. Clinica Chimica Acta, 2020, 502, 280-286.	0.5	26
1555	Graph cluster approach in identifying novel proteins and significant pathways involved in polycystic ovary syndrome. Reproductive BioMedicine Online, 2020, 40, 319-330.	1.1	9
1556	Association between circulating zinc-Î±2-glycoprotein levels and the different phenotypes of polycystic ovary syndrome. Endocrine Journal, 2020, 67, 249-255.	0.7	2
1557	Female infertility is associated with an altered expression of the neurokinin B/neurokinin B receptor and kisspeptin/kisspeptin receptor systems in ovarian granulosa and cumulus cells. Fertility and Sterility, 2020, 114, 869-878.	0.5	20
1558	Associations between pre-pregnancy body mass index and gestational weight gain with pregnancy outcomes in women with polycystic ovary syndrome. Diabetology and Metabolic Syndrome, 2020, 12, 88.	1.2	3
1559	Evaluation of angiopoietin-like protein 3 (ANGPTL3) levels in polycystic ovary syndrome. Life Sciences, 2020, 263, 118595.	2.0	5
1560	Metastatin as a Marker for Hyperandrogenemia in Iraqi Women with Polycystic Ovary Syndrome. Obstetrics and Gynecology International, 2020, 2020, 1-6.	0.5	0
1561	Expression of angiopoietin-like protein 2 in ovarian tissue of rat polycystic ovarian syndrome model and its correlation study. Reproductive Biology and Endocrinology, 2020, 18, 94.	1.4	4
1562	Association between empirically derived dietary patterns and polycystic ovary syndrome: A case-control study. Nutrition, 2020, 79-80, 110987.	1.1	10
1563	Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis. Human Reproduction Update, 2020, 26, 942-960.	5.2	180
1564	Controversies in the diagnosis of polycystic ovary syndrome. Therapeutic Advances in Reproductive Health, 2020, 14, 263349412091303.	1.3	22

#	Article	IF	Citations
1565	Serum estradiol levels in infertile men with non-obstructive azoospermia. Therapeutic Advances in Reproductive Health, 2020, 14, 263349412092834.	1.3	3
1566	Polycystic ovary syndrome (PCOS) and COVID-19: an overlooked female patient population at potentially higher risk during the COVID-19 pandemic. BMC Medicine, 2020, 18, 220.	2.3	78
1567	Role of TGF-Î² signalling in PCOS associated focal segmental glomerulosclerosis. Clinica Chimica Acta, 2020, 510, 244-251.	0.5	9
1568	A prospective study of antiâ€mullerian hormone and other ovarian and adrenal hormones in adult female acne. Dermatologic Therapy, 2020, 33, e13974.	0.8	4
1569	Changes in peripheral mitochondrial DNA copy number in metformin-treated women with polycystic ovary syndrome: a longitudinal study. Reproductive Biology and Endocrinology, 2020, 18, 69.	1.4	14
1570	Effect of gonadotropins and endometrial thickness on pregnancy outcome in patients with unexplained infertility or polycystic ovarian syndrome undergoing intrauterine insemination. Journal of International Medical Research, 2020, 48, 030006052096653.	0.4	4
1571	Risk of Cardiovascular and Cerebrovascular Events in Polycystic Ovarian Syndrome Women: A Meta-Analysis of Cohort Studies. Frontiers in Cardiovascular Medicine, 2020, 7, 552421.	1.1	39
1572	Exposure of human fallopian tube epithelium to elevated testosterone results in alteration of cilia gene expression and beating. Human Reproduction, 2020, 35, 2086-2096.	0.4	25
1573	Does coenzyme Q10 supplementation improve fertility outcomes in women undergoing assisted reproductive technology procedures? A systematic review and meta-analysis of randomized-controlled trials. Journal of Assisted Reproduction and Genetics, 2020, 37, 2377-2387.	1.2	24
1574	Effect of pretreatment oral contraceptives on fresh and cumulative live birth in vitro fertilization outcomes in ovulatory women. Fertility and Sterility, 2020, 114, 779-786.	0.5	6
1575	MORE THAN MEETS THE EYE IN A PATIENT WITH PCOS: ANDROGEN-SECRETING GRANULOSA CELL OVARIAN TUMOR IN A VIRILIZED WOMAN WITH POLYCYSTIC OVARIAN SYNDROME (PCOS). AACE Clinical Case Reports, 2020, 6, e170-e173.	0.4	4
1576	Firing patterns of gonadotropin-releasing hormone neurons are sculpted by their biologic state. Royal Society Open Science, 2020, 7, 201040.	1.1	0
1577	Sexual function and depression in polycystic ovary syndrome: Is it associated with inflammation and neuromodulators?. Neuropeptides, 2020, 84, 102099.	0.9	7
1578	Frequency of potential causes of lower back pain and incidental findings in patients with suspected sacroiliitis: retrospective analysis of 886 patients with negative sacroiliac MRI examination for sacroiliitis. Acta Radiologica, 2020, 62, 028418512096856.	0.5	1
1579	An association study of polymorphisms in the H19 imprinted gene in an Iranian population with the risk of polycystic ovary syndrome. Biology of Reproduction, 2020, 103, 978-985.	1.2	7
1580	Establishment and Analysis of a Combined Diagnostic Model of Polycystic Ovary Syndrome with Random Forest and Artificial Neural Network. BioMed Research International, 2020, 2020, 1-13.	0.9	34
1581	Peripheral hematological parameters in women with polycystic ovary syndrome. Journal of International Medical Research, 2020, 48, 030006052095228.	0.4	3
1582	Beneficial health effects of Menaquinoneâ€7 on body composition, glycemic indices, lipid profile, and endocrine markers in polycystic ovary syndrome patients. Food Science and Nutrition, 2020, 8, 5612-5621.	1.5	20

#	Article	IF	Citations
1583	Prevalence of metabolic disturbances among women with polycystic ovary syndrome in different regions of Brazil. International Journal of Gynecology and Obstetrics, 2020, 151, 383-391.	1.0	11
1584	The effects of spinach-derived thylakoid supplementation in combination with calorie restriction on anthropometric parameters and metabolic profiles in obese women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled clinical trial. Nutrition Journal, 2020, 19, 82.	1.5	8
1585	Impact of comorbid polycystic ovarian syndrome and gestational diabetes mellitus on pregnancy outcomes: a retrospective cohort study. BMC Pregnancy and Childbirth, 2020, 20, 484.	0.9	15
1586	Quality of life in adolescent girls with polycystic ovary syndrome. Journal of Paediatrics and Child Health, 2020, 56, 1351-1357.	0.4	12
1587	Therapeutic efficacy of moxibustion plus medicine in the treatment of infertility due to polycystic ovary syndrome and its effect on serum immune inflammatory factors. Journal of Acupuncture and Tuina Science, 2020, 18, 269-275.	0.1	5
1588	Pentraxin 3 Levels in Young Women with and without Polycystic Ovary Syndrome (PCOS) in relation to the Nutritional Status and Systemic Inflammation. International Journal of Endocrinology, 2020, 2020, 1-7.	0.6	8
1589	Causal Effects of Genetically Determined Metabolites on Risk of Polycystic Ovary Syndrome: A Mendelian Randomization Study. Frontiers in Endocrinology, 2020, 11, 621.	1.5	9
1590	Study of prevalence of insulin resistance and other metabolic abnormalities in various phenotypes of polycystic ovary syndrome in central India. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 2020, 9, 2978.	0.0	0
1591	Polycystic ovary syndrome and offspring risk of congenital heart defects: a nationwide cohort study. Human Reproduction, 2020, 35, 2348-2355.	0.4	5
1592	Response to Letter to the Editor Entitled: Concerning the Article by Arezoo Maleki-Hajiagha et al. Entitled Serum Prostate-Specific Antigen Level in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. Hormone and Metabolic Research, 2020, 52, 252-252.	0.7	0
1593	Increased risk markers in women with polycystic ovary syndrome and gestational diabetes mellitus during mid-pregnancy. Journal of International Medical Research, 2020, 48, 030006052093463.	0.4	2
1594	The appraisal of body content (ABC) trial: obesity does not significantly impact gamete production in infertile men and women. Journal of Assisted Reproduction and Genetics, 2020, 37, 2733-2742.	1.2	9
1595	Association between long-chain non-coding RNA SRA1 gene single-nucleotide polymorphism and polycystic ovary syndrome susceptibility.. Journal of Assisted Reproduction and Genetics, 2020, 37, 2513-2523.	1.2	3
1596	The role of cholecalciferol deficiency in the pathogenesis of polycystic ovary syndrome. Women's Health, 2020, 16, 174550652096960.	0.7	0
1597	Metabolic comparison of polycystic ovarian syndrome and control women in Middle Eastern and UK Caucasian populations. Scientific Reports, 2020, 10, 18895.	1.6	9
1598	Exploration of Lifestyle Choices, Reproductive Health Knowledge, and Polycystic Ovary Syndrome (PCOS) Awareness Among Female Emirati University Students . International Journal of Women's Health, 2020, Volume 12, 927-938.	1.1	21
1599	Polycystic Ovary Syndrome: A Brain Disorder Characterized by Eating Problems Originating during Puberty and Adolescence. International Journal of Molecular Sciences, 2020, 21, 8211.	1.8	32
1600	Evolution of serum Anti-MÃ¼llerian Hormone (AMH) level in young women treated with chemotherapy for breast cancer according to basal AMH level. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 254, 132-137.	0.5	5

#	Article	IF	Citations
1601	The efficacy of vitamin D combined with clomiphene citrate in ovulation induction in overweight women with polycystic ovary syndrome: a double blind, randomized clinical trial. Endocrine, 2020, 69, 393-401.	1.1	9
1602	Human Chorionic Gonadotropin Priming Does Not Improve Pregnancy Outcomes of PCOS-IVM Cycles. Frontiers in Endocrinology, 2020, 11, 279.	1.5	8
1603	Association of IL-1Î², IL-6, TNF-Î±, and TGFÎ²1 Gene Polymorphisms with Recurrent Spontaneous Abortion in Polycystic Ovary Syndrome. Disease Markers, 2020, 2020, 1-8.	0.6	21
1604	Effectiveness of Bariatric Surgery-Induced Weight Loss on Infertility Among PCOS and Non-PCOS Women: Experience of a Maternity Hospital and In Vitro Fertilization (IVF) Center in India. Indian Journal of Surgery, 2020, , 1.	0.2	2
1605	Influence of KISS1 gene polymorphisms on the risk of polycystic ovary syndrome and its associated variables, in Saudi women. BMC Endocrine Disorders, 2020, 20, 59.	0.9	6
1606	Correlation between leptin and IFN-Î³ involved in granulosa cell apoptosis in PCOS. Gynecological Endocrinology, 2020, 36, 1051-1056.	0.7	13
1607	Mitochondrial function in women with polycystic ovary syndrome. Current Opinion in Obstetrics and Gynecology, 2020, 32, 205-212.	0.9	12
1608	Long-term effects of a three-component lifestyle intervention on emotional well-being in women with Polycystic Ovary Syndrome (PCOS): A secondary analysis of a randomized controlled trial. PLoS ONE, 2020, 15, e0233876.	1.1	34
1609	Polycystic Ovary Syndrome and Pelvic Floor Dysfunction: A Narrative Review . Research and Reports in Urology, 2020, Volume 12, 179-185.	0.6	9
1610	Tissue fat quantification by magnetic resonance imaging: proton density fat fraction in polycystic ovary syndrome. Reproductive BioMedicine Online, 2020, 41, 329-334.	1.1	7
1611	A Retrospective Study Examining Phentermine on Preconception Weight Loss and Pregnancy Outcomes. Endocrine Practice, 2020, 26, 990-996.	1.1	3
1612	Reduced ovarian response to controlled ovarian stimulation is associated with increased oxidative stress in the follicular environment. Reproductive Biology, 2020, 20, 402-407.	0.9	9
1613	Pooled genetic analysis identifies variants that confer enhanced susceptibility to PCOS in Indian ethnicity. Gene, 2020, 752, 144760.	1.0	8
1614	Metagenomic analysis identified microbiome alterations and pathological association between intestinal microbiota and polycystic ovary syndrome. Fertility and Sterility, 2020, 113, 1286-1298.e4.	0.5	53
1615	The effects of soy isoflavones on total testosterone and follicle-stimulating hormone levels in women with polycystic ovary syndrome: a systematic review and meta-analysis. European Journal of Contraception and Reproductive Health Care, 2020, 25, 305-310.	0.6	5
1616	Steroid Screening Tools Differentiating Nonclassical Congenital Adrenal Hyperplasia and Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2895-e2902.	1.8	7
1617	Composition of Royal Jelly (RJ) and Its Anti-Androgenic Effect on Reproductive Parameters in a Polycystic Ovarian Syndrome (PCOS) Animal Model. Antioxidants, 2020, 9, 499.	2.2	16
1618	Recent Updates in Female Pelvic Ultrasound. Current Radiology Reports, 2020, 8, 1.	0.4	0

#	Article	IF	Citations
1619	Weekly Osteopathic Manipulative Treatment to Improve Measures of Sympathetic Tone in Women With Polycystic Ovary Syndrome: A Randomized, Controlled Pilot Study. Journal of Osteopathic Medicine, 2020, 120, 310-321.	0.4	4
1620	Endometrial expression of anti-MÃ¼llerian hormone and its type II receptor in women with polycystic ovary syndrome. Reproductive BioMedicine Online, 2020, 41, 128-137.	1.1	5
1621	Effects of follicular fluid oxidative status on human mural granulosa cells, oocyte competency and ICSI parameters. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 252, 127-136.	0.5	8
1622	Role of Androgen Receptor for Reconsidering the â€œTrueâ€•Polycystic Ovarian Morphology in PCOS. Scientific Reports, 2020, 10, 8993.	1.6	8
1623	Are Heavy Metal Exposure and Trace Element Levels Related to Metabolic and Endocrine Problems in Polycystic Ovary Syndrome?. Biological Trace Element Research, 2020, 198, 77-86.	1.9	27
1624	Increased chemerin serum levels in hyperandrogenic and normoandrogenic women from Argentina with polycystic ovary syndrome. Gynecological Endocrinology, 2020, 36, 1057-1061.	0.7	9
1625	Dydrogesteroneâ€primed ovarian stimulation is an effective alternative to gonadotropinâ€releasing hormone antagonist protocol for freezeâ€all cycles in polycystic ovary syndrome. Journal of Obstetrics and Gynaecology Research, 2020, 46, 1403-1411.	0.6	8
1626	Poor Embryo Quality Is Associated With A Higher Risk of Low Birthweight in Vitrified-Warmed Single Embryo Transfer Cycles. Frontiers in Physiology, 2020, 11, 415.	1.3	12
1627	A Systematic Review of the Effects of Exercise on Hormones in Women with Polycystic Ovary Syndrome. Journal of Functional Morphology and Kinesiology, 2020, 5, 35.	1.1	36
1628	Metformin during Pregnancy: Effects on Offspring Development and Metabolic Function. Frontiers in Pharmacology, 2020, 11, 653.	1.6	20
1629	Significance of pro-angiogenic estrogen metabolites in normal follicular development and follicular growth arrest in polycystic ovary syndrome. Human Reproduction, 2020, 35, 1655-1665.	0.4	17
1630	Association of estrogen receptor gene variants (ESR1 and ESR2) with polycystic ovary syndrome in Tunisia. Gene, 2020, 741, 144560.	1.0	10
1631	The correlation between UDP-glucuronosyltransferase polymorphisms and environmental endocrine disruptors levels in polycystic ovary syndrome patients. Medicine (United States), 2020, 99, e19444.	0.4	11
1632	High serum Antimullerian hormone levels are associated with lower live birth rates in women with polycystic ovarian syndrome undergoing assisted reproductive technology. Reproductive Biology and Endocrinology, 2020, 18, 20.	1.4	22
1633	Galectin-3 is a potential biomarker to insulin resistance and obesity in women with polycystic ovary syndrome. Gynecological Endocrinology, 2020, 36, 760-763.	0.7	10
1634	Serum betatrophin levels are significantly increased in obese patients compared to lean patients regardless to the presence of PCOS. Gynecological Endocrinology, 2020, 36, 678-681.	0.7	2
1635	The relationship between obstructive sleep apnoea and quality of life in women with polycystic ovary syndrome: a cross-sectional study. Therapeutic Advances in Endocrinology and Metabolism, 2020, 11, 204201882090668.	1.4	9
1636	Adolescent polycystic ovary syndrome according to the international evidence-based guideline. BMC Medicine, 2020, 18, 72.	2.3	142

#	Article	IF	Citations
1637	Clinical and Metabolic Effects of Alpha-Lipoic Acid Associated with Two Different Doses of Myo-Inositol in Women with Polycystic Ovary Syndrome. International Journal of Endocrinology, 2020, 2020, 1-8.	0.6	8
1638	Overweight and high serum total cholesterol were risk factors for the outcome of IVF/ICSI cycles in PCOS patients and a PCOS-specific predictive model of live birth rate was established. Journal of Endocrinological Investigation, 2020, 43, 1221-1228.	1.8	19
1639	11-Oxygenated androgens in health and disease. Nature Reviews Endocrinology, 2020, 16, 284-296.	4.3	99
1640	Association of Paraoxonase 1 Gene Polymorphisms and Polycystic Ovarian Syndrome Susceptibility: A Systematic Review and Meta-Analysis. Gynecologic and Obstetric Investigation, 2020, 85, 167-177.	0.7	3
1641	Association of genetic variations in phosphatase and tensin homolog (PTEN) gene with polycystic ovary syndrome in South Indian women: a case control study. Archives of Gynecology and Obstetrics, 2020, 302, 1033-1040.	0.8	2
1642	Plasma sclerostin levels are associated with nutritional status and insulin resistance but not hormonal disturbances in women with polycystic ovary syndrome. Archives of Gynecology and Obstetrics, 2020, 302, 1025-1031.	0.8	6
1643	The insulin signaling pathway is dysregulated in cumulus cells from obese, infertile women with polycystic ovarian syndrome with an absence of clinical insulin resistance. Therapeutic Advances in Reproductive Health, 2020, 14, 263349412090686.	1.3	5
1644	Highâ€refined carbohydrate diet leads to polycystic ovary syndrome-like features and reduced ovarian reserve in female rats. Toxicology Letters, 2020, 332, 42-55.	0.4	17
1645	GLP-1/GLP-1R Signaling Regulates Ovarian PCOS-Associated Granulosa Cells Proliferation and Antiapoptosis by Modification of Forkhead Box Protein O1 Phosphorylation Sites. International Journal of Endocrinology, 2020, 2020, 1-10.	0.6	11
1647	Obesity in adolescence. , 2020, , 15-22.		0
1648	Liraglutide: New Perspectives for the Treatment of Polycystic Ovary Syndrome. Clinical Drug Investigation, 2020, 40, 695-713.	1.1	13
1649	Efficacy of clomifene citrate for the treatment of patients with polycystic ovary syndrome. Medicine (United States), 2020, 99, e20590.	0.4	0
1650	Nanocurcumin alleviates insulin resistance and pancreatic deficits in polycystic ovary syndrome rats: Insights on PI3K/AkT/mTOR and TNF-Î± modulations. Life Sciences, 2020, 256, 118003.	2.0	34
1651	Implicating androgen excess in propagating metabolic disease in polycystic ovary syndrome. Therapeutic Advances in Endocrinology and Metabolism, 2020, 11, 204201882093431.	1.4	25
1652	Perspectives on the International Recommendations for the Diagnosis and Treatment of Polycystic Ovary Syndrome in Adolescence. Journal of Pediatric and Adolescent Gynecology, 2020, 33, 445-447.	0.3	18
1653	Disorders of Pubertal Onset. Primary Care - Clinics in Office Practice, 2020, 47, 189-216.	0.7	9
1654	Non-Classic Disorder of Adrenal Steroidogenesis and Clinical Dilemmas in 21-Hydroxylase Deficiency Combined with Backdoor Androgen Pathway. Mini-Review and Case Report. International Journal of Molecular Sciences, 2020, 21, 4622.	1.8	11
1655	Exercise Interventions in Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. Frontiers in Physiology, 2020, 11, 606.	1.3	56

#	Article	IF	Citations
1656	A liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based assay to profile 20 plasma steroids in endocrine disorders. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1477-1487.	1.4	41
1657	Polycystic ovary syndrome management: a review of the possible amazing role of berberine. Archives of Gynecology and Obstetrics, 2020, 301, 53-60.	0.8	29
1658	Prevalence of polycystic ovary syndrome (<scp>PCOS</scp>) among reproductive age women from Kashmir valley: A crossâ€sectional study. International Journal of Gynecology and Obstetrics, 2020, 149, 231-236.	1.0	34
1659	Impact of Bariatric Surgery on Clinical, Biochemical, and Hormonal Parameters in Women with Polycystic Ovary Syndrome (PCOS). Obesity Surgery, 2020, 30, 2294-2300.	1.1	23
1660	The polycystic ovary syndrome and gynecological cancer risk. Gynecological Endocrinology, 2020, 36, 289-293.	0.7	30
1661	Sonographic Assessment of Polycystic Ovaries. , 2020, , 87-99.		1
1662	Severe early-onset ovarian hyperstimulation syndrome with liver dysfunction in an IVF segmentation cycle. BMJ Case Reports, 2020, 13, e233379.	0.2	2
1663	In depth analysis of the association of FTO SNP (rs9939609) with theÂexpression of classical phenotype of PCOS: a Sri Lankan study. BMC Medical Genetics, 2020, 21, 30.	2.1	12
1664	Improving the accuracy and efficacy of diagnosing polycystic ovary syndrome by integrating metabolomics with clinical characteristics: study protocol for a randomized controlled trial. Trials, 2020, 21, 169.	0.7	6
1665	Decreased Insulin Resistance by Myo-Inositol Is Associated with Suppressed Interleukin 6/Phospho-STAT3 Signaling in a Rat Polycystic Ovary Syndrome Model. Journal of Medicinal Food, 2020, 23, 375-387.	0.8	18
1666	Laparoscopic Ovarian Drilling Improves Endometrial Homeobox Gene Expression in PCOS. Reproductive Sciences, 2020, 27, 675-680.	1.1	13
1667	High antimÃ¼llerian hormone levels are associated with preterm delivery in patients with polycystic ovary syndrome. Fertility and Sterility, 2020, 113, 444-452.e1.	0.5	25
1668	Cardiovascular health and menopause in aging women with polycystic ovary syndrome. Expert Review of Endocrinology and Metabolism, 2020, 15, 29-39.	1.2	5
1669	Transvaginal ovarian drilling followed by controlled ovarian stimulation from the next day improves ovarian response for the poor responders with polycystic ovary syndrome during IVF treatment: a pilot study. Reproductive Biology and Endocrinology, 2020, 18, 7.	1.4	6
1670	IL-18 and IL-18 binding protein concentration in ovarian follicular fluid of women with unexplained infertility to PCOS during in vitro fertilization. Journal of Reproductive Immunology, 2020, 138, 103083.	0.8	19
1671	MicroRNA-135a Regulates VEGFC Expression and Promotes Luteinized Granulosa Cell Apoptosis in Polycystic Ovary Syndrome. Reproductive Sciences, 2020, 27, 1436-1442.	1.1	14
1672	Polycystic ovarian syndrome among adolescent and young women: a hospital based observational study in a tertiary care teaching Hospital. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 2020, 9, 1097.	0.0	1
1673	Inhibition of autophagy in theca cells induces CYP17A1 and PAI-1 expression via ROS/p38 and JNK signalling during the development of polycystic ovary syndrome. Molecular and Cellular Endocrinology, 2020, 508, 110792.	1.6	24

#	Article	IF	Citations
1674	Clinical Features of PCOS. , 2020, , .		1
1675	Overweight, obesity and hyperandrogenemia are associated with gestational diabetes mellitus: A followâ€up cohort study. Acta Obstetricia Et Gynecologica Scandinavica, 2020, 99, 1311-1319.	1.3	16
1676	Regular Mindful Yoga Practice as a Method to Improve Androgen Levels in Women With Polycystic Ovary Syndrome: A Randomized, Controlled Trial. Journal of Osteopathic Medicine, 2020, 120, 323-335.	0.4	16
1677	Ovarian 25OH-vitamin D production in young women affected by polycystic ovary syndrome. Journal of Endocrinological Investigation, 2020, 43, 1623-1630.	1.8	0
1678	Polycystic ovary syndrome (PCOS) and adolescence: How can we manage it?. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 250, 235-240.	0.5	5
1679	Effects of continuous and intermittent aerobic physical training on hormonal and metabolic profile, and body composition in women with polycystic ovary syndrome: A randomized controlled trial. Clinical Endocrinology, 2020, 93, 173-186.	1.2	20
1680	Live birth after in vitro maturation versus standard in vitro fertilisation for women with polycystic ovary syndrome: protocol for a non-inferiority randomised clinical trial. BMJ Open, 2020, 10, e035334.	0.8	6
1681	Efficacy and Safety of Tracnilâ„¢ Administration in Patients with Dermatological Manifestations of PCOS: An Open-Label Single-Arm Study. Dermatology Research and Practice, 2020, 2020, 1-10.	0.3	3
1682	The effect of synbiotics supplementation on anthropometric indicators and lipid profiles in women with polycystic ovary syndrome: a randomized controlled trial. Lipids in Health and Disease, 2020, 19, 60.	1.2	23
1683	Comparative study between agonist and antagonist protocols in PCOS patients undergoing ICSI: a cross-sectional study. Middle East Fertility Society Journal, 2020, 24, .	0.5	2
1684	The effect of clomiphene citrate on oxidative stress parameters in polycystic ovarian syndrome. Journal of Obstetrics and Gynaecology, 2021, 41, 112-117.	0.4	9
1685	Long non-coding RNA H19 regulates proliferation of ovarian granulosa cells via STAT3 in polycystic ovarian syndrome. Archives of Medical Science, 2021, 17, 785-791.	0.4	9
1686	National and regional trends in the prevalence of polycystic ovary syndrome since 1990 within Europe: the modeled estimates from the Global Burden of Disease Study 2016. Archives of Medical Science, 2021, 17, 343-351.	0.4	19
1687	Secondary amenorrhoea â€“ a consultation. BMJ Sexual and Reproductive Health, 2021, 47, 75-77.	0.9	0
1688	Sexual function in women with androgen excess disorders: classic forms of congenital adrenal hyperplasia and polycystic ovary syndrome. Journal of Endocrinological Investigation, 2021, 44, 505-513.	1.8	6
1689	New insights into anti-MÃ¼llerian hormone role in the hypothalamicâ€“pituitaryâ€“gonadal axis and neuroendocrine development. Cellular and Molecular Life Sciences, 2021, 78, 1-16.	2.4	69
1690	Indicator of early kidney injury in adolescents with polycystic ovary syndrome: Can urine NGAL level be?. Gynecological Endocrinology, 2021, 37, 117-120.	0.7	0
1691	Identification of miR-16-5p and miR-155-5p microRNAs differentially expressed in circulating leukocytes of pregnant women with polycystic ovary syndrome and gestational diabetes. Gynecological Endocrinology, 2021, 37, 216-220.	0.7	21

#	Article	IF	Citations
1692	Comparing the effect of sitagliptin and metformin on the oocyte and embryo quality in classic PCOS patients undergoing ICSI. Irish Journal of Medical Science, 2021, 190, 685-692.	0.8	5
1693	Highly elevated level of antimÃ¼llerian hormone associated with preterm delivery in polycystic ovary syndrome patients who underwent ovulation induction. Fertility and Sterility, 2021, 115, 438-446.	0.5	11
1694	Differential expression profile of plasma exosomal microRNAs in women with polycystic ovary syndrome. Fertility and Sterility, 2021, 115, 782-792.	0.5	46
1695	Evaluation of the effect of trans-vaginal ovarian needle punctures on women with polycystic ovary syndrome. Journal of Gynecology Obstetrics and Human Reproduction, 2021, 50, 101937.	0.6	1
1696	Subacute cadmium exposure disrupts the hypothalamic-pituitary-gonadal axis, leading to polycystic ovarian syndrome and premature ovarian failure features in female rats. Environmental Pollution, 2021, 269, 116154.	3.7	33
1697	Maternal and paternal carriage of the annexin A5 M2 haplotype: a possible risk factor for recurrent implantation failure (RIF). Journal of Assisted Reproduction and Genetics, 2021, 38, 235-242.	1.2	9
1698	Risk Prediction of the Diabetes Missing Million: Identifying Individuals at High Risk of Diabetes and Related Complications. Diabetes Therapy, 2021, 12, 87-105.	1.2	17
1699	Oxidative stress markers in the follicular fluid of patients with polycystic ovary syndrome correlate with a decrease in embryo quality. Journal of Assisted Reproduction and Genetics, 2021, 38, 471-477.	1.2	36
1700	Î²-Edorphin predict pregnancy outcome of PCOS and DOR women after IVF-ET. Archives of Gynecology and Obstetrics, 2021, 303, 1207-1216.	0.8	4
1701	The adiponectin agonist, AdipoRon, inhibits steroidogenesis and cell proliferation in human luteinized granulosa cells. Molecular and Cellular Endocrinology, 2021, 520, 111080.	1.6	16
1702	Association Between Polycystic Ovary Syndrome and the Polymorphisms of Aryl Hydrocarbon Receptor Repressor, Glutathione-S-transferase T1, and Glutathione-S-transferase M1 Genes. Gynecological Endocrinology, 2021, 37, 558-561.	0.7	2
1703	Ethinyl estradiol vs estradiol valerate in combined oral contraceptives â€“ Effect on glucose tolerance: A randomized, controlled clinical trial. Contraception, 2021, 103, 53-59.	0.8	12
1704	Phenotypic features and fertility outcomes of women with polycystic ovary syndrome: The effect of quality of life. Journal of Obstetrics and Gynaecology Research, 2021, 47, 233-242.	0.6	2
1705	Evaluation of hirsutism and hormonal parameters in acne vulgaris patients treated with isotretinoin. International Journal of Clinical Practice, 2021, 75, e13791.	0.8	5
1706	A lifestyle intervention randomized controlled trial in obese women with infertility improved body composition among those who experienced childhood adversity. Stress and Health, 2021, 37, 93-102.	1.4	9
1707	Expression of ADR-Î±1, 2 and ADR-Î²2 in cumulus cell culture of infertile women with polycystic ovary syndrome and poor responder who are a candidate for IVF: the novel strategic role of clonidine in this expression. Journal of Receptor and Signal Transduction Research, 2021, 41, 263-272.	1.3	2
1708	Dark cortical rim: an MRI feature of polycystic ovarian syndrome. Abdominal Radiology, 2021, 46, 1148-1156.	1.0	4
1709	Characterizing the Clinical and Genetic Spectrum of Polycystic Ovary Syndrome in Electronic Health Records. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 153-167.	1.8	16

#	Article	IF	Citations
1710	The Relationship Between Polycystic Ovarian Syndrome, Periodontal Disease, and Osteoporosis. Reproductive Sciences, 2021, 28, 950-962.	1.1	5
1712	Evaluation of Carotid Artery Intima-Media Thickness as a Cardiovascular Risk Factor in Patients With Polycystic Ovary Syndrome. Cureus, 2021, 13, e13025.	0.2	2
1713	Body mass index rather than the phenotype impacts precocious ultrasound cardiovascular risk markers in polycystic ovary syndrome. European Journal of Endocrinology, 2021, 184, 199-208.	1.9	4
1714	Chronic niacin administration ameliorates ovulation, histological changes in the ovary and adiponectin concentrations in a rat model of polycystic ovary syndrome. Reproduction, Fertility and Development, 2021, 33, 447.	0.1	3
1715	Sex Hormone Disturbances in Athletes: Implications for Voice. , 2021, , 207-227.		0
1716	Metabolic profile of women with PCOS in Brazil: a systematic review and meta-analysis. Diabetology and Metabolic Syndrome, 2021, 13, 18.	1.2	5
1717	Higher blood pressure in normal weight women with PCOS compared to controls. Endocrine Connections, 2021, 10, 154-163.	0.8	13
1718	Low risk of OHSS with follitropin delta use in women with different polycystic ovary syndrome phenotypes: a retrospective case series. Journal of Ovarian Research, 2021, 14, 31.	1.3	4
1719	Genetic Susceptibility to Joint Occurrence of Polycystic Ovary Syndrome and Hashimotoâ€™s Thyroiditis: How Far Is Our Understanding?. Frontiers in Immunology, 2021, 12, 606620.	2.2	16
1720	Optimal Candidates to Do Fresh Embryo Transfer in Those Using Oral Contraceptive Pretreatment in IVF Cycles. Frontiers in Physiology, 2021, 12, 576917.	1.3	7
1721	Distinct Protocols of Physical Exercise May Improve Different Aspects of Well-being in Women With Polycystic Ovary Syndrome. American Journal of Lifestyle Medicine, 2023, 17, 140-151.	0.8	4
1723	Metabolic parameters in cord blood of neonate of mothers with obese and non-obese PCOS and controls: retrospective cohort study. BMC Pregnancy and Childbirth, 2021, 21, 223.	0.9	1
1724	Live births after in vitro maturation of oocytes in women who had suffered adnexal torsion and unilateral oophorectomy following conventional ovarian stimulation. Journal of Assisted Reproduction and Genetics, 2021, 38, 1323-1329.	1.2	11
1725	Identification of predictors of the ovarian response to clomiphene citrate in infertile women with polycystic ovary syndrome: a prospective cohort study. Journal of International Medical Research, 2021, 49, 030006052110005.	0.4	0
1726	Differentiation Between Phenotypes of Polycystic Ovarian Syndrome With Sonography. Journal of Diagnostic Medical Sonography, 2021, 37, 337-344.	0.1	2
1727	Thin endometrium is associated with the risk of hypertensive disorders of pregnancy in fresh IVF/ICSI embryo transfer cycles: a retrospective cohort study of 9,266 singleton births. Reproductive Biology and Endocrinology, 2021, 19, 55.	1.4	16
1728	Endocrinological and metabolic characteristics in patients who are non-obese and have polycystic ovary syndrome and different types of a family history of type 2 diabetes mellitus. Journal of International Medical Research, 2021, 49, 030006052110166.	0.4	5
1729	Polycystic Ovary Syndrome and Sleep Disorders: Association Between Metabolic and Androgenic Alterations with Sleep Components.. KahramanmaraÅŸ SÃ¼tÃ§Ã¼ Ä°mam Ãœniversitesi TÄ±p FakÃ¼ltesi Dergisi, 0, , .	0.1	0

#	Article	IF	Citations
1730	Free testosterone is related to aspects of cognitive function in women with and without polycystic ovary syndrome. Archives of Women's Mental Health, 2022, 25, 87-94.	1.2	9
1731	Effects of hormone replacement therapy on glucose and lipid metabolism in peri- and postmenopausal women with a history of menstrual disorders. BMC Endocrine Disorders, 2021, 21, 121.	0.9	5
1733	Endometrial Receptivity in Patients with Polycystic Ovary Syndrome. , 0, , .		0
1734	LRH-1 high expression in the ovarian granulosa cells of PCOS patients. Endocrine, 2021, 74, 413-420.	1.1	2
1735	Epigenetic inheritance of polycystic ovary syndrome â€" challenges and opportunities for treatment. Nature Reviews Endocrinology, 2021, 17, 521-533.	4.3	72
1736	Effects of probiotic and synbiotic supplementation on insulin resistance in women with polycystic ovary syndrome: a meta-analysis. Journal of International Medical Research, 2021, 49, 030006052110317.	0.4	16
1737	Differences in the individual curative effect of acupuncture for obese women with polycystic ovary syndrome based on metagenomic analysis: study protocol for a randomized controlled trial. Trials, 2021, 22, 454.	0.7	3
1738	Polycystic ovary syndrome: epidemiologic assessment of prevalence of systemic rheumatic and autoimmune diseases. Clinical Rheumatology, 2021, 40, 4837-4843.	1.0	9
1739	Alterations of brain metrics in fetuses of women with polycystic ovary syndrome : a retrospective study based on fetal magnetic resonance imaging. BMC Pregnancy and Childbirth, 2021, 21, 557.	0.9	1
1740	Clinical and biochemical signs of polycystic ovary syndrome in young women born preterm. European Journal of Endocrinology, 2021, 185, 279-288.	1.9	1
1741	Depression and anxiety in women with polycystic ovarian syndrome: a literature survey. International Journal of Adolescent Medicine and Health, 2021, 33, 367-373.	0.6	10
1742	The effectiveness and safety of liraglutide in treating overweight/obese patients with polycystic ovary syndrome: a meta-analysis. Journal of Endocrinological Investigation, 2022, 45, 261-273.	1.8	17
1743	Replication study and meta-analysis of selected genetic variants and polycystic ovary syndrome susceptibility in Asian population. Journal of Assisted Reproduction and Genetics, 2021, 38, 2781-2789.	1.2	9
1744	Decidualized endometrial stromal cells present with altered androgen response in PCOS. Scientific Reports, 2021, 11, 16287.	1.6	10
1745	Total cholesterol/HDL cholesterol ratio and monocyte/HDL cholesterol ratio are related with subclinical hypothyroidism in polycystic ovary syndrome. Turkish Journal of Biochemistry, 2021, .	0.3	1
1746	Lower sexual satisfaction in women with polycystic ovary syndrome and metabolic syndrome. Endocrine Connections, 2021, 10, 1035-1044.	0.8	2
1747	Polycystic ovary syndrome: clinical and laboratory variables related to new phenotypes using machine-learning models. Journal of Endocrinological Investigation, 2022, 45, 497-505.	1.8	14
1748	A recurrent familial partial lipodystrophy due to a monoallelic or biallelic LMNA founder variant highlights the multifaceted cardiac manifestations of metabolic laminopathies. European Journal of Endocrinology, 2021, 185, 453-462.	1.9	11

#	Article	IF	Citations
1749	Birthweight, Childhood Body Mass Index, Height and Growth, and Risk of Polycystic Ovary Syndrome. Obesity Facts, 2021, 14, 283-290.	1.6	5
1750	A review of maternal overweight and obesity and its impact on cardiometabolic outcomes during pregnancy and postpartum. Therapeutic Advances in Reproductive Health, 2021, 15, 263349412098654.	1.3	32
1751	Ultrasound and PCOS. , 2014, , 75-91.		1
1752	Polycystic Ovary Syndrome and Its Metabolic Complications. , 2006, , 255-276.		1
1753	Impact of Diagnostic Criteria. , 2008, , 333-344.		1
1754	Ovarian Steroidogenic Abnormalities in the Polycystic Ovary Syndrome. , 2006, , 203-211.		3
1755	Hormonal and Biochemical Evaluation of Polycystic Ovary Syndrome. , 2007, , 241-248.		1
1756	Anti-Androgens. , 2007, , 69-78.		1
1757	Effects of curcumin on body weight, glycemic control and serum lipids in women with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled trial. Clinical Nutrition ESPEN, 2020, 36, 128-133.	0.5	59
1759	Genotype-independent association between vitamin D deficiency and polycystic ovarian syndrome in Lahore, Pakistan. Scientific Reports, 2020, 10, 2290.	1.6	8
1760	Removal of DHT can relieve polycystic ovarian but not metabolic abnormalities in DHT-induced hyperandrogenism in mice. Reproduction, Fertility and Development, 2019, 31, 1597.	0.1	3
1763	Prenatal Exposure to Endocrine Disruptors: A Developmental Etiology for Polycystic Ovary Syndrome. Reproductive Sciences, 2017, 24, 19-27.	1.1	46
1764	Lifestyle and environmental contributions to ovulatory dysfunction in women of polycystic ovary syndrome. BMC Endocrine Disorders, 2020, 20, 19.	0.9	33
1765	Endometrial scratch for infertile polycystic ovary syndrome (PCOS) women undergoing laparoscopic ovarian drilling: a randomized controlled trial. Middle East Fertility Society Journal, 2020, 24, .	0.5	8
1766	Should All Women with Polycystic Ovary Syndrome Be Screened for Metabolic Parameters?: A Hospital-Based Observational Study. PLoS ONE, 2016, 11, e0167036.	1.1	17
1767	Patatin-like phospholipase domain containing 3-gene (adiponutrin), preptin, kisspeptin and amylin regulates oocyte developmental capacity in PCOS. Cellular and Molecular Biology, 2019, 64, 7-12.	0.3	8
1768	Sam68 mediates leptin signaling and action in human granulosa cells: possible role in leptin resistance in PCOS. Endocrine Connections, 2020, 9, 479-488.	0.8	12
1769	Metformin decreases miR-122, miR-223 and miR-29a in women with polycystic ovary syndrome. Endocrine Connections, 2020, 9, 1075-1084.	0.8	20

#	Article	IF	Citations
1770	Diagnosis and follow-up of type 2 diabetes in women with PCOS: a role for OGTT?. European Journal of Endocrinology, 2018, 179, D1-D14.	1.9	29
1771	Prolactin and breast increase during pregnancy in PCOS: linked to long-term metabolic health?. European Journal of Endocrinology, 2019, 180, 373-380.	1.9	6
1772	MANAGEMENT OF ENDOCRINE DISEASE: Female sexual dysfunction for the endocrinologist. European Journal of Endocrinology, 2020, 182, R101.	1.9	23
1773	Psychological well-being and personality in relation to weight loss following behavioral modification intervention in obese women with polycystic ovary syndrome: a randomized controlled trial. European Journal of Endocrinology, 2020, 183, 1-11.	1.9	30
1774	Why does Polycystic Ovary Syndrome (PCOS) Need Long-term Management?. Current Pharmaceutical Design, 2019, 24, 4685-4692.	0.9	23
1775	POLYCYSTIC OVARIAN SYNDROME(PCOS), AWARENESS AMONG FEMALE STUDENTS, QASSIM UNIVERSITY, QASSIM REGION, SAUDI ARABIA. International Journal of Research -GRANTHAALAYAH, 2018, 6, 395-406.	0.1	3
1776	Indexes of Insulin Resistance in Hyperinsulinemic Polycystic Ovary Syndrome in a Macedonian Cohort of Women of Reproductive Age: A Cross-Sectional Study. Open Access Macedonian Journal of Medical Sciences, 2016, 4, 607-612.	0.1	3
1777	Lower Levels of Serum Adiponectin and the T Allele of rs1501299 of the ADIPOQ Gene Are Protective against Polycystic Ovarian Syndrome in Jordan. Korean Journal of Family Medicine, 2018, 39, 108.	0.4	22
1778	Usefulness of Insulin Sensitivity Indexes derived from Oral Glucose Tolerance Test in Women with Polycystic Ovary Syndrome. The Journal of Korean Diabetes Association, 2006, 30, 277.	0.1	1
1779	Serum luteinizing hormone level and luteinizing hormone/follicle-stimulating hormone ratio but not serum anti-MÃ¼llerian hormone level is related to ovarian volume in Korean women with polycystic ovary syndrome. Clinical and Experimental Reproductive Medicine, 2014, 41, 86.	0.5	30
1780	Metabolic and hormonal assessment of adolescent and young adult women with prior premature adrenarche. Clinics, 2019, 74, e836.	0.6	9
1781	Management of PCOS Women Preparing Pregnancy. ISGE Series, 2021, , 135-147.	0.2	0
1782	Clinical Profile of Polycystic Ovarian Syndrome Patients In Tertiary Care Hospital. Vimshealth Science Journal, 2021, 8, 99-103.	0.0	0
1783	Effect of Curcumin on Glycaemic and Lipid Parameters in Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Reproductive Sciences, 2022, 29, 3124-3133.	1.1	4
1784	Association between baseline LH/FSH and live-birth rate after fresh-embryo transfer in polycystic ovary syndrome women. Scientific Reports, 2021, 11, 20490.	1.6	13
1785	Anti-MÃ¼llerian Hormone: Current Understanding and Clinical Use. Current Obstetrics and Gynecology Reports, 2021, 10, 61.	0.3	1
1786	Improvement in diagnostic performance of the revised total testosterone measuring system in Japanese women with polycystic ovary syndrome . Journal of Medical Investigation, 2000, 40, 65-71.	0.2	0
1787	Medical management of polycystic ovarian syndrome and its sequelae. , 2006, , 159-176.		0

#	Article	IF	Citations
1788	Chronic Treatment of Polycystic Ovary Syndrome. , 2007, , 115-132.		1
1789	Die anovulatorische Patientin in der Reproduktionsmedizin. , 2007, , 39-49.		0
1790	Adrenarche. , 2007, , 163-179.		0
1791	Indication of Laparoscopic ovarian drilling. Japanese Journal of Gynecologic and Obstetric Endoscopy, 2007, 23, 257-260.	0.0	0
1793	Statins, Oxidative Stress, and Polycystic Ovary Syndrome. , 2007, , 263-278.		1
1794	Polycystic Ovary Syndrome in the Peripubertal Period. , 2007, , 285-308.		0
1795	Polycystic Ovary Syndrome and the Metabolic Syndrome. , 2007, , 537-552.		1
1796	StÃ¶rungen des Androgenhaushalts. , 2009, , 385-417.		0
1797	Praktisches Vorgehen bei gestÃ¶rter Ovarfunktion und damit assoziierten PhÃnomenen. , 2009, , 633-712.		0
1798	Ovulation Induction in PCOS. , 2009, , 243-252.		1
1800	HyperandrogenÃmie. , 2013, , 53-64.		0
1802	Ultraschall. , 2013, , 153-171.		0
1803	Marcadores genÃ©ticos en pacientes con sÃndrome de ovario poliquÃstico y dos de sus familiares en primer grado de consanguinidad. Estudio de casos y controles. Revista Colombiana De Obstetricia Y Ginecologia, 2013, 64, 115-120.	0.2	0
1804	Adipokines resistin and lipokalin-2 and its role in the pathogenesis of polycystic ovary syndrome and metabolic syndrome.. Medicni Perspektivi, 2013, 18, 95-110.	0.1	1
1805	MaduraciÃ³n in vitro de ovocitos: alternativa efectiva en reproducciÃ³n asistida. Revista Peruana De GinecologÃa Y Obstetricia, 2013, 58, 263-266.	0.1	0
1806	Abnormal Menstrual Cycles. , 2014, , 67-72.		0
1807	Ovarian Reserve and Ovarian Cysts. , 2014, , 63-74.		0
1808	3D Ultrasound for Follicle Monitoring in ART. , 2014, , 263-282.		0

#	Article	IF	Citations
1809	Pathophysiology and Clinical Assessment of Hyperandrogenic States. ISGE Series, 2014, , 69-76.	0.2	0
1811	Abdominal Pain and Weight Gain. , 0, , 213-218.		0
1812	Embarazo mediante tratamiento de maduraciÃ³n in vitro de ovocitos en paciente amenorreica y con historia de anorexia nervosa. Revista Peruana De GinecologÃa Y Obstetricia, 2015, 58, 133-136.	0.1	1
1813	Rol de la ecografÃa en el manejo de la Infertilidad. Revista Peruana De GinecologÃa Y Obstetricia, 2015, 58, 95-100.	0.1	0
1815	Menstrual dysfunction in women with metabolic syndrome. Reproductive Endocrinology, 2014, .	0.0	0
1817	Diagnosis and Assessment. , 2015, , 71-87.		0
1819	Endokrinologie. , 2017, , 111-118.		0
1820	Endocrine and metabolic disorders in women with polycystic ovary syndrome and new possibilities of their correction. Reproductive Endocrinology, 2016, .	0.0	3
1824	Uso de metformina em mulheres obesas com SÃ¬ndrome do OvÃ¡rio PolicÃstico. Revista De Ciencias Medicas (Campinas): Journal of Medical Sciences, 2017, 25, 87.	0.3	1
1825	Asymptomatic Fibroids and Infertility. , 2018, , 235-250.		0
1827	Cross-validation Studies of a Novel Low-cost Hepatitis B Virus Quantitative Polymerase Chain Reaction System. Euroasian Journal of Hepato-gastroenterology, 2018, 8, 38-41.	0.1	0
1828	JugendgynÃkologie. , 2018, , 299-314.		0
1830	Frequency of Polycystic Ovaries Syndrome in Reproductive Age Women. Journal of the Dow University of Health Sciences, 2018, 12, 53-57.	0.2	0
1831	Ultrasound and Ovarian Reserve. , 2019, , 75-90.		1
1832	Molecular links between angiogenesis and inflammation in polycystic ovary syndrome. Medicina, 2019, 50, .	0.0	0
1833	Assessment of quality of life among women with polycystic ovary syndrome of different reproductive age. ZaporoÅ¾skij Medicinskij Å½urnal, 2019, .	0.0	1
1834	Combined Oral Contraceptive in Adolescent and Young Adult Women: Current Evidence and Future Perspectives. Current Women's Health Reviews, 2019, 15, 109-118.	0.1	1
1835	Serum retinol-binding protein 4 levels in polycystic ovary syndrome. Endocrine Connections, 2019, 8, 709-717.	0.8	6

#	Article	IF	Citations
1837	Pregnancy Issues and Bariatric Surgery. , 2020, , 545-552.		0
1839	Evaluation of the treatment with D-chiroinositol on levels of oxidative stress in pcos patients. Reproductive Endocrinology, 2019, .	0.0	0
1841	Awareness and opinion about polycystic ovarian syndrome (PCOS) among young women: a developing country perspective. International Journal of Adolescent Medicine and Health, 2021, 33, 123-126.	0.6	7
1842	Effect of Body Mass Index on Serum CA125 Level in Females with PCOS. Iraqi Journal of Embryos and Infertility Researches, 2020, 10, 101-118.	0.1	1
1844	Polycystic Ovarian Syndrome. , 2020, , 253-274.		0
1845	Exploring the activity of the enzyme 11Î²-hydroxylase in the polycystic ovary syndrome. Hormone Molecular Biology and Clinical Investigation, 2020, 41, .	0.3	2
1846	Polycystic Ovary Syndrome in Adolescents. , 2020, , 449-455.		0
1851	Erkrankungen der Ovarien. , 2005, , 1010-1024.		0
1852	Endocrinology of the Ovary. , 2005, , 391-403.		1
1853	Metabolic and Endocrine Effects of Statins in Polycystic Ovary Syndrome. , 2008, , 241-258.		1
1854	Recommended Treatment Modalities for Hyperandrogenism. , 2008, , 295-306.		0
1855	Variations in the Expression of the Polycystic Ovary Syndrome Phenotype. , 2008, , 123-132.		0
1856	Idiopathic Hirsutism. , 2006, , 139-144.		0
1858	Hypertension and Cardiovascular and Lipoprotein Abnormalities in the Polycystic Ovary Snydrome. , 2006, , 325-331.		0
1859	Overview of Long-Term Morbidity and Economic Cost of the Polycystic Ovary Syndrome. , 2006, , 353-362.		3
1861	Metabolic Complications of Polycystic Ovary Syndrome. , 2008, , 377-390.		0
1862	Factors related to follicular oxidative stress in intracytoplasmic sperm injection cycles and its effects on granulosa cells. Zygote, 2021, 29, 59-65.	0.5	2
1863	Chemerin level in a sample of Egyptian females with PCOS and its relation to insulin resistance. The Egyptian Journal of Internal Medicine, 2020, 32, .	0.3	3

#	Article	IF	Citations
1864	N-acetyl-cysteine as adjuvant therapy in female infertility: a systematic review and meta-analysis. Journal of Basic and Clinical Physiology and Pharmacology, 2021, 32, 899-910.	0.7	4
1865	Involvement of impaired CD8+ mucosal-associated invariant T cells and myeloid-derived suppressor cells in polycystic ovary syndrome. Reproductive Biology and Endocrinology, 2021, 19, 175.	1.4	5
1866	Utility of wrist circumference in recognition of metabolic syndrome in overweight and obese South Indian children and adolescents. Journal of Pediatric Endocrinology and Metabolism, 2022, 35, 65-71.	0.4	3
1867	Molecular determination of progesterone receptorâ€™s PROGINS allele (Alu insertion) and its association with the predisposition and susceptibility to polycystic ovary syndrome (PCOS). Mammalian Genome, 2022, 33, 508-516.	1.0	3
1868	Antimullerian Hormone Levels and Association with Abortion and Preterm Delivery in Patients with Polycystic Ovary Syndrome Who Conceived with Assisted Reproductive Techniques. Journal of Obstetrics and Gynecology of India, 0, , 1.	0.3	0
1869	Lipid ratios and obesity indices are effective predictors of metabolic syndrome in women with polycystic ovary syndrome. Therapeutic Advances in Endocrinology and Metabolism, 2022, 13, 204201882110666.	1.4	4
1870	Hyperandrogenism and menstrual imbalance are the best predictors of metformin response in PCOS patients. Reproductive Biology and Endocrinology, 2022, 20, 6.	1.4	11
1872	Curcumin and Polycystic Ovary Syndrome: a Systematic Review. Reproductive Sciences, 2022, 29, 2105-2118.	1.1	2
1874	Preliminary Results for Personalized Therapy in Pregnant Women with Polycystic Ovary Syndrome During the COVID-19 Pandemic. Archivum Immunologiae Et Therapiae Experimentalis, 2022, 70, 13.	1.0	3
1875	Effect of artificial cycle with or without GnRH-a pretreatment on pregnancy and neonatal outcomes in women with PCOS after frozen embryo transfer: a propensity score matching study. Reproductive Biology and Endocrinology, 2022, 20, 56.	1.4	8
1876	Estrogen Biosynthesis and Signal Transduction in Ovarian Disease. Frontiers in Endocrinology, 2022, 13, 827032.	1.5	12
1877	Evolution of serum progesterone levels in the very early luteal phase of stimulated IVF/ICSI cycles post hCG trigger: a proof of concept study. Journal of Assisted Reproduction and Genetics, 2022, 39, 1095-1104.	1.2	3
1880	Ovulation Induction for Anovulatory Patients. , 2022, , 15-28.		0
1881	Association of FTO gene variant rs9939609 with hyperandrogenemia and fasting glucoseÂlevels in South Indian women with polycystic ovarian syndrome. Egyptian Journal of Medical Human Genetics, 2022, 23, .	0.5	1
1890	Burden of polycystic ovary syndrome in the Middle East and North Africa region, 1990â€“2019. Scientific Reports, 2022, 12, 7039.	1.6	11
1891	Transtheoretical model-based mobile health application for PCOS. Reproductive Health, 2022, 19, 117.	1.2	10
1892	Family history of menstrual irregularity or diabetes mellitus enhances the susceptibility to polycystic ovary syndrome among subjects harboring rs7903146 genetic variant of TCF7L2. Journal of Diabetes and Metabolic Disorders, 2022, 21, 769-776.	0.8	2
1893	Does Alpha-1-Acid Glycoprotein Determine for Infertility in Polycystic Ovary Syndrome?. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2022, , .	0.5	0

#	Article	IF	Citations
1894	Prediction of follicle development after laparoscopic ovarian drilling by the pre-operative LH/FSH ratio and number of drillings per ovarian unit volume.. Japanese Journal of Gynecologic and Obstetric Endoscopy, 2022, 38, 19-25.	0.0	0
1895	Bibliometric analysis. International Journal of Health Sciences, 0, , 8459-8476.	0.0	1
1896	Correlation of Serum Visfatin Level in Non-obese Women with Polycystic Ovary Syndrome and Matched Control. Reproductive Sciences, 2022, 29, 3285-3293.	1.1	4
1897	The immune systemâ€™s role in PCOS. Molecular Biology Reports, 2022, 49, 10689-10702.	1.0	9
1898	Female Infertility Is Associated with an Altered Expression Profile of Different Members of the Tachykinin Family in Human Granulosa Cells. Reproductive Sciences, 0, , .	1.1	2
1899	Peripheral Hematological Parameters in Sudanese Women with Polycystic Ovary Syndrome. Case Reports in Clinical Medicine, 2022, 11, 253-260.	0.1	0
1900	MIR146A and ADIPOQ genetic variants are associated with birth weight in relation to gestational age: a cohort study. Journal of Assisted Reproduction and Genetics, 2022, 39, 1873-1886.	1.2	2
1901	Endometrial thickness is an independent risk factor of hypertensive disorders of pregnancy: a retrospective study of 13,458 patients in frozen-thawed embryo transfers. Reproductive Biology and Endocrinology, 2022, 20, .	1.4	8
1902	Updates on Molecular Targets and Epigenetic-Based Therapies for PCOS. Reproductive Sciences, 2023, 30, 772-786.	1.1	6
1903	Role of genomic DNA methylation in PCOS pathogenesis: a systematic review and meta-analysis involving case-controlled clinical studies. Molecular Human Reproduction, 2022, 28, .	1.3	9
1905	Steroid Hormone Profiling in Hyperandrogenism and Non-hyperandrogenism Women with Polycystic Ovary Syndrome. Reproductive Sciences, 2022, 29, 3449-3458.	1.1	2
1906	A randomised controlled trial on the effects of a structural education module among women with polycystic ovarian syndrome on nutrition and physical activity changes. BMC Women's Health, 2022, 22, .	0.8	2
1907	Implications of endocrine-disrupting chemicalsÂon polycystic ovarian syndrome:ÂA comprehensive review. Environmental Science and Pollution Research, 2022, 29, 58484-58513.	2.7	2
1908	Efficacy of multi-strain probiotic along with dietary and lifestyle modifications on polycystic ovary syndrome: a randomised, double-blind placebo-controlled study. European Journal of Nutrition, 2022, 61, 4145-4154.	1.8	10
1909	The Associations Between Alanine Aminotransferase and Other Biochemical Parameters in Lean PCOS. Reproductive Sciences, 0, , .	1.1	1
1910	A study on micronucleus frequency in cervical smear as biomarker for genetic damage in polycystic ovarian syndrome. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 2022, 11, 2106.	0.0	0
1911	Discovery of immune-related diagnostic biomarkers and construction of diagnostic model in varies polycystic ovary syndrome. Archives of Gynecology and Obstetrics, 2022, 306, 1607-1615.	0.8	8
1913	Polycystic Ovarian Syndrome and Increased Risk of Female Cancers. , 2022, , .		1

#	Article	IF	Citations
1914	A Prospective Study to Determine the Predictive Ability of HDP-Gestosis Score for the Development of Pre-eclampsia. Journal of Obstetrics and Gynecology of India, 2022, 72, 485-491.	0.3	4
1915	The Effect of Oral Antidiabetic Drugs on Improving the Endocrine and Metabolic States in Women with Polycystic Ovary Syndrome: A Systematic Review and Network Meta-analysis. Drugs, 2022, 82, 1469-1480.	4.9	5
1916	Predicting success of intrauterine insemination using a clinically based scoring system. Archives of Gynecology and Obstetrics, 0, , .	0.8	0
1917	Kisspeptin: a potential therapeutic target in patients with unexplained infertility?. Irish Journal of Medical Science, 0, , .	0.8	0
1918	SÃndrome do OvÃ¡rio PolicÃstico e Vitamina D. Research, Society and Development, 2022, 11, e521111131907.	0.0	0
1919	Distress response in granulosa cells of women affected by PCOS with or without insulin resistance. Endocrine, 2023, 79, 200-207.	1.1	3
1920	Polycystic ovarian syndrome and miscarriage in IVF: systematic revision of the literature and meta-analysis. Archives of Gynecology and Obstetrics, 2023, 308, 363-377.	0.8	1
1922	Evaluation of circulating microRNA profiles in Brazilian women with polycystic ovary syndrome: A preliminary study. PLoS ONE, 2022, 17, e0275031.	1.1	5
1923	SCREENING OF PRE-DIABETES IN PATIENTS PRESENTING WITH POLYCYSTIC OVARIAN SYNDROME: A TERTIARY CARE EXPERIENCE. Khyber Medical University Journal, 2021, 14, 237-43.	0.1	0
1924	Can Red cell distribution width screen for metabolic abnormality in women with Polycystic Ovarian Syndrome?. Journal of Medical Investigation, 2022, 69, 191-195.	0.2	0
1925	Bulimia Nervosa: Reproduction and Consequences for Mother and Child. , 2022, , 1-15.		0
1926	Ovarian functions and polycystic ovary syndrome in adult women with type 1 diabetes mellitus in a Turkish population. Journal of Endocrinological Investigation, 0, , .	1.8	0
1927	CaracterÃsticas clÃnicas, hormonales, bioquÃmicas y prevalencia del SÃndrome de Ovario PoliquÃstico en mujeres del Eje Cafetero, Colombia, 2016-2020. Revista Colombiana De EndocrinologÃa, Diabetes & Metabolismo, 2022, 9, .	0.1	0
1928	Role of pyroglutamic acid in cumulus cells of women with polycystic ovary syndrome. Journal of Assisted Reproduction and Genetics, 2022, 39, 2737-2746.	1.2	3
1929	A Comprehensive Review on Tailoring an Herbal Approach for Treatment of Poly Cystic Ovarian Syndrome. , 2022, 2, 27-32.		0
1931	Pathological Role of Reactive Oxygen Species on Female Reproduction. Advances in Experimental Medicine and Biology, 2022, , 201-220.	0.8	3
1932	Nomogram models to predict low fertilisation rate and total fertilisation failure in patients undergoing conventional IVF cycles. BMJ Open, 2022, 12, e067838.	0.8	2
1933	The physiological sonographic features of the ovary in healthy subjects: a joint systematic review and meta-analysis by the Italian Society of Gynecology and Obstetrics (SIGO) and the Italian Society of Endocrinology (SIE). Journal of Endocrinological Investigation, 2023, 46, 439-456.	1.8	3

#	Article	IF	Citations
1934	Evaluation of socio-demographic and clinical characteristics of PCOS patients attending a tertiary care institute in Colombo. BMC Endocrine Disorders, 2022, 22, .	0.9	0
1936	Benign Gynecological Conditions in Transgender and Gender Diverse People. , 2022, , 82-88.		0
1937	Pentacam corneal topography and densitometry features of PCOS patients. BMC Ophthalmology, 2023, 23, .	0.6	0
1938	Granulosa cells from immature follicles exhibit restricted glycolysis and reduced energy production: a dominant problem in polycystic ovary syndrome. Journal of Assisted Reproduction and Genetics, 2023, 40, 343-359.	1.2	2
1939	Evaluation of serum Podocalyxin in Iraqi women with Polycystic Ovary Syndrome. Journal of the Faculty of Medicine, Baghdad, 2023, 64, .	0.1	0
1940	Association of TCF7L2 Gene Variant (rs12255372) with Polycystic Ovary Syndrome and its Effect Modification of the Disease Phenotype. Indian Journal of Clinical Biochemistry, 0, , .	0.9	0
1941	Astaxanthin treatment ameliorates ER stress in polycystic ovary syndrome patients: a randomized clinical trial. Scientific Reports, 2023, 13, .	1.6	6
1943	Serum levels of anti-MÃ¼llerian hormone influence pregnancy outcomes associated with gonadotropin-releasing hormone antagonist treatment: a retrospective cohort study. Scientific Reports, 2023, 13, .	1.6	2
1944	Association between self-reported sedentary behavior and health-related quality of life among infertile women with polycystic ovary syndrome. BMC Women's Health, 2023, 23, .	0.8	1
1945	Oral contraceptive pill (OCP) treatment alters the gene expression of intercellular adhesion molecule-1 (ICAM-1), tumor necrosis factor-Î± (TNF-Î±), monocyte chemoattractant protein-1 (MCP-1) and plasminogen activator inhibitor-1 (PAI-1) in polycystic ovary syndrome (PCOS) women compared to drug-naive PCOS women. BMC Women's Health, 2023, 23, .	0.8	2
1946	Analysis of the effect of hashimoto's thyroiditis and insulin resistance on ovarian volume in patients with polycystic ovary syndrome. BMC Women's Health, 2023, 23, .	0.8	0
1949	Bulimia Nervosa: Reproduction and Consequences for Mother and Child. , 2023, , 923-937.		0
1950	Amenorrhea in Eating Disorders. ISGE Series, 2023, , 35-51.	0.2	0
1951	A comparative study of insulin levels in lean versus obese polycystic ovarian syndrome patients. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 2023, 12, 893-897.	0.0	1
1952	The Roles of Autophagy in the Genesis and Development of Polycystic Ovary Syndrome. Reproductive Sciences, 2023, 30, 2920-2931.	1.1	1